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Abstract 
 
Atopic Dermatitis (AD) is a chronic inflammatory disease characterised by 
pruritus, hyperkeratosis, parakeratosis and dry skin. Association of filaggrin mutations 
with AD has been reported, however not all AD patients have filaggrin mutations 
suggesting other mechanisms give rise to the barrier defect present in AD. Akt1 activity 
is essential for cornified envelope formation and correct profilaggrin processing, 
although the functional role of Akt1 in these processes remains unclear. The aim of this 
study was to investigate the role of downstream targets of Akt1 signaling in profilaggrin 
processing and cornified envelope formation. Using shRNA to knock down Akt1 
activity in rat epidermal keratinocyte cell lines, an in vitro organotypic model was 
created that phenocopies AD displaying hyperkeratosis, parakeratosis and impaired 
filaggrin processing. Results show that reduced Akt activity led to decreased lamin A/C 
degradation disrupting nuclear disintegration process giving rise to parakeratosis. 
HspB1 is reported to interact with filaggrin and also involved in filaggrin processing. 
Inhibition of Akt activity demonstrated a switch between HspB1-filaggrin to HspB1-
actin interaction in the upper epidermis, which may interfere with filaggrin processing. 
Cathepsin H (Ctsh) was down regulated 4-fold in our Akt1 knockdown cultures and its 
expression co-localized with filaggrin in the granular layer of human epidermis. 
Filaggrin processing was impaired in Ctsh shRNA knockdown cell lines, and both 
Ctsh+/−	   and	   Ctsh−/−	   mice displayed hyperkeratosis and reduced filaggrin expression. 
Inhibition of RAPTOR (a component of mTORC1) has previously been reported to 
increase Akt1 activity. Raptor overexpression in REKs showed a decrease in Akt 
phosphorylation, Ctsh and filaggrin processing, and treatment with Rapamycin, an 
mTORC1 inhibitor, reverses these effects. In uninvolved AD skin, increase in RAPTOR 
correlated with decrease in both Akt phosphorylation and filaggrin expression. This 
thesis presents a novel mechanism where increase in RAPTOR can lead to a reduction 
in epidermal granular Akt1 phosphorylation leading to impaired filaggrin processing 
and barrier defects in AD.  
 	  	  	  	  
	  	   4	  
Acknowledgements 
 
First and foremost, I owe my deep gratitude to my supervisor, Dr. Ryan 
O’Shaughnessy for being a great mentor, and providing the support that made 
completion of this thesis possible. I deeply appreciate his patience and encouragement 
through out my project, as well as the effort he put into reviewing this thesis. I would 
like to thank my secondary supervisor Dr Wei-Li Di for her support and helpful advice. 
I would also like to extend my gratitude to Professor John Harper and the other 
members of the skin group. I would like to thank my group members Gehad Youssef 
and Dr Stuart Brown for being such great colleagues, for the invaluable advice, for all 
the fun discussions and laughs along the way. My warmest thanks to my fellow PhD 
students and friends at ICH for making the lab an enjoyable place to work in. Thank 
you all for the help and most importantly for the wonderful friendships formed and the 
memorable times I have experienced during the past few years.  
 
My special thanks go to Ada for always being there for me and keeping me 
grounded whenever I got stressed. I owe a debt of gratitude to my partner, Patrick, for 
standing by me, supporting me, and for always believing in me. You made this journey 
possible with your constant encouragement and invaluable advice, and I cannot thank 
you enough for that.   
 
My warmest appreciation goes to my family. I have been blessed with a loving 
family that without their continuous support and encouragement I could not have come 
this far. I would like to specially thank my uncles Hassan and Ismail, and my aunts 
Khadeeja, Abida and Aminath for always being there for me and for supporting me in 
all aspects of my life. Finally the gratitude and affection I feel for my parents and 
siblings are so substantial, that to describe them would be a dissertation by itself. I am 
forever thankful for my beautiful sister, Haifa, and my wonderful brother, Azzam, for 
their continuous love and support. I thank them for all the encouragement and patience 
in my times of need. You both make me a better person. I love you both so much and 
am so incredibly lucky to have you in my life. My deepest heartfelt thanks to my father 
and mother, for being the two most incredible people in my life. I am forever thankful 
for my father, for his unwavering faith in his children, for being such an honest person 
and for always encouraging us. My never-ending gratitude goes to my mother, for being 
such a strong, patient and caring person, whose constant reassurance helped me reach 
	  	   5	  
this far in my life. Without the support and unconditional love from my parents and 
sibblings, I would not have come this far in my career and this thesis would not have 
been achievable.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  	   6	  
 
 
 
 
 
 
 
 
 
 
 
 
 
Dedicated 
 
to 
 
my father & mother 
 
For your love, encouragement and continuous assurance 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  	   7	  
Table of Contents 
The role of Akt1 in skin barrier formation ................................................................... 1 
Declaration ....................................................................................................................... 2 
Abstract 3 
Acknowledgements .......................................................................................................... 4 
Table of Contents ............................................................................................................ 7 
List of figures ................................................................................................................. 11 
List of tables ................................................................................................................... 14 
Abbreviations ................................................................................................................. 15 
 : Introduction .............................................................................................. 19 Chapter 1
1.1 Skin: A protective barrier .................................................................................. 19 1.1.1	  Overview	  of	  skin	  .............................................................................................................................	  19	  1.1.2	  Structure	  and	  function	  of	  epidermis	  ......................................................................................	  19	  1.1.3	  Barrier	  function	  ..............................................................................................................................	  20	  1.1.4	  Skin	  immune	  system	  .....................................................................................................................	  21	  
1.2 Atopic Dermatitis ................................................................................................ 24 1.2.1	  Atopic	  dermatitis:	  An	  overview	  ...............................................................................................	  24	  1.2.2	  Epidemiology	  of	  AD	  .......................................................................................................................	  24	  1.2.3	  Clinical	  manifestations	  and	  diagnosis	  of	  AD	  ......................................................................	  25	  1.2.4	  Pathophysiology	  of	  AD	  .................................................................................................................	  29	  1.2.5	  Immunological	  abnormalities	  in	  AD	  ......................................................................................	  30	  1.2.6	  Barrier	  defect	  in	  AD	  ......................................................................................................................	  32	  1.2.7	  Genetics	  of	  AD	  ..................................................................................................................................	  35	  1.2.8	  Current	  treatments	  of	  AD	  ...........................................................................................................	  36	  
1.3 Filaggrin ............................................................................................................... 37 1.3.1	  Profilaggrin	  structure	  and	  function	  .......................................................................................	  37	  1.3.2	  Profilaggrin-­‐filaggrin	  processing	  pathway	  .........................................................................	  37	  1.3.3	  Filaggrin	  and	  AD	  .............................................................................................................................	  43	  
1.4 PI3 Kinase/Akt signaling pathways ................................................................... 45 1.4.1	  Akt/PKB	  structure	  and	  activation	  mechanism	  .................................................................	  45	  1.4.2	  Akt	  in	  cell	  differentiation	  ............................................................................................................	  48	  1.4.3	  PI3	  Kinase/Akt	  pathway	  in	  skin	  development	  ..................................................................	  48	  1.4.4	  The	  role	  of	  	  RAPTOR-­‐mTORC1	  in	  modulating	  Akt	  activity	  ..........................................	  49	  
	  	   8	  
1.5 Heat shock protein 27 and actin ........................................................................ 51 
1.6 Lamin A/C ............................................................................................................ 51 
1.7 Cathepsin H ......................................................................................................... 53 
1.8 Aims and objectives ............................................................................................. 53 1.8.1	  Rationale	  for	  the	  study	  ................................................................................................................	  53	  1.8.2	  Hypothesis	  ........................................................................................................................................	  55	  1.8.3	  Objectives:	  .........................................................................................................................................	  55	  
 : Materials and methods ............................................................................. 57 Chapter 2
2.1 Reagents and Solutions ....................................................................................... 57 
2.2 General cell culture techniques .......................................................................... 63 2.2.1	  General	  trypsinisation	  protocol	  ...............................................................................................	  63	  2.2.2	  Freezing	  and	  thawing	  of	  cells	  ...................................................................................................	  64	  2.2.3	  Growth	  assays	  ..................................................................................................................................	  64	  2.2.4	  Rat	  Epidermal	  Keratinocyte	  (REK)	  and	  Swiss	  mouse	  3T3	  fibroblast	  (NIH	  3T3)	  culture	  .................................................................................................................................................	  64	  2.2.5	  Human	  keratinocyte	  cell	  culture	  .............................................................................................	  65	  2.2.6	  General	  transfection	  protocol	  ...................................................................................................	  65	  2.2.7	  shRNA	  plasmids,	  RAPTOR	  over	  expression	  ........................................................................	  66	  2.2.8	  Lamin	  contructs	  ..............................................................................................................................	  66	  2.2.9	  Post	  Confluent	  cultures	  ...............................................................................................................	  66	  2.2.10	  Organotypic	  culture	  ...................................................................................................................	  67	  2.2.11	  Cell	  treatments	  .............................................................................................................................	  67	  
2.3 Protein expression analysis by western blotting ............................................... 67 2.3.1	  Sample	  preparation	  .......................................................................................................................	  67	  2.3.2	  Protein	  quantification	  ..................................................................................................................	  68	  2.3.3	  SDS-­‐PAGE	  gel	  electrophoresis	  ..................................................................................................	  68	  2.3.4	  Transfer	  ..............................................................................................................................................	  69	  2.3.5	  Ponceau	  staining	  and	  blocking	  .................................................................................................	  70	  2.3.6	  Protein	  detection	  ............................................................................................................................	  70	  
2.4 Co-immunoprecipitation assay .......................................................................... 71 
2.5 AD uninvolved skin sections and normal skin sections. .................................. 71 
2.6 Immunoflourescent Analysis .............................................................................. 71 2.6.1	  Confocal	  microscopy	  and	  Nuclear	  Volume	  calculations	  ...............................................	  73	  2.6.2	  Immunofluoresent	  analysis	  of	  Ctsh	  -­‐/-­‐	  and	  Ctsh	  +/-­‐	  mouse	  epidermis,	  and	  cornified	  envelope	  analysis	  .......................................................................................................	  74	  
2.7 Haematoxylin and Eosin (H&E) staining ......................................................... 74 
	  	   9	  
2.8 Gene expression analysis .................................................................................... 74 2.8.1	  RNA	  extractions	  ..............................................................................................................................	  74	  2.8.2	  cDNA	  synthesis	  and	  PCR	  .............................................................................................................	  75	  
2.9 Microarray analysis and IPA analysis .............................................................. 77 
2.10 Mass spectrometry ............................................................................................ 77 
2.11 Statistics ............................................................................................................. 78 
 : Akt1 controls key processes in epidermal terminal differentiation and Chapter 3
cornified envelope formation ....................................................................... 79 
3.1 Introduction ......................................................................................................... 79 
3.2 Results .................................................................................................................. 81 3.2.1	  	  Post	  confluent	  REKs	  mimic	  terminally	  differentiating	  cells	  in	  granular	  and	  transitional	  layer	  ............................................................................................................................	  81	  3.2.2	  Filaggrin	  processing	  is	  Akt	  dependent	  and	  the	  Akt1	  shRNA	  REK	  organotypic	  model	  phenocopies	  AD	  skin	  ......................................................................................................	  83	  3.2.3	  Akt	  inhibition	  reduced	  filaggrin	  and	  pSerHspB1	  co-­‐localisation	  ..............................	  87	  3.2.4	  Increased	  HspB1-­‐Actin	  interaction	  in	  Akt1	  shRNA	  cells	  ..............................................	  90	  
3.3 Discussion ............................................................................................................. 93 
 : Cathepsin H, an Akt1 dependent epidermal protease in profilaggrin Chapter 4
processing, is reduced in eczema ................................................................. 95 
4.1 Introduction ......................................................................................................... 95 
4.2 Results .................................................................................................................. 96 4.2.1	  Ctsh	  is	  down	  regulated	  in	  Akt1	  knock	  down	  REKs	  (microarray	  data)	  ...................	  96	  4.2.2	  Cathepsin	  H,	  a	  novel	  epidermal	  protease	  that	  co	  localizes	  with	  filaggrin	  ..........	  101	  4.2.3	  Aberrant	  profilaggrin	  processing	  and	  hyperkeratosis	  observed	  in	  both	  Ctsh	  +/−	  and	  Ctsh	  −/−	  mice.	  ............................................................................................................................	  107	  4.2.4	  Granular	  layer	  Akt	  phosphorylation	  and	  Ctsh	  reduced	  in	  AD	  non-­‐affected	  skin	  .............................................................................................................................................................	  110	  4.2.5	  Increased	  RAPTOR	  leads	  to	  decreased	  filaggrin	  expression	  ....................................	  113	  
4.3 Discussion ........................................................................................................ 120 
 : Reduced Akt activity alters Lamin A/C degradation resulting in skin Chapter 5
barrier abnormalities ................................................................................. 124 
5.1 Introduction ....................................................................................................... 124 
5.2 Results ................................................................................................................ 126 5.2.1	  Parakeratosis	  is	  observed	  in	  AD	  uninvolved	  skin	  and	  the	  Akt-­‐1	  shRNA	  organotypic	  culture	  model	  .....................................................................................................	  126	  
	  	   10	  
5.3.2	  Increased	  Lamin	  A/C	  expression	  in	  Akt-­‐1	  siRNA	  expressing	  cells	  ........................	  128	  5.3.3	  Reduced	  Akt	  activity	  decreases	  Lamin	  A/C	  degradation	  and	  causes	  lamin	  A/C	  expression	  around	  retained	  nuclei	  in	  the	  cornified	  layer	  .........................................	  129	  5.3.4	  Reduced	  Akt-­‐1	  mediated	  Lamin	  phosphorylation,	  leads	  to	  a	  reduction	  in	  keratinocyte	  terminal	  differentiation	  markers.	  ............................................................	  135	  
5.4 Discussion ........................................................................................................... 138 
 : General discussion .................................................................................. 143 Chapter 6
6.1 Akt1 is activity required for filaggrin processing and the normal 
cornification process ............................................................................................... 143 
6.2 Granular layer pSer473Akt and cathepsin H, an Akt1 dependent epidermal 
protease in profilaggrin processing, is reduced in eczema .................................. 145 
6.3 Reduced Akt activity alters Lamin A/C degradation resulting in skin barrier 
abnormalities ........................................................................................................... 147 
6.4 Increased RAPTOR leads to decreased filaggrin expression ........................ 149 
6.5 Final conclusions and future work .................................................................. 150 
 : References ................................................................................................ 153 Chapter 7
Publications .................................................................................................................. 188 
Appendix: Akt1 shRNA microarray data ................................................................. 189 
 
 
 
 
 
 
 
 
 	  	  	  	  
	  	   11	  
List of figures 	  	  
Figure 1.1 Schematic showing normal anatomy of human skin consisting of epidermis, 
dermis and hypodermis. .......................................................................................... 22	  
Figure 1.2 Illustration of the stratified epidermis. ........................................................... 23	  
Figure 1.3 Clinical presentation of AD ........................................................................... 28	  
Figure 1.4 Comparison between normal and AD. ........................................................... 29	  
Figure 1.5 Immunological changes in AD skin. ............................................................. 31	  
Figure 1.6 Schematic demonstrating the brick and mortar structure of the cornified 
layer. ........................................................................................................................ 34	  
Figure 1.7 Profilaggrin gene structure. ........................................................................... 41	  
Figure 1.8 Profilaggrin to filaggrin processing pathway. ............................................... 42	  
Figure 1.9 Structure of the profilaggrin showing both rare (black) and common (red) 
loss of function filaggrin mutations identified. ....................................................... 44	  
Figure 1.10 PI3 Kinase/Akt pathway. ............................................................................. 47	  
Figure 1.11 Modulation of Akt activity by mTORC1. .................................................... 50	  
Figure 1.12  Model describing established and possible downstream effects of Akt 
signaling pathway leading to barrier defects. .......................................................... 55	  
Figure 3.1 Post confluent REKs mimic terminally differentiating cells in stratum 
granulosum. ............................................................................................................. 82	  
Figure 3.2. Real Time PCR results of filaggrin mRNA expression levels in scram and 
both Akt1 shRNA expressing cell lines. ................................................................. 83	  
Figure 3.3. Reduced Akt phosphorylation is associated with decrease in filaggrin 
processing. ............................................................................................................... 84	  
Figure 3.4. Reduced Akt activity is associated with over all reduction in filaggrin 
processing in human keratinocytes. ........................................................................ 85	  
Figure 3.5. Akt1 shRNA REK model phenocopies AD skin. ......................................... 86	  
Figure 3.6. Reduced Akt activity reduced levels of pSerHspB1. .................................... 88	  
Figure 3.7. Akt inhibition reduced filaggrin and pSerHspB1 co localisation. ................ 89	  
Figure 3.8. Decreased HspB1-filaggrin and increased HspB1-Actin interaction in REKs 
with reduced Akt phosphorylation. ......................................................................... 91	  
Figure 3.9. Enhanced F-actin staining at the cell periphery in cells with reduced Akt 
phosphorylation. ...................................................................................................... 92	  
Figure 4.1  Cathepsin H is downregulated by 4 fold in Akt-1 knock down REKS. ....... 98	  
	  	   12	  
Figure 4.2 Canonical pathways and gene networks in Akt1 knock down cells. ............. 99	  
Figure 4.3 Two major networks based on 86 genes differentially regulated in Akt1 
knockdown cells. ................................................................................................... 100	  
Figure 4.4 Granular Ctsh expression peaks during barrier acquision. .......................... 102	  
Figure 4.5 Ctsh protein is detected only in differentiated cells and is reduced in Akt-1 
knockdown cells. ................................................................................................... 103	  
Figure 4.6 Ctsh co-localizes with filaggrin in the granular layer. ................................. 104	  
Figure 4.7  Ctsh over expression restores filaggrin protein levels in Akt-1 knock down 
REKs. .................................................................................................................... 106	  
Figure 4.8  Increased cornified envelope fragility in Ctsh+/- mice. ............................... 108	  
Figure 4.9 Hyperkeratosis observed in both Ctsh+/- and Ctsh-/- skin. ............................ 109	  
Figure 4.10 Significant reduction in both granular pSerAkt and filaggrin in AD non-
affected skin. ......................................................................................................... 111	  
Figure 4.11 CTSH expression reduced in AD non-affected skin. ................................. 112	  
Figure 4.12 Raptor increase causes dose dependent decrease in pSerAkt and filaggrin.
 ............................................................................................................................... 114	  
Figure 4.13 Rapamycin restores pSerAkt, Ctsh and filaggrin protein levels and 
processing in Raptor overexpressing cells. ........................................................... 115	  
Figure 4.14 Increase in granular RAPTOR expression correlates with decrease in 
filaggrin. ................................................................................................................ 117	  
Figure 4.15 Retinoic acid treatment reduces RAPTOR expression in keratinocytes. .. 118	  
Figure 4.16 Model of a possible mechanism of how retinoic acid treatment can increase 
both Ctsh and filaggrin expression, and restore barrier defects. ........................... 119	  
Figure 5.1 AD uninvolved skin is parakeratotic and displays reduced granular layer Akt 
phosphorlyation. .................................................................................................... 126	  
Figure 5.2 Parakeratosis in the Akt1 shRNA expressing culture model. ...................... 127	  
Figure 5.3 Coomassie stained gel showing the differentially expressed proteins in the 
Akt1 shRNA expressing cells at 60 – 80 kDa range. ............................................ 128	  
Figure 5.4 Lamin A/C expression is retained in the cornified layer and degradation was 
reduced when in Akt1 shRNA knockdown cultures ............................................. 131	  
Figure 5.5 Reduced Akt activity increases lamin A/C protein levels in loricrin positive 
keratinocytes. ........................................................................................................ 133	  
Figure 5.6 Granular nuclei volume significantly reduced in Akt1 shRNA expressing 
cells. ...................................................................................................................... 134	  
	  	   13	  
Figure 5.7 Reduced lamin A degradation associated with reduction in altered filaggrin 
processing and expression of other keratinocyte differentiation markers. ............ 136	  
Figure 5.8 Reduced lamin A/C phosphorylion decreases expression of keratinocyte 
differentiation markers. ......................................................................................... 137	  
Figure 6.1 Proposed mechanism of how retinoic acid treatment may lead to skin barrier 
restoration in AD ................................................................................................... 152	  
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
 	  	  	  	  	  
	  	   14	  
List of tables 
 
Table 1-1 Diagnostic criteria of AD................................................................................27 
Table 2-1 Reagents list....................................................................................................57 
Table 2-2 Media and stock solutions...............................................................................59 
Table 2-3 Primary and secondary antibodies..................................................................62 
Table 2-4 Recipe for 8% SDS-PAGE gel and loading buffer.........................................69 
Table 2-5 Recipe for blocking solution used in Western blot analysis...........................70 
Table 2-6 Recipe for fixative and blocking solution used in immunofluorescence 
analysis............................................................................................................................73 
Table 2-7 Master mix for cDNA synthesis and PCR......................................................76 
Table 2-8 PCR program...................................................................................................76 
Table 2-9 Quantitect primer assays.................................................................................76 
Table 5-1 Proteins identified by ESI QTOF MS/MS....................................................129 
 
 
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	   15	  
Abbreviations 	  
%   Percentage 
°C   Degrees centigrade 
      
aa    Amino acid 
AB   Antibiotic 
ACTB   β-Actin gene 
ACTL9   Actin like protein 9 
AD   Atopic dermatitis 
Akt   V-akt murine thymoma viral oncogene homolog 1 
AM   Antimycotic 
AMPs   Antimicrobial peptides 
ANOVA   Analysis of variance 
AP-1   Activator protein 1 
APS   Ammonium per sulphate 
ATRA   All trans retinoic acid 
au   Arbitrary units 
      
BCA   Bicinchoninic acit 
BMP   Bone morphogenic protein 
bp   Base pairs 
BSA   Bovine serum albumin 
      
CAD   Caspase-activated Dnase 
CD   Cluster of differentiation 
cDNA   Complimentary dioxyribonucleic acid 
cm   Centimetre 
Co-IP   Co-Immunoprecipitation 
CO2   Carbondioxide 
Conc.   Concentrated 
CTSH   Cathepsin H 
CuSO4   Copper Sulphate 
      
DAPI   4',6-diamidino-2-phenylindole  
DCs    Dendritic cells 
DED   De-epidermalised dermis 
dLNs   Draining lymph nodes 
DMEM   Dulbecco's Modified Eagle's Medium 
DMSO   Dimethyl sulfoxide 
DNA   Deoxyribonucleic acid 
DNase1L2   Dnase-1-Like-2 
      
ECL   Enhanced chemiluminescence 
EDC   Epidermal differentiation complex 
EDMD   Emery-Dreifuss muscular dystrophy 
EDTA   Ethylene-dinitrilo tetraacetic acid 
	  	   16	  
EGF   Epidermal growth factor 
ESI-QTOF    ElectroSpray Ionisation-Time-of-Flight 
      
F-actin   Filamentous actin 
FBS   Foetal bovine serum 
FLG   Filaggrin 
      
GAPDH   Glyceraldehyde 3-phosphate dehydrogenase 
GWAS   Genome wide association studies 
      
H&E   Haematoxylin & eosin 
HC   Hydrocortisone 
HCl   Hydrochloric acid 
HGPS   Hutchinson-Guilford Progeria Syndrome 
HPLC   High Performance Liquid Chromatography 
HRP   Hydrogen peroxide 
Hsp27   Heat shock protein 27 
HspB1   Heat shock protein beta-1 
      
IFN-Υ   Interferon-Υ 
Ig   Immunoglobin  
IL   Interleukin 
INM   Inner nuclear membrane 
Inv   Involucrin 
IPA   Ingenuity Pathway Analysis 
IRS-1   Insulin receptor substrate 1 
IV   Ichthyosis Vulgaris 
      
K1   Keratin 1 
K10   Keratin 10 
K14   Keratin 14 
K5   Keratin 5 
kDa   Kilo dalton 
      
L   Litre 
LCs   Langerhans cells 
LEKTI   Lymphoepithelial Kazal type related inhibitor 
LINC   Linker of nucleoskeleton cytoskeleton 
LMNA   Lamin gene 
Lor   Loricrin 
LXR   Liver X receptor 
      
ml   Milli litre 
mM   Milli molar 
MMPs   Metalloproteinases 
mRNA   messenger ribonucleic acid 
MS   Mass spectrometry 
mTORC   Mammalian target of rapamycin complex 
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NA   Numerical aperture 
Na-Citrate    Sodium Citrate 
NaCl   Sodium Hydroxide 
NF-AT   Nuclear-factor for activated T-cells 
NHEKs   Normal human epidermal keratinocytes 
nm   nanometer 
nM   nano molar 
NMF   Natural moisturising factor 
NS   Netherton Syndrome 
      
OVOL1   OVO homologue-like 1 
      
p   Probability 
PAGE   Polyacrylamide gel electrophoresis 
PAMPs   Pathogen associated molecular patterns 
PBS   Phosphatee-buffered saline  
PBST   Phosphatee-buffered saline tween-20 
PC   Proprotein convertase 
PCA   Pyrrolidone carboxylic acid 
PCR   Polymerase chain reaction 
PDK1   3-phosphoinositide-dependent protein kinase 1 
PEP1   Profilaggrin endopeptidase 1 
PH domain   Pleckstrin homology  domain 
PI3K   Phosphoinositide-3-kinase 
PIP2   Phosphatidylinositol-3, 4, 5-diphosphates 
PIP3   Phosphatidylinositol-3, 4, 5-triphosphates 
PLGS   ProteinLynx Global Server 
PMSF   Phenylmethanesulfonyl Fluoride solution  
PTEN   Phosphatase and tensin homolog 
      
RAPTOR   Regulatory associated protein of mTOR 
RAR   Retinoic acid receptor 
REK   Rat epidermal keratinocyte 
Rictor   Rapamycin insentitive companion of mTOR 
RIPA   Radioimmuno precipitation buffer 
RPTOR   Raptor gene 
RTK   Receptor tyrosine kinase 
RXR   Retinoid X receptor 
      
Ser473   Serine 473 
SCORAD   Scoring of Atopid Dermatitis 
SDS   Sodium dodecyl sulphate 
SEM   Standard error of mean 
Ser301   Serine 301 
Ser404   Serine 404 
shRNA   short hairpin ribonucleic acid 
	  	   18	  
SNPs   Single nucleotide polymorphism 
SP   Serine protease 
Sp-B   Surfactant protein B 
SPINK5   
SP inhibitor lymphoepithelial Kazal-type trypsin 
inhibitor 
      
T308   Threonine 308  
TBS   Tris-buffered saline 
TBST   Tris-buffered saline Tween-20 
TEMED   N,N,N’,N’-Tetramethylethylenediamine  
TEWL   Transepidermal water loss 
TGM1   Transglutaminase 1 
Th   T helper 
TLRs   Toll like receptors 
TNF   Trypsin Neutralizing Factor 
      
UCA   Urocanic acid 
UCL   University College London 
UV   Ultra violet 
      
V   Voltage 
v/v   volume by volume 
      
w/v   weight by volume 
      
µg   micro gram 
µl   micro litre 
µM   micro molar 
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 : Introduction Chapter 1
1.1 Skin: A protective barrier 
 
1.1.1 Overview of skin 	  
The skin is a vital organ of the human body consisting of organized and 
functionally distinct layers that form a tough and impermeable structure protecting the 
organism from the harsh environment (Fuchs & Raghavan, 2002). It is comprised of 
three layers, the epidermis, the dermis and the hypodermis. The epidermis, which is the 
outermost layer, mainly contributes to the physical barrier function. The dermis is 
predominantly composed of connective tissue matrix but also has specialized cells such 
as macrophages, mast cells, lymphocytes and fibroblasts. Finally the innermost layer, 
the hypodermis, which is attached to the dermis via collagen and elastin fibres, consists 
mainly of adipocytes acting as an energy reserve and heat insulator (Fig 1.1) (Fuchs, 
1990; Fuchs & Raghavan, 2002). Skin primarily acts as a protective barrier and apart 
from its function in maintaining its structural integrity, the skin also plays important 
roles in temperature regulation, protection from UV radiation and the innate immune 
system (Mack et al., 2005; Reichrath, 2006). Maintenance of epidermal homeostasis 
and morphogenesis is important, and any disruptions can result in skin disorders, 
therefore it is important to understand fully the intricate pathways involved for 
designing better therapeutic approaches. 
 
1.1.2 Structure and function of epidermis  
 
The epidermis is a self-renewing stratified squamous epithelium that is 
predominantly composed of keratinocytes although specialized cells such as Merkel 
cells, melanocytes and Langerhans cells contribute to a small percentage of the total 
epidermal cell population (reviewed in Arwert et al., 2012; Koster & Roop, 2007). The 
epidermis is organized into four histologically distinct layers, which are the basal, 
spinous, granular, and the outermost cornified layer (stratum corneum), each at a 
histologically defined point along a continuum of keratinocyte differentiation (Fig 1.2). 
The efficiency of barrier function of the epidermis relies on the proper execution of the 
keratinocyte terminal differentiation program (Kypriotou et al., 2012; Hedge & 
Raghavan, 2013). The process is initiated in the basal layer, which is the innermost 
layer of the epidermis and comprises of a single layer of mostly mitotically active cells, 
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which produce all the suprabasal cells in the epidermis. In the presence of the 
appropriate stimuli, basal cells proliferate and give rise to daughter cells that lose the 
integrin mediated contacts allowing them to detach from the basement membrane and 
migrate towards the spinuous layer (Hall & Watt, 1989; Watt, 2002; Fuchs, 2007). As 
the cells move into the spinous layer, they undergo mitotic arrest, stop expressing the 
basal keratins K5 and K14 and begin expression of early differentiation markers K1 and 
K10, the presence of which is considered the most dependable sign that the 
keratinocytes have committed to differentiation (Fig 1.2) (Fuchs and Green, 1980; 
Fuchs, 2007). At this stage cell-cell contacts mediated by adherens and desmosomal 
junctions are established (Owens et al., 2000). In the granular layer, named for the 
presence of the basophilic keratohyalin granules, the cornified envelope proteins such as 
loricrin and transglutaminases are expressed which are necessary for the formation of 
the main epidermal barrier structure, the cornified layer (Fuchs & Raghavan, 2002). 
Filaggrin, a filament aggregating protein, is expressed here in its precursor form, 
profilaggrin, which is the major component of the keratohyalin granules (Presland et al., 
1992). Filaggrin binds and collapses the keratin network in the upper granular layer 
promoting the formation of the flattened shape characteristic of the corneocyte (Mack et 
al., 1993; Presland et al., 2001; Kuechle et al., 2000). At the transitional stage, prior to 
cornified envelope formation, the nucleus and other cellular organelles get degraded, 
forming an enucleated corneocyte (Gan et al., 1990; Presland et al., 1992). This non-
viable cornified layer is made of a covalently crosslinked multiprotein complex of key 
structural proteins such as involucrin, loricrin and filaggrin, which are heavily cross-
linked by transglutaminases and surrounded by a lipid matrix providing an excellent 
barrier to the environment (Candi et al., 2005). The cornified layer is eventually shed in 
a process called desquamation. In humans the whole process, starting from the 
undifferentiated basal cell ending with the dead squame, takes approximately 14 days 
(Subramanyan, 2004) .  
 
1.1.3 Barrier function 
 
A vital function of the skin is to provide a competent barrier between the 
organism and the environment (Reviewed in Proksch et al., 2008). The skin structure 
has been likened to a system of bricks and mortar, with the multiprotein complex of the 
cornified keratinocyte designated as bricks and the intercellular lipid layer representing 
the mortar (Nemes and Steinert, 1999), where defects in either of these compartments 
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can compromise the barrier function of the skin (reviewed in Fuchs and Cleveland, 
1998; Jungersted et al., 2008). The heavily cross-linked cornified envelope proteins 
such as filaggrin, involucrin and loricrin contribute greatly to the integrity of the skin 
barrier whereas the lipid component along with epidermal tight junctions play important 
roles in regulating the skin permeability (Kypriotou et al., 2012; Lopez et al., 2007; 
Furuse et al., 2002). The lipids, mainly comprising of ceramides, cholesterol and fatty 
acids, are synthesized in the granular layer and temporarily stored in lamellar bodies 
(LB) (Feingold, 2007; Wertz et al., 1984). During cornification the contents of LB are 
released into extracellular space and incorporated into the stratum corneum (Elias et al., 
2014). Tight junctions in the granular layer help promote skin barrier by forming 
adhesion like contacts between cells allowing only selective passage of small molecules 
and preventing water loss (Kirshner et al., 2010; Furuse et al., 2002). Incorporated into 
the cornified layer are also specialized proteins such as plakin proteins and 
corneodesmosin, which strengthen adhesion in the stratum corneum (DiColandrea et al., 
2000; Lundstrom et al., 1994). 
 
1.1.4 Skin immune system 
 
As the outer most organ of the body with constant exposure to potential 
pathogens, the skin is required to also act as an immune protective organ, a role fulfilled 
by a thorough immune surveillance system coordinated by a network of epithelial and 
immune cells residing in the skin (Nestle et al., 2009). Importance of well-coordinated 
skin immune system towards maintaining epidermal homeostasis is demonstrated by the 
incidence of skin infections in immune compromised individuals and in inflammatory 
disorders such as psoriasis and atopic dermatitis (Bonness and Bieber, 2007; Lowes et 
al., 2007). The stratum corneum along with the tight junctions in the granular layer 
forms a formidable barrier against environmental insults (Candi et al., 2005), however 
to reinforce this defense both the epidermis and dermis are populated with immune cells 
that work in concert to detect and initiate immune responses that successfully repair any 
breach to the barrier (Nestle et al., 2009). Similar to cells of the immune system, 
keratinocytes also have an innate role in detecting pathogens by expressing germ line 
encoded pattern recognition receptors such as toll like receptors (TLRs) that recognise a 
wide range of pathogen components (Takeuchi et al., 2002; Martinon et al., 2009). 
Epidermal immune cells such as macrophages and epidermal dendritic cell (DC) 
populations called Langerhans cells (LCs) and inflammatory dendritic epidermal cells 
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(IDECs) play a central role in uptake of invading pathogens and presenting them to 
either Th1 or Th2 type cells (Nestle et al., 2009). They can migrate to draining lymph 
nodes (dLNs), present the pathogen to T cells activating adaptive immune responses. 
Many immune cells such as CD4+, natural killer T cells, mast cells and DCs are also 
found in the dermis where traversing blood and lymphatic vessels facilitate their access 
and exit from the skin (Nestle et al., 2009). Keratinocytes, LCs, dermal DCs and mast 
cells also release chemokines, cytokines and antimicrobial peptides (AMPs) that can 
also initiate an immune response (Murphy et al., 2000; Yang et al., 2001). 
 
 
 
 
 	  
Figure 1.1 Schematic showing normal anatomy of human skin consisting of epidermis, dermis and 
hypodermis. 
The outer layer epidermis is primarily composed of keratinocytes. The dermis is populated with various 
types of immune cells including neutrophils, mast cells and dermal dendritic cells. The hypodermis, 
mainly consists of adipocytes, is interspersed with blood and lymph vessels. 
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Figure 1.2 Illustration of the stratified epidermis. 
H&E stained human skin sample (Guttman-Yassky et al., 2010) accompanied with a schematic of the four 
layers of the epidermis, stratum basale, spinosum, granulosum and corneum. The basal layer rests on the 
basement membrane via attachments facilitated by integrin based junctions and expresses keratins 5 & 
14. Melanocytes are also visible in the basal layer. The early differentiation markers: Keratin 1 (K1), 
Keratin 10 (K10) and Involucrin (Inv) are expressed in the spinuous layer. The cornified envelope 
proteins, filaggrin (FLG) and loricrin (Lor) are expressed in the granular layer along with the 
crosslinking enzyme transglutaminase 1 (TGM 1). Filaggrin is found in the keratohyalin granules that 
are present in abundance in the granular layer. Tight junctions, desmosomes and adherens junctions 
assist in organizing the rigid structure of the epidermis. Skin resident immune cells such as Langerhans 
cells and T cells in the epidermis along with dendritic cells and mast cells in the dermis are part of the 
immune surveillance system in the skin. SC – Stratum corneum, SG – Stratum granulosum, SS – Stratum 
spinosum, SB – Stratum basale, D – Dermis. 
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1.2 Atopic Dermatitis 
 
1.2.1 Atopic dermatitis: An overview  
 
Atopic Dermatitis (AD) is a chronic inflammatory disease that affects up to 10-
20 % of children and 1-3 % of adults worldwide. The etiology of AD is complex, 
resulting from interactions between genetic factors, dysfunctional skin barrier, 
immunological responses and environmental triggers (Elias & Schmuth, 2009; Barnes, 
2009; Brandt & Sivaprasad, 2011). Despite the multifactorial nature of the disease, and 
varying clinical patterns with age, the common symptoms of AD are relapsing pruritus, 
chronic lesions, increased transepidermal water loss and lichenification (Leung and 
Bieber, 2003). AD is the first clinical manifestation in patients during the process of 
atopic march, a concept that characterizes subsequent progression from AD to other 
atopic disorders such as allergic rhinitis and asthma.  In fact, almost 70 % of patients 
with severe AD develop asthma (Spergel, 2010). An underlying atopy is considered 
important in linking these diseases where atopy is defined as a personal or familial 
inclination to produce elevated levels of IgE antibodies and sensitization to 
environmental allergens (Leung and Bieber, 2003).  
 
There is currently no cure for AD, and management of the disease is a clinical 
challenge due its complex pathophysiology and varying severity of clinical presentation 
(Simpson, 2010; Eichenfield et al., 2014). The current therapies that exist for AD 
involve anti-inflammatory drugs to target the inflammatory responses observed during 
the acute and chronic phase of disease, antibiotics to treat secondary skin infections and 
emollients to hydrate the skin and maintain skin barrier function (Elias et al., 2014; 
Boguniewicz & Leung, 2013). Understanding the mechanisms involved in causing 
barrier disruption in eczema may therefore lead to more targeted therapies for treating 
this disease. 
 
1.2.2 Epidemiology of AD 
 
Prevalence of AD has increased 2-3 fold in the past three decades, mostly in 
industrialized countries and has become a national health burden (Bieber, 2010; Asher 
et al., 2006). Studies have estimated that the annual cost of AD to the health services in 
the USA in 1993 was US $364 million (Lapidus et al., 1993). This study was only 
limited to children and excluding the costs to patient and family. Estimated annual cost 
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of AD to third parties in the United States from 1997 to 1998 ranged from US $0.9 
billion to US$ 3.8 billion (Ellis et al., 2002). In the UK, a community study of AD in 
Scotland estimated annual cost of £465 million (Herd et al., 1996). Another UK study 
reported the annual cost owing to AD in children between the ages of 1 to 5 estimated to 
be £47 million in 1995 to 1996 (Emerson et al., 2001). In Canada, the total cost of AD 
was estimated to be Cdn $1.4 billion annually. Apart from financial burden, the disease 
can have a major impact on other aspects of life. Surveys have indicated that almost 60 
% of AD patients have reported that the disease impaired the performance of their daily 
activities such as school performance, sports, leisure and social activities (Paller et al., 
2002). AD prevalence varies extensively between countries from around 20 % in 
industrialised countries such as Australia, New Zealand, Urban Africa, England and 
Scandinavia to less than 5 % in regions such as China, Eastern Europe, rural Africa and 
central Asia (Leung and Bieber, 2003). Lifestyle and environment play a major part in 
the development of AD, in fact higher prevalences have been recorded in urban regions 
and in higher socioeconomic groups (Leung and Bieber, 2003; Bieber, 2010). AD 
usually emerges for the first time during early infancy, with 45 % of cases appearing 
during first 6 months of life and 85 % being showing symptoms before the age of 5. 
Though eczematous lesions often appear during early infancy, it may persist into or in 
some cases even start in adulthood (Leung and Bieber 2003). 
 
1.2.3 Clinical manifestations and diagnosis of AD 
 
AD typically occurs as a relapsing condition where the patients may experience 
periods of remission and exacerbations. The disease presents a diverse clinical spectrum 
ranging from pityriasis alba (dry depigmented patches) to severe eczematous lesions 
and excoriations (skin abrasions caused by repetitive scratching) (Leung and Bieber. 
2003). The most common symptoms are pruritus (itching) and xerosis (dry skin).  AD 
can occur in three age related stages that may be separated by periods of remission (Fig 
1.3). During infancy (under the age of 2 years) the affected areas include the cheeks, 
neck, groin and extensor part of arms and legs. These affected areas display a more 
acute stage of AD and consist of highly pruritic, dry and scaly patches that can 
sometimes ooze and weep fluid. During childhood, (between age of 2 and 12 years), the 
most affected areas are usually the flexural areas especially in antecubital (creases of 
elbow) and popliteal fossae (back of the knee), with rashes also appearing in other areas 
such as ankles, wrists and necks (Rudikoff and Lebwohl, 1998). During this stage, 
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chronic lesions are observed characterized by thickened plaques that show 
lichenification caused by repeated scratching of skin. The lesions can also display 
papules (small pimple or swelling of the skin) and excoriation. It is rare for adults to get 
AD and when they do, symptoms are different from those in childhood AD. The lesions 
are more diffuse with prominent xerosis and underlying erythema (Banfield et al., 
2001). Amongst affected areas, facial involvement is common with possible 
lichenification present in flexural areas (Rudikoff and Lebwohl, 1998). Using the 
diagnostic criteria set down by Hanifin and Rajka as a basis, the clinical features listed 
in table 1-1 are often used as a criterion for a diagnosis of AD (Table 1-1). The most 
widely used method for diagnosing the severity of AD is the SCORAD (SCORing of 
Atopic Dermatitis) system. SCORAD is a clinical tool that assesses the extent and 
intensity of AD, which comprises scoring the affected areas as a percentage of whole 
body, and also assigning a representative area a score based on the clinical signs of the 
disease including itch and sleep loss (Oranje et al., 2007).  
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Table 1-1 Diagnostic criteria of AD  
	  
Table based on Eichenfield et al., 2014 and Yazganoglu & Ozkaya, 2011 
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Figure 1.3 Clinical presentation of AD 
(A) Typical facial eczematous rash on a child. (B) Lesions on the back of the knee appears lichenified and 
hyperpigmented. (C) Face and neck affected on an adult. (D) Hand eczema on an adult (Images adapted 
from http://www.aad.org/dermatology-a-to-z/diseases-and-treatments/a---d/atopic-dermatitis/signs-
symptoms). 
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1.2.4 Pathophysiology of AD 
 
Even clinically unaffected skin of AD patients tends to be dry with terminal 
differentiation defects and some immune abnormalities (Suarez et al., 2011). The 
natural course of AD flares follows both an acute and chronic phase each with differing 
histologies and immunological processes (Allam & Novak, 2005). Acute skin lesions 
are characterized by marked intercellular oedema in the epidermis (spongiosis) and 
large number of antigen presenting cells such as Langerhans cells, inflammatory 
dendritic epidermal cells and macrophages binding IgE molecules on their surface. 
Marked dermal infiltration of CD4 activated T cells are also observed in acute lesions. 
Chronic lichenified lesions display thickening of the stratum corneum (hyperkeratosis), 
retention of nuclei in stratum corneum (parakeratosis) and thickening of the stratum 
basale and spinosum (acanthosis) and elongated rete ridges (reviewed in Leung et al., 
2013; Allam & Novak, 2005). Figure 1.4 demonstrates the common histological 
changes observed in AD skin. Increased numbers of IgE bearing antigen presenting 
cells are also observed in chronic lesions with majority of dermal infiltrate comprising 
of macrophages (Tanei et al., 2013). Additionally chronic lesions also contain 
eosinophils, a hallmark of end stage inflammatory response during allergic reactions. 
Eosinophils are thought to contribute to chronic inflammation by producing 
proinflammatory cytokines and eosinophilic toxic granule proteins that can cause tissue 
damage (Reviewed in Eyerich & Novak, 2013; Leung et al., 2013). 
 
 
Figure 1.4 Comparison between normal and AD.  
The epidermis in individuals with AD have a thickened cornified layer characteristic of AD (black arrow 
head, middle panel). Parakeratosis (retained nuclei in the cornified layer) is another feature sometimes 
observed in AD (white arrow heads, last panel) (adapted from Guttman-Yassky et al., 2011 ; Nakamura 
et al., 2011). 
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1.2.5 Immunological abnormalities in AD 
 
AD has a strong immune component with perturbations to both innate and 
adaptive immune system. AD patients display a tendency to have frequent bacterial and 
viral skin infections, hyper reactivity to environmental elements and predisposition to 
IgE-mediated sensitization (Fig 1.5) (Eyerich & Novak, 2013). AMPs such as B-
defensins produced by keratinocytes that have high antibiotic properties are reduced in 
AD patients. The skin of these patients is often prone to skin infections with over 90 % 
of patients affected by Staphylococcus aureus, a phenomenon that is attributed to 
reduced levels of B-defensins in the skin (Leung & Bieber, 2003). Most AD patients 
have elevated serum IgE levels and increased peripheral blood eosinophil count. These 
patients display a predominant Th2 immune response with increased frequency of 
allergen specific T cells producing the interleukins 4 (IL-4), 5 (IL-5) and 13 (IL-13) and 
decreased levels of interferon-γ (IFN-γ) in peripheral blood (Eyerich et al., 2011; 
Eyerich & Novak, 2013). A wide range of allergens have been implicated in causing 
immune activation via a Th2 dominant mechanism in AD such as toxins produced by 
skin staphylococci and house-dust mites (Cardona et al., 2006; Leung and Bieber, 
2003). This increases the frequency of IgE receptor bearing antigen-presenting cells 
(APCs) in eczematous lesions that play a key role in allergen presentation to T-cells 
residing in atopic skin. IgE bearing Langerhans cells can also migrate to lymph nodes 
where naïve T cells are stimulated contributing to Th2 cell pool expansion (Eyerich and 
Novak, 2013). Moreover, IL-4 and IL-13 can reduce expression of some important 
stratum corneum proteins such as filaggrin further aggravating the barrier function 
(Hanel et al., 2013). Persistent inflammation observed in chronic lesions may be 
mediated by IL-5 and granulocyte-macrophage colony-stimulating factor (GM-CSF) 
that prolongs the survival of eosinophils, and other factors that contribute to 
inflammations such as Langerhans cells and macrophages (Pastore et al., 1997; Van 
Reijsen et al., 1992). Acute eczematous lesions contain mostly Th1 type cytokine 
activity with increased levels of interleukins 4, 5 and 13, while mainly Th2 type cells 
such as IL-12 and IFN-γ are observed in chronic lesions. IFN-γ is a key cytokine 
involved in the induction of T cell mediated apoptosis in eczematous lesions 
contributing to the observed spongiotic process in acute lesions (Allam et al., 2005). 
The switch from Th2 to Th1 type response is thought to be mediated by production of 
IL-12 from either infiltrating eosinophils or dendritic cells in the epidermis or both 
(Leung et al., 2004).  
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Figure 1.5 Immunological changes in AD skin. 
Defective barrier can allow penetration of allergens and pathogens to trigger release of proinflammatory 
factors that can elicit immune responses. Scratching can damage cells and amplify inflammatory reaction 
in the skin. Pathogen associated molecular patterns (PAMPs) which include flagellin, peptidoglycan and 
nucleic acids are recognized by TLRs expressed on keratinocytes and other skin immune cells triggering 
the release of chemokines, antimicrobial peptides (AMPs) and cytokines which in turn can perpetuate 
inflammatory responses.  Langerhans cells, which are key immunological sentinels in the epidermis, can 
take up and present the allergen to skin resident T cells activating Th2 responses. SC – Stratum corneum, 
SG – Stratum granulosum, SS – Stratum spinosum, SB – Stratum basale, D - Dermis 
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1.2.6 Barrier defect in AD 	  
 Even though abnormalities in the immune system have been strongly attributed 
to development of AD, the skin barrier defect is a key component in this disease and is 
in fact thought to be the primary cause in initiating and driving the pathogenesis of AD 
in the majority of AD cases therefore suggesting the observed inflammation is 
secondary to this inherent barrier defect (Callard and Harper, 2007; Jakasa et al., 2006). 
Even clinically unaffected AD skin that is devoid of inflammation is dry with increased 
sensitization to allergens hence supporting the theory of an inherent barrier defect in AD 
that is susceptible for cutaneous inflammation (Suarez et al., 2011; Leung et al., 2013). 
The epidermis primarily functions as a physical barrier to the external environment, and 
a skin barrier defect will therefore promote water loss and permit pathogens, toxins, and 
other environmental allergens to penetrate the skin layers and elicit an immune response 
(Fig 1.6) (reviewed in Candi et al., 2005). Several factors such as altered expression of 
filaggrin, reduced lipid component (ceramide and sphingosine) and disrupted cell-to-
cell junctions have been identified as being altered in AD skin and linked to 
contributing to barrier defect (Bieber, 2008).  
The strongest evidence for an impaired epidermal barrier being the primary 
cause for AD comes from the strong link between loss of function mutations in the gene 
encoding the key epidermal protein filaggrin (FLG) and AD (Baurecht et al., 2007). 
Filaggrin is an integral component of the epidermis and has pivotal roles in barrier 
function by contributing to the structural integrity and hydration of the stratum corneum 
(Presland et al., 2001). Those homozygous for FLG mutations lack a functional copy of 
FLG, and display dry skin and increased predisposition for AD (Fallon et al., 2009; 
Bisgaard et al., 2008). The functional roles of filaggrin will be covered in more depth in 
section 1.3. There is evidence however that barrier dysfunction can occur independently 
from the FLG genotype suggesting the existence of other factors impairing epidermal 
barrier function (Thawer-Esmail et al., 2014). Amongst these is increased epidermal 
serine protease activity that has been identified in AD leading to stratum corneum 
abnormalities (Walley et al., 2001). Epidermal proteases and their inhibitors are 
important contributors to barrier function with roles in processing of key epidermal 
proteins, desquamation and epidermal permeability homeostasis (Ovaere et al., 2009).  
Serine protease (SP) hyperactivity is observed in AD with increased activity attributed 
due to both genetics and changes in skin pH. Serine proteases function optimally in 
neutral to alkaline range and AD skin has a generally higher pH level, which is 
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associated with high transepidermal water loss (TEWL) (Ovaere et al., 2009; Walley et 
al., 2001). Increase in SP activity can have detrimental effects on the barrier function as 
it can prematurely degrade corneodesmosomes and increase corneocyte desquamation 
(Hachem et al., 2006). Excessive SP activity can also lead to disruption of lipid 
synthesis in epidermis leading to a decrease in stratum corneum lipid content, which is 
essential for epidermal permeability homeostasis (Hachem et al., 2006). Finally, serine 
protease hyperactivity can lead to an increase in Th2 inflammation and research has 
shown introduction of serine protease inhibitor during sensitization has a dampening 
effect on allergic inflammation (reviewed in Levin et al., 2013).   
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Figure 1.6 Schematic demonstrating the brick and mortar structure of the cornified layer.  
Barrier defects effectively loosen this structure allowing increased water loss, entry of environmental 
pathogens and allergens.  	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1.2.7 Genetics of AD 
 
Epidemiological research has revealed a strong genetic component to AD 
(Schultz, 1993; Cork et al., 2006). Twin studies of AD have shown higher concordance 
rates in monozygotic twins (0.72 – 0.86) than dizygotic twin pairs (0.21 – 0.23) 
indicating there is a strong genetic influence in the development of AD (Larsen et al., 
1986; Bowcock and Cookson, 2004; Schultz Larsen, 1993). Additionally incidence rate 
of AD in children is doubled if one parent has AD and tripled if AD is present in both 
parents (Bieber, 2010). Various Genome wide association studies (GWAS) have 
revealed genes associated with AD with linkage detected on chromosomes 1, 3 4, 5, 11, 
13, 15, 17, 18, 19 and 20, with FLG (filaggrin) at 1q21 being the most highly replicated 
risk locus among these studies (Barnes, 2010). Genetic linkage to the loci 1q21 was 
interesting as this region contains the Epidermal Differentiation Complex (EDC) 
comprising of genes encoding filaggrin and other structural proteins involved in 
keratinocyte terminal differentiation (Cookson, 2001). Null mutations in FLG are 
associated with the inherited eczematous disease and ichthyosis vulgaris (Presland et 
al., 2000; Palmer et al., 2006). In fact, presence of FLG mutations leads to more severe 
and early onset AD (Bieber, 2010). A recent GWAS study identified two new risk loci 
in chromosome 11 upstream of transcription factor OVO homologue-like 1 (OVOL1) 
and in chromosome 19 near actin like protein 9 (ACTL9), both genes implicated in 
keratinocyte proliferation and differentiation hence emphasizing the importance of skin 
barrier function abnormalities in AD development (Paternoster et al., 2012). Immune 
responsive genes including IL-5, IL-13, IL18, CD14, toll like receptor 2 (TLR2) and 
those involved in cell signaling such as CSF2 (colony-stimulating factor 2) are also 
associated with AD (Barnes, 2010). An association was also seen between AD and 
SPINK5 encoding the protein lymphoepithelial Kazal type related inhibitor (LEKTI), a 
serine protease inhibitor which in skin is expressed within the granular layer (Hachem et 
al., 2006; Barnes, 2010). Mutations in SPINK5 lead to uncontrolled protease activity 
and underlie the disease Netherton Syndrome (NS), which is a compelling case for 
excessive serine protease activity leading to skin barrier dysfunction. NS patients 
display increased filaggrin processing and increased desquamation and frequently 
develop atopic manifestations including AD (Hachem et al., 2006).  
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1.2.8 Current treatments of AD 
 
Currently there is no cure for AD probably because it is a heterogeneous disease. 
The existing treatments are targeted to suppress and relieve symptoms of the disease. 
The patients are advised to apply emollients to keep the skin hydrated and smooth 
(Loden, 2003). For mild to moderate AD, first-line treatments are usually topical 
steroids of different strengths as they have been effective at reducing inflammation 
(Novak and Simon, 2011). Short courses of oral steroids are sometimes given in cases 
of severe flares. However, as steroid treatments can have side effects, the patient is 
generally kept under review by a dermatologist (Hata et al., 2008). Since skin infections 
are quite common in AD skin, both oral and topical antibiotics are frequently prescribed 
to treat these secondary infections (Novak and Simon, 2011). In situations where the 
patients are non-responsive to steroid treatment, immunomodulators such as tacrolimus 
and pimecrolimus, which are calcineurin inhibitors, can be used (Buchau et al., 2008). 
Calcineurin is an enzyme that dephosphorylates and activates nuclear-factor for 
activated T-cells (NF-AT), which regulates the transcription and proliferations of both 
Th1 and Th2 type cells. The immunomodulators can block transcription and 
proliferation of T cells and also downregulate T cell mediated apoptosis in AD. 
Tacrolimus can also reduce T cell proliferation caused by superantigens released by S. 
aureus (reviewed in Novak et al., 2005). Phototherapy or ultra violet (UV) treatment 
can also be used but is usually reserved for severe forms of AD as it is expensive and 
can have side effects (Novak and Simon, 2011).  
 
 Since filaggrin is a key component of epidermal barrier function, and its 
expression is commonly found down-regulated in AD skin (reviewed in Irvine & 
McLean, 2006), filaggrin replacement therapies offer wide potential in treatment of 
barrier compromised disorders such as AD. Recently, Stout et al demonstrated that by 
introducing a monomeric filaggrin subunit linked to a cell-penetrating peptide into 
FLG- deficient flaky tail mouse, the phenotype can be rescued (Stout et al., 2014). 
Although the results are promising, the introduced filaggrin peptide was detected in all 
layers of the epidermis including the basal layer, therefore more work is required to 
evaluate the consequence of filaggrin expression in these areas (Stout et al., 2014). The 
chronic relapsing nature of AD can make the disease costly, not just financially but also 
in terms of the psychological and emotional impact as it can greatly affect relationships, 
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social activities and quality of life in general (Carroll et al., 2005). Hence there is a need 
for better therapeutic approaches to treat this disease. 
 
1.3 Filaggrin  	  
1.3.1 Profilaggrin structure and function 
 
Filaggrin is expressed as the precursor protein profilaggrin, in the terminally 
differentiating keratinocytes within the granular layer and is the main constituent of the 
keratohyalin granules (Presland et al., 1992). The human profilaggrin is encoded by the 
FLG gene, which belongs to the S100 ‘fused’ type family of gene cluster located within 
the epidermal differentiation complex (EDC) at 1q21 that also includes other 
keratinocyte differentiation related genes such as trichohyalin, hornerin and repetin. 
Also located in the EDC is filaggrin-2 that has strong homology to both hornerin and 
filaggrin (Fig 1.7A) (Presland et el., 1992; Markova et al., 1993).  The FLG gene 
consists of three exons and two introns, where exon 1 is non coding and protein 
translation is initiated with exon 2, with exon 3 encoding almost the whole profilaggrin 
protein (Fig 1.7B) (Presland et al., 1992). Profilaggrin is a ∼400 kDa histidine-rich 
highly phosphorylated insoluble precursor which consists of 10 to 12 filaggrin repeats 
separated by small linker peptides flanked on each side with partial filaggrin repeats, a 
S100-type calcium binding domain, a unique C-terminal domain and an N-terminal 
domain containing the highly conserved A domain and slightly less conserved B 
domain (Presland et al., 1992; Gan et al., 1990). The B domain contains a bipartite 
nuclear localization sequence that is conserved between human, mouse and rat. In 
humans the filaggrin subunits are identical in size (324 aa) with some sequence 
similarity, whereas in mice and rats the repeats show greater than 90% amino acid 
sequence identity (Resing et al., 1993). 
 
1.3.2 Profilaggrin-filaggrin processing pathway 
 
Filaggrin is a highly cationic protein whose particular charge distribution is vital 
for its primary function, which is to aggregate and collapse the keratin filament network 
of the cell, leading to nuclear degradation and formation of the cornified layer (Presland 
et al., 1992). Profilaggrin mRNA is initially detected in the granular layer, and once 
transcribed, the profilaggrin gets highly phosphorylated, a process that is thought to 
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inhibit keratin association prematurely, as only dephosphorylated filaggrin monomers 
can aggregate keratins (Lonsdale-Eccles et al., 1982). It is predicted that conformational 
changes induced by phosphorylation might block access to proteolytic activity (Resing 
et al., 1993). Hence both transcription and processing of filaggrin molecules is 
presumably a tightly controlled process to prevent improper keratinocyte differentiation. 
The importance of correct filaggrin expression and processing is demonstrated by 
pathological conditions such as Ichthyosis Vulgaris (Fleckman and Brumbaugh, 2002) 
and Netherton Syndrome (Hewet et al., 2005) where lack of functional filaggrin or 
excessive filaggrin processing respectively leads to skin barrier defects.  
 
Profilaggrin processing occurs in the upper granular layer in keratinocytes, 
where it undergoes numerous dephosphorylation and proteolytic events with several 
proteases implicated in the process (Fig 1.8) (Pearton et al., 2002). Dephosphorylation 
is thought to require more than one phosphatase with studies showing involvement of 
acid phosphatases and a PP2A-type enzyme (Kam et al., 1993). Since filaggrin 
intermediates lack detectable phosphorylated residues it is thought most 
dephosphorylation occurs prior to processing of profilaggrin  (Harding and Scott, 1983). 
Proprotein convertase  (PC) cleavage sites are located at the N termini of profilaggrin, 
where PC family members’ furin and PACE 4 (a subtilisin-like endoprotease) have been 
shown in vitro to process and release the N-terminus of profilaggrin (Pearton et al., 
2001). The cleaved N-terminus containing the sub domains A and B, relocates to the 
nucleus facilitated by a bipartite nuclear localization sequence where it is thought to 
play a role in nuclear degradation as the N terminal domain was detected in the nuclei 
of transitioning cells where DNA has started to fragment, a feature characteristic of 
cells undergoing apoptosis (Pearton et al., 2002; Ischida-Yamamoto et al., 1998). The 
precise function of the C terminal is unclear but it is somehow involved in profilaggrin 
processing as individuals carrying a mutations resulting in truncated filaggrin repeats 
without the C terminal domain are unable to process profilaggrin to filaggrin monomers 
(Presland et al., 2000; Sandilands et al., 2007). Calpain 1 and the serine protease termed 
profilaggrin endopeptidase 1 (PEP1) have been implicated in processing of small 
peptide linker regions between the filaggrin monomer units to subsequently release the 
functional filaggrin monomer subunit (Yamazaki et al., 1997; Resting et al., 1995). In 
mice, the filaggrin monomers are joined by two different types of linker peptides 
differing by either the addition or omission of a FYPV motif. The linker containing the 
FYPV motif is processed first leading to a transient accumulation of filaggrin 
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intermediate species. A second processing step yields the single 37 kDa filaggrin 
monomer units (Resting et al., 1989). In humans the linker peptide sequences are 
identical (Gan et al., 1990).  
 
Several other proteases have been identified via mouse knockout experiments as 
being involved in profilaggrin processing. In vivo studies have demonstrated mice 
deficient for Matriptase/MT-SP1, a type II transmembrane serine protease, have 
impaired profilaggrin to filaggrin processing and barrier dysfunction (List et al., 2003). 
Knockout mice of the serine protease prostasin CAP1/Prss8 also display defects in 
filaggrin processing and barrier defects (Leyvraz et al., 2005). The Spink5-deficient 
homozygous mouse displays contrasting effects with accelerated profilaggrin 
processing, hence implying involvement of the inhibitor LEKTI in regulating the 
proteases that process profilaggrin (Hewet et al., 2005). Altered profilaggrin processing 
is also observed in 12R-lipoxygenase (12R-Lox) deficient mice. 12R-lox, transcribed by 
the gene Alox12B, is an epidermal deoxygenase of fatty acid substrates where 
deficiency in the enzyme alters profilaggrin processing leading to accumulation of 
filaggrin intermediates and total absence of filaggrin monomers (Epp et al., 2007). 
Although the exact mechanism is not clear, it is possible 12R lox deficiency may 
interfere with membrane bound or sequestering of proteases involved in end stages of 
profilaggrin processing. During final stages of terminal differentiation the filaggrin 
monomers are further processed into amino acids and their derivatives. Similar to other 
epidermal proteins such as keratin 1 and trichohyalin, filaggrin undergoes deamination 
where arginine is converted to citrulline residues. Deamination neutralizes the charge on 
filaggrin which is found to correlate with disruption of filaggrin-keratin complex 
(Tarcsa et al., 1996; Ishida-Yamamoto et al., 2002). Filaggrin is further broken to 
smaller sized fragments (approx. 12-15 kDa) by the enzymes caspase 14, calpain 1, and 
further degraded by bleomycin hydrolase to generate free amino acids and derivatives 
such as pyrrolidone carboxylic acid (PCA) (Denecker et al., 2007; Kamata et al., 2009). 
PCA is a major contributor to production of natural moisturing factors (NMFs), which 
are essential for keeping the stratum corneum hydrated. Another derivative of filaggrin 
break down products is trans- urocanic acid (UCA), which is converted to cis-UCA by 
UVB radiation and mediate UVB- induced immunosuppression (Fig 1.8) (Walterscheid 
et al., 2006). In fact Caspase-14 knockout mice display reduced skin hydration, 
increased transepidermal water loss and sensitivity to UVB radiation (Denecker et al., 
2007). Hence this indicates that filaggrin is an integral part of skin barrier function by 
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maintaining stratum corneum integrity and hydration. In addition to hydration, NMFs 
also maintain optimum acidic pH and buffering capacity in the stratum corneum, and 
decrease bacterial colonization in the skin (Levin et al., 2013; Miajlovic et al., 2010).  
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Figure 1.7 Profilaggrin gene structure. 
(A) Schematic of the expanded EDC complex at 1q21 shows location of filaggrin at this loci (adapted 
from Strong et al., 2010). (B) The Profilaggrin protein is mostly encoded by exon 3 and has 10-12 
filaggrin repeats flanked on each side by partial filaggrin repeat sequence, a C terminal domain and an 
N terminal domain comprised of two sub domains A and B.  
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Figure 1.8 Profilaggrin to filaggrin processing pathway. 
Profilaggrin is located in the keratohyalin granules in the granular layer, where increase in Ca2+ 
concentration promotes dephosphorylation and proteolysis by several proteases to release the monomeric 
filaggrin units. N terminal domains A and B relocate to the nucleus. Filaggrin monomers bind to and 
collapse the keratin filaments during the cornified envelope formation. Caspase 14, calpain and 
bleomycin hydrolase degrade filaggrin into free amino acids and the amino acid derivatives UCA and 
PCA leading to hydration of the cornified layer and protection from UV radiation. 
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1.3.3 Filaggrin and AD 
 
Filaggrin deficiency has been attributed to both nonsense and frameshift FLG mutations 
resulting in mostly truncated profilaggrin or non-functional filaggrin monomers 
(Sandilands et al., 2009). More than 20 different mutations in different AD populations 
have been identified, however with a combined allele frequency of 18 % to 48 % for 
mutations R501X and 2282del14, these two null mutations represent the strongest risk 
factors for AD (Fig 1.9) (Sandilands et al., 2009). It is estimated that in AD patients 
with moderate to severe forms of the disease, 50% can be attributed to filaggrin changes 
(McAleer et al., 2013). Additionally AD patients with filaggrin involvement have 
higher incidence of skin infections (McAleer et al., 2013). It is clear AD can occur 
independently of FLG mutation as not all individuals with filaggrin null mutations 
develop AD, and there are AD patients with reduced filaggrin in absence of FLG 
mutations (O’Regan et al., 2008; Thawer-Esmail et al., 2014). In fact in a recent study 
conducted in African AD population, a significant reduction of 20 % in filaggrin 
degradation products PCA and UCA were observed with FLG genotype not making a 
significant contribution, hence implying a defect in the filaggrin processing (Thawer-
Esmail et al., 2014). Since PCA and UCA are reduced by 50 % in those carrying 
filaggrin mutations, it is likely a profilaggrin processing defect gives rise to a milder 
phenotype (Kezic et al., 2011). It is therefore possible that abnormalities in pathways 
involved in the processing of profilaggrin can give rise to reduced filaggrin and 
subsequent barrier defects. 
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Figure 1.9 Structure of the profilaggrin showing both rare (black) and common (red) loss of function 
filaggrin mutations identified. 
Mutations listed here include those identified in European, European American, Chinese, Singaporean 
Chinese and Japanese populations. Adapted from Sandilands et al., 2009 and Brown et al., 2009. 	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1.4 PI3 Kinase/Akt signaling pathways 	  
1.4.1 Akt/PKB structure and activation mechanism 
 
Akt, also known as protein kinase B (PKB), is a serine threonine kinase that is 
involved in a diverse array of cellular functions such as cell cycle regulation, cellular 
survival, glucose metabolism, cell differentiation, cell growth and proliferation 
(reviewed in Manning and Cantley, 2007). Originally discovered as the human 
homologue of the viral oncogene v-Akt (Staal, 1987; Bellacosa et al., 1991), Akt has 
now emerged as a central signaling node in higher eukaryotes and a crucial protein 
kinase in human physiology and diseases including cancer, metabolic disorders and 
cardiovascular diseases (Bellacosa et al., 2005). Akt has a highly conserved general 
structure across a wide spectrum of species and has three isoforms (Akt1, Akt2 and 
Akt3) encoded by three separate genes, which once activated can phosphorylate 
numerous target proteins involved in regulation of processes such as cell growth, 
differentiation, proliferation, survival (Bellacosa et al., 1998). Akt1 is the most 
ubiquitously expressed isoform with Akt2 expressed at a lower level in comparison, 
while Akt3 is the least expressed in adult tissues with expression mostly confined to 
testes and brain (Hanada et al., 2004). Akt structure is composed of an N-terminal 
Pleckstrin Homology domain (PH) that mediates membrane recruitment, a catalytic 
domain and a hydrophobic domain that contains a T activation loop with a conserved 
threonine residue (T308) and serine residue (S473) (Hanada et al., 2004; Manning & 
Cantley, 2007).  
 
Akt is a key downstream effector of phosphoinositide-3-kinases (PI3K). Studies 
have shown that membrane recruitment via the PH domain and phosphorylation (Kohn 
et al., 1996) at the residues T308 and S473 is required for full Akt activity (Bellacosa et 
al., 2005). Akt is activated by several extracellular signals such as growth factors, 
cytokines and hormones binding to receptor tyrosine kinases (RTK) in the membrane 
that activate PI3 kinase. Once activated PI3 kinase phosphorylates phosphatidylinositol-
4,5-biphosphates (PIP2) to generate phosphatidylinositol-3,4,5-triphosphates (PIP3) 
which then binds to Akt via the PH domain and recruiting it to the cell membrane 
(Franke et al., 1997). PIP3 also recruits 3-phosphoinositide-dependent protein kinase 1 
(PDK1) to the membrane, which phosphorylates Akt at the site threonine 308 (T308) 
leading to partial activation of Akt. Full activation of Akt is only achieved when the 
serine 473 residue at the hydrophobic motif is phosphorylated by rictor-mTORC2  
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(mammalian target of rapamycin complex 2) (Sarbassov et al., 2005) leading to 
additional substrate specific phosphorylation events (Fig 1.10A) (Guertin et al., 2006). 
Following activation Akt may translocate to either the cytoplasm or nucleus where it 
exerts numerous substrate specific phosphorylation events such as inhibitory 
phosphorylation of pro-apoptotic FOXO proteins and activation mTORC1 pathway 
regulating protein synthesis and cell growth (Fig 1.10B) (Manning & Cantley, 2007). 
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Figure 1.10 PI3 Kinase/Akt pathway. 
(A) RTK receptor activates PI3 Kinase leading to generation of PIP3 which binds Akt and facilitates 
phosphorylation of Akt at T308 and S473 by PDK1 and mTORC2 respectively. (B) Activated Akt 
phosphorylates various downstream substrates resulting in increase of cell growth and cell survival 
pathways and decrease of apoptotic pathways.  
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1.4.2 Akt in cell differentiation 
 
 While Akt is most well-known for promoting cell survival and growth, it has 
also been implicated in controlling cell differentiation with roles in aspects of 
differentiation in different types of cells such as myocytes, osteocytes, neurons and 
adipocytes (Gardner et al., 2012; Mukherkee et al., 2010). Even though the different 
isoforms of Akt share their substrate repertoire, studies have shown that they sometimes 
display unique functions, which may be attributed partly to different cellular 
localization determining selective substrate accessibility to different isoforms 
(Grabinski et al. 2011). Mice deficient for Akt1 and Akt2 display a muscle deficiency 
phenotype (Peng et al., 2003). Akt1 is required for initial stages of muscle 
differentiation and Akt2 is not needed for differentiation but rather the maturation of 
myofibres (Gardner et al., 2012). Akt1 is essential for adipocyte differentiation (Xu et 
al., 2004) while Akt2 is required for initiation of osteoblast differentiation (Mukherjee 
et al., 2010). Sometimes Akt isoforms can compensate each other, like in the case of 
either Akt1 or Akt2 restoring myofiber development in myoblasts in the absence of 
Akt2 (Gardner et al., 2012). However this is not always the case, as Akt1 cannot make 
up for lack of Akt2 in osteoblast differentiation (Mukherjee et al., 2010).  
 
1.4.3 PI3 Kinase/Akt pathway in skin development 
 
Akt signaling is considered important for proper skin development in human 
with reports associating Akt with keratinocyte survival and differentiation (Calutti et 
al., 2005; Thrash et al., 2006; O’Shaughnessy et al., 2007). Increased expression of Akt 
in keratinocytes promotes growth arrest and differentiation while inhibition of Akt 
activity results in selected death of terminally differentiating keratinocytes suggesting 
that Akt protects the cells from possible apoptotic like events induced during terminal 
differentiation (Calautti et al., 2005). Both Akt1 and Akt2 activity has been detected in 
human keratinocytes, with Akt3 activity reported at significantly low levels (Calautti et 
al., 2005; O'Shaughnessy et al., 2007). Akt1 and Akt2 deficient mice display impaired 
skin development with reduced filaggrin expression while those doubly null for both 
isoforms lack stratum corneum and die shortly after birth (O’Shaughnessy et al., 2007; 
Peng et al., 2003). However Akt1 is the predominant Akt activity detected in the upper 
epidermis during the barrier acquisition stage of keratinocyte differentiation and 
targeted knock down of Akt1 leads to impaired epidermal barrier (O’Shaughnessy et al., 
2007; Thrash et al., 2006). Furthermore sonication experiments on isolated cornified 
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envelopes demonstrated that Akt1 null mouse cornified envelopes displayed 
significantly more fragility than the wild type (O’Shaughnessy et al., 2007). Taken 
together these findings suggest that Akt1 plays a key role in keratinocyte differentiation 
and barrier formation, possibly by mediating profilaggrin-to-filaggrin processing. 
 
1.4.4 The role of  RAPTOR-mTORC1 in modulating Akt activity 
 
Akt activity can be regulated by dephosphorylation at T308 and S473 by 
phosphatases such as Pp2A (protein phosphatase 2A) (Andjekovic et al., 1996). The 
tumour suppressor PTEN (phosphatase and tensin homolog) can also inhibit Akt 
activity by converting PIP3 to PIP2 (Stambolic et al., 1998). Epidermal specific PTEN 
knockout mice have hyperactive epidermal Akt, display hyperplasia and hyperkeratosis 
(Suzuki et al., 2003). This indicates that careful regulation of Akt activity is important 
for normal skin development as reduced or hyper active Akt can lead to impaired 
epidermal differentiation, structure and barrier function.  Perhaps to ensure proper 
regulation, several negative feedback loops are thought to exist, with one negative 
regulation loop existing between mTORC1 and Akt. S6K1/2, a component of mTORC1 
can directly phosphorylate receptor accessory protein insulin receptor substrate 1 (IRS-
1) at several inhibitory residues, resulting in the degradation of the adapter molecule, 
which prevents the docking of PI3K and downregulate the PI3K/Akt signaling pathway 
(Harrington et al., 2004; Shah et al., 2004; Sully et al., 2013). Research has shown 
knock down of Raptor (regulatory associated protein of mTOR) increases Akt activity 
(Sarbassov et al., 2005). Raptor forms complexes with the regulatory kinase mTORC1. 
A recent publication by Sully et al. (2013) has demonstrated that treatment of 
keratinocytes with rapamycin, a drug that specifically inhibits the Raptor-mTORC1, 
increases Akt activity, by inhibiting the negative feedback loop that exists between 
mTORC1 and the IRS-1 (Sully et al., 2013). This indicates that this negative feedback 
loop is present in keratinocytes and can hence modulate Akt activity in the skin (Fig 
1.11). Given the importance of Akt for epidermal barrier formation, identifying its 
downstream effectors involved in this process will further our understanding of 
keratinocyte differentiation process and aetiology of skin diseases such as AD. 
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Figure 1.11 Modulation of Akt activity by mTORC1.             
mTORC1 (mTOR) mediates phosphorylation of specific residues on IRS-1 which activates a negative 
feedback loop that inhibits PI3 Kinase activation and Akt activation.  
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1.5 Heat shock protein 27 and actin  
 
Heat shock protein 27 (Hsp27) also known as Heat shock protein beta-1 
(HspB1), belongs to the large family of Heat Shock Protein (Hsps). Common functions 
of Hsps include chaperone activity, inhibition of apoptosis, thermotolerance and 
stabilization of the cytoskeleton (Merck et al., 1993; Garrido et al., 2001). Like all 
members of the Hsps, HspB1 can form large oligomers and its function is often 
modulated by its phosphorylation status. Phosphorylated HspB1 has been reported to 
have a regulatory role in actin filament dynamics. Actin is one of the most abundant 
eukaryotic proteins and is critical for various cellular functions such as cell motility, 
maintenance of cell shape and regulation of transcription. Actin can exist in its 
monomeric form (G actin) or polymerize to form filamentous actin (F acin) (Reviewed 
in Dominguez and Holmes, 2011). A well characterised function of monomeric HspB1 
is its ability to bind to actin microfilaments and stabilize F-actin polymerization 
(Benndorf et al., 1994;  Guay et al., 1997). Actin dynamics has an important role in 
keratinocyte stratification with studies showing disruption of the actin cytoskeleton 
leading to abnormal keratinocyte differentiation (Koegel et al., 2009; Luxenburg et al., 
2011). HspB1 is a substrate of Akt (Konishi et al., 1997) and studies have shown Hsp25 
phosphorylation (the murine homologue of HspB1) has a similar expression pattern to 
Akt1 phosphorylation with expression being more prominent in the upper epidermis 
during keratinocyte differentiation (O’Shaughnessy et al., 2007). In addition HspB1 has 
been found to co-localize with cornified envelope proteins. (O’Shaughnessy et al., 2007 
& Jonak et al., 2002). Interestingly, recent findings have established that both 
phosphorylation of HspB1 in the upper epidermis and its transient co-localisation with 
filaggrin in the keratohyalin granules in the cytoplasm occurs in an Akt1-dependent 
manner (O’Shaughnessy et al., 2007). Furthermore targeted knock down of HspB1 in 
keratinocytes leads to reduced filaggrin expression and hyperkeratosis (O’Shaughnessy 
et al., 2007). 
 
1.6 Lamin A/C 
 
Lamins are type V intermediate filaments that are part of the nuclear lamina, 
which is a matrix of proteins lining the nucleoplasmic surface of the inner nuclear 
membrane (Prokocimer et al., 2009). Lamins are classified into two groups, A-type 
lamins and B-type lamins, both components of the nuclear lamina. B type lamins are 
expressed in most cells while A type lamins tend to be more differentially expressed 
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with suggestions of involvement in more specialized functions such as differentiation 
(Prokocimer et al., 2009).  In humans homozygous loss of A-type lamins result in 
lethality at birth (Muchir et al., 2003). A-type lamins comprise of Lamin A and C, two 
alternately spliced products of a single transcript transcribed by the LMNA gene 
(Stewart and Burke, 1987). Lamin C is produced as a mature protein while other 
transcript, Prelamin A, is further processed with modifications leading to 
isoprenylation, carboxymethylation and endoproteolysis at the C-terminal CaaX motif 
before forming mature lamin A (Sinensky et al., 1994). Alterations in prelamin A 
processing are at the centre of lamin A/C related disease called laminopathies (Maraldi 
et al., 2011). Apart from providing structural scaffolding for the nucleus, lamin proteins 
can interact with various proteins including chromatin associated proteins, transcription 
factors and with inner nuclear membrane proteins (INM) such as SUN and nesprin that 
form the LINC (linker of Nucleoskeleton and cytoskeleton) complex at the nuclear 
envelope (Dechat et al., 2008). This involves lamins in the regulation of gene 
expression, DNA replication and also mediate interactions between lamin and actin 
network.  
 
Lamin A/C are reported to interact with specific transcription factors such as c-
fos and Oct-1 suggesting that mutations in lamin A/C can lead to distinct tissue specific 
diseases as these lamins have tissue specific roles during differentiation (Gonzalez et 
al., 2008). This is the case in laminopathies such as muscular dystrophy and Emery-
Dreifuss muscular dystrophy (EDMD), which affects striated muscles, peripheral nerves 
and adipose tissue (Maraldi et al., 2011). However in the case of premature ageing 
syndromes such as Hutchinson-Guilford progeria Syndrome (HGPS) a more widespread 
ageing of most tissues are observed with skin changes considered an early clue to a 
diagnosis of HGPS with patients displaying scleroderma (Mounkes et al., 2003). HGPS 
in vivo mouse model displayed skin abnormalities with hyperkeratosis and 
parakeratosis (Sagelius et al., 2008). EDMD patients also display nuclear abnormalities 
(Maraldi et al., 2011). Research has shown that during apoptosis, lamin A/C is 
degraded, a process initiated by phosphorylation (Peter et al., 1990). It has also been 
reported that uncleavable mutant lamins cause delays in chromatin condensation and 
nuclear degradation during apoptosis (Rao et al., 1996).  Interestingly, studies have 
shown lamin A is a downstream nuclear target of Akt and is phosphorylated by Akt in 
the evolutionary conserved Akt motif at the amino acid residue Ser404 (Cenni et al., 
2008). In view of the fact that nuclear retention in the cornified layer is a phenotype 
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observed in AD, it will be interesting to elucidate whether Akt may mediate nuclear 
degradation via lamin A during keratinocyte differentiation. 
 
1.7 Cathepsin H 
 
Cathepsin H (Ctsh) belongs to a group of papain-like lysosomal cysteine 
proteases consisting of 11 members mainly located in the endolysosomal compartments 
and within the exocytosis pathways of some secretory cells (Tedelind et al., 2010; 
Reiser et al., 2010). Similar to other proteases, Ctsh is synthesized as a procathepsin 
which consists of disulphide-linked heavy and a light chains (Baudys et al., 1991). Ctsh 
also has a glycosylated octapeptide called mini-chain covalently linked to the main 
protein, the presence of which makes Ctsh predominantly an exopeptidase with limited 
endopeptidase activities (Guncar et al., 1998). Procathepsin undergoes glycosylation 
and proteolysis to form the single chain 28 kDa mature Ctsh. Ctsh also can exist as its 
processed forms Ctsh heavy chain (22 kDa) and Ctsh light chain (6 kDa) (Popovic et 
al., 1988). Ctsh is ubiquitously expressed in all tissues with a well characterized role in 
lung surfactant SP-B processing in type II pneumocytes (Brasch et al., 2002; Buhling et 
al., 2011). Ctsh activity is increased in breast, colorectal and prostate carcinoma while it 
is decreased in squamous cell carcinoma of the head and neck (Reiser et al., 2010). 
 
1.8 Aims and objectives  
 
1.8.1 Rationale for the study 
 
A skin barrier defect is the major driver of pathogenicity in AD. A defective 
barrier allows entry of allergens and pathogens resulting in inflammatory responses 
(Callard & Harper, 2007; Leung et al., 2014). Skin barrier defects in AD have been 
shown to result from reduced expression of the skin barrier protein filaggrin, which can 
result from mutations in the FLG gene (Presland et al., 2000; Palmer et al., 2006). 
However reduced filaggrin independent of FLG mutations, has also been observed in 
AD, hence implying alternative mechanisms leading to defects in profilaggrin 
processing (Thawer-Esmail et al., 2014). The processing of profilaggrin to filaggrin is 
poorly understood with only a few proteases identified (List et al., 2003). As filaggrin is 
involved in several aspects of barrier function, further knowledge about the 
profilaggrin-processing pathway will broaden the knowledge of later stages of 
keratinocyte differentiation leading to barrier formation.  The Akt signaling pathway is 
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involved in skin barrier formation (Thrash et al., 2006; O’Shaughnessy et al., 2007), 
however the epidermal downstream targets of the Akt signaling pathway are not well 
characterized. In particular, Akt activity is important for filaggrin processing as reduced 
Akt activity leads to reduced filaggrin protein levels and hyperkeratosis 
(O’Shaughnessy et al., 2007). A substrate of Akt, HspB1, was found to be involved in 
filaggrin processing in an Akt mediated manner however the exact mechanism was not 
determined (Fig 1.12) (O’Shaughnessy et al., 2007 & Jonak et al., 2002). Even though 
Akt activity in AD skin has not been evaluated, it is possible that Akt activity in the skin 
is reduced in AD as experimental evidence shows a reduction in granular Akt 
phosphorylation can give rise to mild barrier defects similar to AD (Thrash et al., 2005; 
O’Shaughnessy et al., 2007).  
                  
This study will therefore focus on evaluating Akt activity in uninvolved AD skin 
and identifying downstream targets of Akt signaling pathway that are involved in 
filaggrin processing and other aspects of keratinocyte differentiation leading to barrier 
formation. As lesional AD skin has elevated immune responses, which can further 
exacerbate barrier defects, uninvolved skin sections are chosen for this study so any 
abnormalities observed should be due to skin barrier defects only. The study will also 
evaluate RAPTOR as a modulator of Akt activity in skin. A better understanding of the 
molecular components involved in AD-associated epidermal barrier and differentiation 
defects can hopefully lead to novel targeted therapies. 
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Figure 1.12  Model describing established and possible downstream effects of Akt signaling pathway 
leading to barrier defects.  
Dotted arrows indicate relationships with mechanisms unknown. 	  	  
1.8.2 Hypothesis 
 
In AD, reduction in epidermal granular Akt phosphorylation leads to misprocessing of 
profilaggrin and barrier defects, potentially due to up-regulation of epidermal RAPTOR 
expression  
                                    
1.8.3 Objectives: 	  
1. Generate an Akt1 shRNA knockdown rat epidermal keratinocyte culture model 
in both submerged monolayer culture and organotypic culture to examine the 
effects on profilaggrin processing and other aspects of barrier formation.  
 
2. Profile differentially expressed genes in this Akt1 knocked down (kd) culture 
model.  
 
3. Obtain mechanistic insights of how Akt-mediated HspB1 phosphorylation is 
involved in filaggrin processing. 
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4. Extend the analysis of relevant differentially expressed proteins, RAPTOR and 
pSerAkt in the granular layer of unaffected skin from AD patients. 
 
5. Clarify the role of RAPTOR in modulating Akt activity and profilaggrin 
processing.  
 
6. Stimulate and inhibit function of components differentially expressed in our 
Akt1 knockdown ‘model’ to determine their function in epidermal 
differentiation and barrier disruption.	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 : Materials and methods Chapter 2
2.1 Reagents and Solutions 	  
Table 2-1 Reagents list 	  	  
Item Supplier Catalogue Number 
0.25 % Trypsin Sigma Aldrich Co. T3924 
1 Kb DNA ladder NEB N0467S 
100 bp DNA ladder NEB N0468S 
100x Antimycotic (Antibiotic Antimycotic) Life Technologies 15240-062 
100x Penicillin/Streptomycin with L-Glutamine Life Technologies 15140-122 
2-Mercaptoethanol Sigma Aldrich Co. M6250 
2x Laemmli Sample Buffer Bio-Rad 161-0737 
Agarose Sigma Aldrich Co. A9539 
AGN193109 Santa Cruz Biotechnologies Sc210768 
All Trans Retinoic Acid (ATRA) Fisher Scientific 10552611 
Ammonium persulphate VWR 443073 
BCA protein assay kit Fisher 23227 
Bovine Serum Albumin Sigma Aldrich Co. A9418 
Bouin’s Fixative  Polysciences, Inc. 16045-1 
Chloroform solution Sigma Aldrich Co. 25666 
Cholera Enterotoxin stock Merk Biosciences 227036 
Concentrated HCl (Conc. HCl) (37%)   Science Company NC-5844 
Coomassie Blue G250 colloidal pre-mixed Fisher Scientific 12778039 
OCT embedding cryoembedding Matrix Thermo Scientific 0370024 
DEPEX Fisher Scientific 50-980-371 
Dimethyl Sulfoxide (DMSO) Sigma Aldrich Co. D2650 
Dulbecco's Modified Eagle's Medium (DMEM) Life Technologies 11960-044 
Eosin Sigma Aldrich Co. E4009 
Epidermal Growth Factor (EGF) Peprotech EC Ltd 100 15 
Fish skin gelatin Sigma Aldrich Co. 1001444578 
Haematoxilin Solution Merck 105174 
Ham's F12 Invitrogen 41966-029 
Hydrocortisone (HC) Merk Biosciences 
 
386698 
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Item Supplier Catalogue Number 
Insulin stock Sigma Aldrich Co. 15500 
Lipofectamine plus Reagent Life Technologies 15338030 
Mitomycin C Sigma Aldrich Co. M0503 
N,N,N’,N’-Tetramethylethylenediamine 
(TEMED) Sigma Aldrich Co. T9281 
Novex® Tris-Glycine SDS Running buffer (10x) Invitrogen LC2675 
Novex® Sharp Pre-stained Protein Standard Life Terchnologies LC5800 
Phenol Solution Sigma Aldrich Co. P4557 
Phenylmethanesulfonyl Fluoride solution (PMSF) Sigma Aldrich Co. 93482 
Phosphate Buffer Solution (PBS) Life Technologies 14190-094 
Phosphate Buffer Solution (PBS) without Ca2+ and 
Mg 2+ (for cell culture) 
Life Technologies 14190-169 
Pierce® Western Blot Transfer Buffer 10x 
Methanol-free 
Fisher Scientific 10565604 
Ponceau S Staining Solution Sigma Aldrich Co. 09276 
QIAfilter Plasmid Midi kit Qiagen 12243 
Quantitect SYBR® Green PCR Kit Qiagen 204141 
Rapamycin Cell Signalling 9904 
RNase OUT Life Technologies 10777019 
Sodium dodecyl sulphate (SDS) Sigma Aldrich Co. 71727 
SuperScript II RT Life Technologies 18064014 
SYBR®Green JumpStart™ Taq ReadyMix™ Sigma Aldrich Co. S4438 
Taq DNA Polymerase 
New England 
Biotechnologies (NEB) 
M0480L 
One Shot® Top10 Competent Cells Invitrogen C4040-03 
Tri Sodium Citrate  Sigma Aldrich Co. S1804 
Triton X-100 Sigma Aldrich Co. T8787 
Trypsin Neutralizing Factor (TNF) Lonza CC-5002 
Tween® 20 Sigma Aldrich Co. P5927 
Wortmannin Sigma Aldrich Co. W1628 	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Table 2-2 Media and stock solutions 	  
   DMEM+     
Component Amount (ml) 
Final 
concentration 
DMEM 450  -  
FBS 40 10% 
100x AM 5 1x 
100x AB 5 1x 
      
      
FAD + 10% FBS     
Component Amount (ml) 
Final 
concentration 
DMEM 300  - 
Ham's F12 100  - 
FBS 45 10% 
      
      
100x HCE     
Component Amount (ml) 
Final 
concentration 
Hydrocortisone (HC) 1 10% 
Cholera Enterotoxin 0.1 1% 
Epidermal Growth Factor 1 1% 
FAD + 10% FBS 7.9  -  
      
      
FAD HCE     
Component Amount (ml) 
Final 
concentration 
FAD + 10 % FBS 44.5  - 
100x HCE 5 1x 
Insulin 0.4 1% 
      
      
Versene     
Component Amount 
Final 
concentration 
10x PBS 50 ml 1x 
0.5 M EDTA stock  54 ml 2% 
Distilled water adjust to 500ml   
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Total Lysis Buffer 
Component Amount (ml) 
Final 
Concentration 
2-Mercaptoethanol 1 2% 
SDS 1 2% 
1M Tris HCl pH 7.5 0.5 10mM 
Distilled H20 47.5  -  
      
      
RIPA Lysis Buffer     
Component Amount (ml) 
Final 
Concentration 
1M Tris-Hcl pH7.4 2.5 50mM 
5M NaCl 1.5 150ml  
0.5M PMSF 0.1 1mM  
0.5M EDTA 0.2 1mM  
Triton x100 0.5 1% 
Roche Inhibitor Tablet  1 per 50 ml  -  
Distilled water adjust to 50 ml  - 
      
      
10mM NaCitrate pH 6.0     
Component Amount 
Final 
Concentration 
Tri Na Citrate 2.94 g 10mM 
Tween 20 0.5 ml 0.05% 
Conc. HCl  few drops to adjust pH to 6.0  - 
Distilled water adjust to 1L  -  
      
      
10x PBS     
Component Amount 
Final 
concentration 
PBS tablets 100 10x 
Distilled water adjust to 1 L  -  
      
      
1x PBS     
Component Amount 
Final 
concentration 
10x PBS 100 ml 1x 
Distilled water adjust to 1 L  -  
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PBST     
Component Amount 
Final 
concentration 
PBS 1 L 1X 
TWEEN-20 1 ml 0.1% 
      
      
 TBS     
Component Amount 
Final 
concentration 
Tris  6.05 g 50 mM 
NaCl 8.76 g 150 mM 
HCl few drops to adjust to pH 7.5  - 
Distilled water adjust to 1 L  - 
      
      
TBST     
Component Amount 
Final 
concentration 
TBS 1  L  - 
Tween-20 1ml 0.1% 
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Table 2-3 Primary and secondary antibodies  	  	  
Primary Antibodies Type Company Catalogue Number 
IHC/IF 
dilution 
WB 
dilutio
n 
Agarose-conjugated Hsp27 Rabbit polyclonal Santa Cruz 
Sc1048 
AC  - 1:50 
Akt phophorylated 
(pSer473) 
Rabbit 
polyclonal 
Cell 
Signalling 9271 1:10 1:100 
Akt-1 Mouse monoclonal 
Cell 
Signalling 2967 1:10 1:1000 
Flag Mouse monoclonal Sigma 8146 1:10 1:100 
β-Actin Mouse monoclonal Millipore 
MAB1501
R  - 1:1000 
c-myc Mouse monoclonal Sigma  9E10  - 1:500 
Cathepsin H Rabbit polyclonal Santa Scruz Sc6496R 1:50 1:200 
Filaggrin Rabbit polyclonal Santa Cruz Sc30230 1:50 1:500 
GAPDH Mouse monoclonal Millipore MAB374  - 1:5000 
Hsp27 Rabbit polyclonal abcam ab12351 1:100 1:500 
Hsp27 phospho-Ser82 Rabbit polyclonal abcam ab17938 1:100 1:500 
Involucrin Mouse monoclonal Genetex 
GTX7241
5 1:10 1:50 
Keratin 1 Rabbit polyclonal Covance PRB-165P 1:100 1:1000 
Keratin 5 Rabbit polyclonal Covance PRB-160P  -  1:1000 
Keratin 10 Rabbit polyclonal Covance PRB-159P 1:10 1:1000 
Lamin A/C Mouse monoclonal Santa Cruz Sc-7293 1:200 1:500 
Loricrin Rabbit polyclonal Covance 
PRB-
145P-100 1:100 1:1000 
Raptor Rabbit polyclonal 
Cell 
Signalling 2280 1:10 1:500 
Rictor Rabbit polyclonal 
Cell 
Signalling 2114 1:10 1:500 
Total Akt Rabbit polyclonal 
Cell 
Signalling 9272  -  1:500 	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Secondary Antibodies Company 
Catalogu
e 
Number 
IHC/IF 
dilution 
WB 
dilution 
HRP conj. Swine anti rabbit DakoCytomation P0447  - 1:2000 
HRP conj. Goat anti mouse DakoCytomation P0399  - 1:2000 
Alexa Flour  488 Goat anti mouse 
IgG Invitrogen A11001 1:500  - 
Alexa Flour 594 Goat anti rabbit 
IgG Invitrogen A11012 1:500  - 
Alexa Flour 488 Goat anti rabbit 
IgG Invitrogen A11008 1:500  - 
Biotinylated Goat anti Rabbit Vector BA-1000 1:200  - 
Biotinylated Goat anti mouse Vector BA-9200 1:200  - 
Donkey anti-goat Santa Cruz Sc-2020  - 1:2500 	  	  	  
2.2 General cell culture techniques  
 
All tissue culture work was performed in class II safety cabinets using sterile 
techniques. Cell cultures including organotypic cultures were carried out in humidified 
incubators at 37°C and 5% CO2. Mouse fibroblast cell cultures were carried out in 
humidified chambers at 37°C and 10% CO2. Tissue culture flasks and plates were 
standard tissue culture treated plates purchased either from CORNING® or Nunc 
(Thermo Fisher Scientific). 
 
2.2.1 General trypsinisation protocol 
 
 The culture medium was removed and the cells gently rinsed twice with sterile 
versene. Fresh 5-10 ml of sterile versene was added to the flask again and incubated at 
room temperature for 5 min. The versene was removed and replaced with 4 ml of 0.25 
% Trypsin and incubated for 5 min at 37 °C in the incubator. Excess DMEM+ medium 
neutralized the trypsin and the suspension was then centrifuged at 1600 x g for 20 
minutes. The cell pellet was resuspended in fresh DMEM+ medium. For continuous 
culture, cells were split 1 in 10 into a new T75 flask. For experiments, cell count was 
done and appropriate number of cells plated in culture plates or flasks.  
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2.2.2 Freezing and thawing of cells 
 
For long term storage of viable cells they were prepared as follows- Cells were 
counted and pelleted after centrifugation for 20 min at 1600 x g. Supernatant was 
discarded and the pellet resuspended in 10% DMSO (v/v) (Sigma Aldrich) in FBS at a 
concentration of 1 million cells/ml. 1 ml of the suspension was aliquoted to labeled 
cryovials (Nunc, Thermo Fisher Scientific). To freeze the cells slowly, the vials were 
placed in an isopropanol container (Nalgene) and placed in -80° for 24 hours before 
transferring to liquid nitrogen for long-term storage. Frozen cells were recovered by 
thawing an aliquot quickly in a 37°C water bath before transferring to 14 ml of 
prewarmed DMEM+ to dilute the cell suspension. Cells were plated in a T75 flask and 
media was replaced 24 hours later to remove traces of DMSO. 
 
2.2.3 Growth assays 	  
Growth assays were performed by plating 100,000 REK cells per well (6 well 
plate) containing DMEM+ media with increasing concentrations of G418 (0.1 ng/ml, 
1ng/ml, 10ng/ml, 30ng/ml and 100ng/ml). Cells were cultured for a week with media 
changes with the indicated G418 concentrations every other day.  
 
2.2.4 Rat Epidermal Keratinocyte (REK) and Swiss mouse 3T3 fibroblast (NIH 
3T3) culture 
 
Aliquots of single cell suspensions were transferred to culture plates or flasks 
with modified DMEM (DMEM+) and placed in the incubator. Media was replaced with 
fresh DMEM+ every two or three days and cells were subcultured before they reach 90 
% confluency. For transfected cell lines, the cells were selected using DMEM+ 
supplemented with G418 at a concentration of 10 ng/ml as this is the concentration that 
prevented REK cell growth in assays (section 2.2.3). Cells were collected after washing 
the flasks or plates 3 times with PBS, followed by trypsinisation with 0.25 % Trypsin 
for 5 minutes, and pelleted after centrifugation at 1,600 x g for 20 minutes at room 
temperature. Note: The NIH 3T3 cells (ATCC) were a gift from Dr. Wei Li Di. 
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2.2.5 Human keratinocyte cell culture 	  
Human keratinocyte culture was established by plating aliquots of single cell 
suspension in a flask or plate coated with mitocycin C (Sigma Aldrich) treated Swiss 
mouse 3T3 fibroblasts. Preparation of mitomycin treated NIH 3T3 plates: Mitomycin C 
was added to 3T3 fibroblasts suspended in a 50 ml falcon tube (Corning) with DMEM+ 
medium at a concentration of 40 ng/ml. This was then plated in a T25 flask and placed 
in an incubator for 3 hours after which the medium was aspirated, plate gently washed 
three times with PBS to remove traces of mitomycin c treatment. 3T3 cells were then 
trypsinized for 5 minutes, cells pelleted and resuspended in FAD HCE media and plated 
at a density of 1.0-1.5x105/cm2. Aliquots of single cell suspension Normal Human 
epidermal keratinocytes (NHEKs) were resuspended in FAD HCE and transferred to 
mitomycin C treated 3T3 coated plates or flasks. For collection of cultured NHEKs, 
cells were trypsinised with 0.25 % Trypsin for 5 min. Trypsin was neutralized using 
Trypsin Neutralising Solution (TNS) (Trypsin: TNS = 1:2). Cells were spun down 300 x 
g and resuspended in FAD HCE.  
 
2.2.6 General transfection protocol 	  	   All transfections were done using Lipofectamine™ 2000 reagent (Invitrogen) 
according to manufacturer’s protocol. Briefly, 24 hours before transfection, 8 x105 cells 
in 2 ml of DMEM with 10% v/v FBS (without antibiotics) were plated in each well of a 
6 well plate so the cells will reach 90 – 95% confluency at the time of transfection. The 
transfection complexes were prepared as follows: Complexes were prepared using the 
plasmid DNA (µg) to Lipofectamine™ 2000 (µl) of 1:2. For each transfection sample 
1g of plasmid DNA was mixed with 250 µl of DMEM and mixed gently. 2 µl of 
lipofectamine was mixed with 250 µl of DMEM and mixed gently. These were 
incubated for 5 minutes at room temperature before combining the diluted plasmid 
DNA and lipofectamine solution that was allowed to stand at room temperature for 20 
minutes. 500 µl of the complex was transferred to each well and mixed gently. Plates 
were then incubated at 37°C in an incubator with a media change to fresh DMEM+ after 
6 hours of transfection. For stable transfection, cells were split 1 in 10 24 hours after 
transfection and media replaced with 0.1 mM G418 selection media. For transient 
transfection, lysates were collected 24 hours after trasnsfection. 
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2.2.7 shRNA plasmids, RAPTOR over expression 
 
Four SureSilencing shRNA plasmids (Qiagen, Paisley, UK) were used to 
knockdown Akt1 expression in REKs; shRNA1-GCA CCG CTT CTT TGC CAA CAT, 
shRNA2-AAG GCA CAG GTC GCT ACT AT, shRNA3-GAG GCC CAA CAC CTT 
CAT CAT, shRNA3-GCT GTT CGA GCT CAT CCT AAT, and of these 1 and 3 were 
used for further experiments. Ctsh knockdown was successfully achieved by 
transfecting NHEKs and REKs with two shRNA plasmids (shRNA1-CAA GAA TGG 
TCA GTG CAA ATT; shRNA2-CTA GAG TCA GCT GTG GCT ATT) using 
lipofectamine 2000 according to manufacturers’ protocol briefly described above 
(Qiagen, Paisley, UK). One scrambled control was used 
(GGAATCTCATTCGATGCATAC). Lysates were collected after selection in 0.1mM 
G418 for 2 weeks. A Myc-tagged RAPTOR expressing plasmid (OriGene, Rockville, 
Maryland, USA) was transiently transfected into REKs using lipofectamine 2000 at 
increasing plasmid concentrations 0.1 µg/ml, 0.5 µg/ml and 1 µg/ml.  
 
2.2.8 Lamin contructs 
  
Flag tagged wild-type and 3 mutant lamin A contructs (Cenni et al., 2008) were 
transfected into REKs and NHEKs using lipofectamine 2000 according to 
manufacturers’ protocol briefly described in section 3.2.5. Stable transfection was 
achieved after selection under 0.1 mM G418 for two weeks. Lamin A mutant constructs 
comprise of single mutants S301A, S404A and double mutants S301A/S404A where 
serine resides have been mutated to alanine. Acknowledgements: I would like to thank 
Professor Sandra Marmiroli (University of Modena and Reggio Emilia) for providing 
the wild type and mutant lamin constructs. 
 
2.2.9 Post Confluent cultures 
 
Cells were defrosted, put in culture and allowed to recover for a week. Before 
reaching 90 % confluency, cells were then trypsinised, counted, pelleted and 
resuspended in DMEM+ for untransfected cells and DMEM+ with 0.1 mM G418 for 
transfected cells. For all post confluent cultures, 100,000 cells were plated in a 6 cm 
plate and media changed every other day. With day of plating designated day 0, lysates 
were collected on days 2,3,4,5 and 6.  
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2.2.10 Organotypic culture 
 
Organotypic culture was performed using keratinocytes seeded onto de-
epidermalised dermis (DEDs) (Euro Skin Bank) with a fibroblast feeder layer on the 
lower side of DED. To prepare the feeder layer, 200,000 NIH 3T3 cells were transferred 
into a culture chamber ring placed in centre of the DED. After 24-48 hours, the DEDs 
are turned over and 200,000 sample cells (REKs transfected with Akt1 shRNA or 
scrambled shRNA) are transferred into a culture chamber ring in centre of DED. After 
24 hours, the REK organotypic culture was raised to liquid/air interface and grown 
under selection in DMEM+ with 0.1 mM G418 for 14 days. Media was changed every 
two days. On the 14th day, the DEDs were cut in two with one half embedded in cryo 
freezing medium and stored in -80°C until required. The other half was fixed in Bouin’s 
solution for 2 hours on a shaker at room temperature, replaced with 70% ethanol for 5 
min (repeated with fresh 70 % ethanol a few times until colour of fixative fades). The 
fixed DEDs are then embedded in paraffin or frozen in OCT and stored at -80° C as 
appropriate. 
 
2.2.11 Cell treatments 
 
Cells were treated with the inhibitor Rapamycin at 10 nM for four hours prior to 
lysate collection. Wortmannin (Sigma), a PI3 kinase inhibitor, was introduced into REK 
cells at 2 µM for 24 hours (O’Shaughnessy et al., 2007a) prior to lysate collection. 
Human keratinocytes were treated with 5 µM all-trans retinoic acid (ATRA) and 0.1 
µM Retinoic acid receptor antagonist (AGN193109) for 24 hours prior to lysate 
collection. DMSO was used as a control at a concentration not exceeding 0.1 %. 
 
2.3 Protein expression analysis by western blotting 	  
2.3.1 Sample preparation 	  
Cells were lysed using radio immunoprecipitation assay (RIPA) buffer for 
cytoplasmic protein extraction. After rinsing the cells with ice cold PBS, 150 µl of 
RIPA buffer was added to each well of a 6 well plate on ice and placed on ice for 10 
minutes. Cells were then scraped off into labeled eppendorfs and sheared with a 2 ml 31 
G needle approximately 8 times. The samples were centrifuged at 10,000 RPM at 4°C 
for 10 minutes. The supernatants were then aliquoted into labeled eppendorfs and stored 
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at -20°C until required. Total cellular protein was extracted from cells using total lysis 
buffer as follows.	  Cells in culture plates were rinsed with ice cold PBS approximately 4 
or 5 times. 150 µl of lysis buffer was added to each well of a 6 well plate on ice and 
placed on a shaker for 10 minutes. The cells were then scraped off the wells using a cell 
scaper, transferred to labeled eppendorfs and placed on a 95°C heat block for 10 
minutes. Cells were incubated on ice for 1 min and cell suspension was sheared at least 
8 times using a 2 ml syringe with a 25 G needle. The samples were centrifuged for 5 
minutes at 10,000 RPM, and supernatant aliquoted into labeled 1.5 ml tubes and stored 
at -20°C until required. 
 
2.3.2 Protein quantification 
 
Protein was quantified using Bicinchoninic Acid Protein Assay Kit (BCA) as 
follows. Protein standards were prepared using Bovine serum albumin at 
concentrations: 10, 200, 400, 800 and 1000 µg/ml. BCA working solution was prepared 
according to instructions: 100 µl of CuSO4 to 5 ml of BCA solution. Master mixes of 
total volume 100 µl were prepared of 2 dilutions from each lysate: 1: 2  and 1: 10 
dilutions. 25 µl of each dilution was added to a 96 well plate with each dilution loaded 
in triplicate. 25 µl of each standard in triplicate was also loaded into the plate and one 
well with 25 µl RIPA solution as a blank. Each well including the blank was then 
topped with 200 µl of the BCA working solution. Plate was covered with foil and 
allowed to incubate for 30 minutes. A Plate Reader (Bio-Tek Instruments, Ascent 
Software Version 2.6) was used to measure the absorbance at 620 nm. Absorbance 
value of the blank was deducted from the rest of the readings. The protein 
concentrations were calculated using the line equation generated from a standard curve. 
 
2.3.3 SDS-PAGE gel electrophoresis 	  
The glass plates (Biorad) were assembled and gel chamber between the plates 
filled up to two thirds of the way with 8 % resolving buffer made up according to Table 
2.4. Gel was overlaid with a layer of water and gel was left to set at room temperature 
for 30 minutes. Once the gel has set the stacking gel was made up (Table 2.4) and 
poured into the gel chamber and a 1.5 mm comb (Biorad) placed between the plates. 
Stacking gel was allowed to set for 30 minutes at room temperature. After the gel has 
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set, the comb was carefully removed and plates were set up in a Mini protean 3 gel tank 
system (Biorad). The gel tank was filled with 1x Running Buffer with final 
concentration of 50 mM Tris-base, 384 mM Glycine and 0.4 % SDS. 1 x Running 
Buffer was obtained by diluting 10x Running Buffer stock (Invitrogen). Approximately 
15 µg of each protein sample combined with 2x loading buffer was loaded with a pre-
stained protein ladder (Life technologies). The gel was run at constant voltage of 130 V 
for 1 hour. 
 
Table 2-4 Recipe for 8% SDS-PAGE gel and loading buffer 
 	  
2.3.4 Transfer 	  
The gel was carefully placed inside the gel cassette with one side in contact with 
a wet blotting paper and other side in contact with presoaked Hybond™- C 
Nitrocellulose membrane (Amersham, Biosciences). Presoaked sponge pads and more 
blotting paper were placed on either side of this assembly and the assembled gel 
cassette was placed inside the transfer apparatus in the gel tank. The tank was filled 
with 1x transfer buffer (diluted from 10x transfer buffer stock, Thermo Scientific 
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Pierce). Transfer was done at constant current of 0.1 A (approximately 30-35 V) for 1.5 
hours.  
2.3.5 Ponceau staining and blocking 	  
After transfer, the nitrocellulose membrane was washed in a clean tray with 
Milli Q water for 2 minutes on a shaker. Water was removed from the tray and replaced 
with Ponceau S solution (made up by dissolving 70 ml of Ponceau S stock in Milli Q 
water topped up to 250 ml) to determine even loading of the gel. The tray was placed on 
the shaker for 5 minutes after which the Ponceau S solution was removed and 
membrane rinsed with Milli Q. 
 
For blocking, membrane was placed in 5% w/v skimmed milk proteins (Marvel) 
made up in TBST buffer (Table 2.5) and placed on a shaker at room temperature for 30 
minutes. After which the membrane was washed for 3 times 5 minutes each with TBST 
buffer prior to primary antibody incubation. 
 
Table 2-5 Recipe for blocking solutions used in western blot analysis 
 
 
 
2.3.6 Protein detection 	  
Primary antibodies were diluted in either 5% bovine serum albumin (Sigma) or 
5% skimmed milk proteins dissolved in TBST (Table 2.5) and incubated overnight at 
4ºC. After primary antibody incubation membranes were washed 3 times for 5 minutes 
each in TBST. Secondary antibody incubation was for 1 hour at room temperature at 
concentrations; goat anti-mouse horseradish peroxidase 1:3000, swine anti-rabbit 
horseradish peroxidase 1:3000 (both DakoCytomation). Following 3 5-minute washes 
in TBST, the protein was visualized using an ECL™ Prime Western Blotting Detection 
Reagent (Amersham, GE Healthcare) according to manufacturer’s instructions. Briefly, 
the detection agents A and B were mixed in the ratio 1:1 and the mixture spread over 
the entire membrane and incubated at room temperature for 4 minutes. In a dark room 
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the Hyperfilm ECL (Amersham, GE Healthcare) was placed on top of the membrane for 
the required exposure time and developed in a autoradiography developer by Xograph 
imaging systems.  
 
2.4 Co-immunoprecipitation assay 	  
Cell extracts for co-immunoprecipitation assay were obtained using ice cold 
RIPA buffer as described in section 3.3.1. 500 µl of RIPA lysates from each sample 
were combined with 20 µl of agarose-conjugated HspB1 antibody (Santa Cruz) in 
labeled eppendorfs to form immunocomplexes. Mixture was vortexed and incubated on 
ice on a shaker for four hours. After incubation, the tubes were centrifuged at 5000 
RPM for 4 min and supernatant discarded retaining the viscous ‘pellet’. The ‘pellet’ was 
washed 4 times with 300 µl of ice cold RIPA buffer and centrifuged at 5000 RPM for 5 
min and the supernatant discarded each time. For final wash, fresh RIPA buffer was 
added to the pellet, centrifuged at 10,000 RPM for 5 minutes and the supernatant was 
discarded. The ‘pellet’ was dissolved in 80 µl of 2x loading buffer (table 2.4) and either 
loaded to a gel (20 µl per well) and proceeded with western blot analysis as described 
above or stored at -20° for later use. In this protocol the agarose beads are not recycled. 
Just prior to leading for western blot analysis, the samples which are resuspended in 2x 
loading buffer, are boiled for 5 min at 95°C which elutes the antibodies from the beads. 
 
2.5 AD uninvolved skin sections and normal skin sections. 	  
AD uninvolved skin sections were a gift from Dr. Wei Li Di. They were archived punch 
biopsy samples from non-affected areas from the arm of AD children (age 3 to 5 years). 
Samples were formalin-fixed paraffin embedded. 
 
Normal skin sections were formalin-fixed and paraffin embedded tissue array sections 
obtained from Biomax (US, Biomax Inc).  	  
2.6 Immunoflourescent Analysis 
 
Prior to primary antibody addition, the samples were prepared as follows. 
Frozen sections were cut at a thickness of 7 µm using a 5030 Microtome Cryostat 
(Bright Instrument Co. Ltd,. Huntington, UK). These sections were fixed for 5 min at 
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room temperature in 4% paraformaldehyde in phosphate-buffered saline (PBS) 
containing 0.2 % Triton X-100 (Sigma) (Table 2.6). Cultured cells on coverslips were 
also fixed as above. Paraffin embedded sections and formalin embedded sections were 
cut at 4 µm using a microtome (Microm International GmbH) and incubated at 37°C 
overnight. These sections were then dewaxed with xylene and hydrated through alcohol 
gradients. Following this, formalin-fixed paraffin embedded sections were subjected to 
antigen recovery where slides were heated to over 65°C for 4 minutes in 10mM Na-
Citrate buffer.  
 
All sections and cells were then blocked for 30 min in 0.4% fish skin gelatin 
dissolved in TBS and 0.2 % Triton X-100 (Table 2.6). For sections primary antibody 
incubation was overnight at 4 °C and secondary antibody incubation was 45 minutes at 
room temperature with Alexa fluoro-conjugated antibodies (Molecular Probes). Tissue 
sections were mounted in Prolong Gold anti-fade reagent (Invitrogen) with 4',6-
diamidino-2-phenylindole (DAPI), which was used as a counter stain. For cultured cells 
on coverslips, both primary and secondary antibody incubation was for 45 minutes each 
at room temperature. Images were taken with a Nikon Eclipse E600 microscope with 
x20 (NA 0.4) objectives, using CoolSnap digital camera (QImaging Inc., Canada) using 
QCapturePro software. Image J software suite was used to perform image analysis. 
Confocal images were obtained using a Zeiss LSM 710 inverted confocal microscope 
(Zeiss).  
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Table 2-6 Recipes for fixative and blocking solutions used in immunofuorescent analysis 
 
 
 
2.6.1 Confocal microscopy and Nuclear Volume calculations 	  
Confocal images were obtained using Zeiss LSM 510 (Zeiss) laser confocal 
microscope with a Plan Apochromat 63x NA 1.40 oil immersion lens. Using the Z-stack 
function of ZEN 2009 software (Zeiss), a quick scan along XY axis was done to 
determining the end and start point of each stack. Once these were chosen, confocal Z-
stacks of lamin constructs transfected REKs immunostained for anti-flag and loricrin 
were acquired with Z-stacks, each consisting of 65 optical slices. Once images were 
acquired threshold settings and background elimination was done using Fiji Image J 
software suite. The files were then converted to 8-bit images in greyscale and were 
uploaded to Volocity®3D Image Analysis Software. Nuclear volumes were thus 
determined setting the parameters to find objects based on intensity and exclude objects 
smaller than 3000 µm3. 
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2.6.2 Immunofluoresent analysis of Ctsh -/- and Ctsh +/- mouse epidermis, and 
cornified envelope analysis 
 
Both wild type and Ctsh deficient mice skin were fixed in Bouin’s solution and 
embedded in paraffin, sectioned and stained as described in section 2.5. Cornified 
envelopes were extracted from whole neonatal skin by boiling for 10 min in Buffer IB 
(2% SDS in 0.1M Tris and 2mM EDTA). Large pieces of skin were discarded and 
remaining solution containing the cornified envelopes were pelleted by centrifugation at 
10,000 RPM for 5 minutes and washed in PBS, pelleted again and resuspended in PBS 
for counting under microscope. Sonication was done for 5 seconds on 50 µl of cornified 
envelope suspension using Vibra-Cell™Ultrasonic Processor (Sonics®). 
Acknowledgement: I would like to thank Professor Thomas Reinheckel (Institute of 
Molecular Medicine and Cell Research, University of Freiburg) for providing wild type, 
Ctsh +/- and -/- mouse skin samples. 
2.7 Haematoxylin and Eosin (H&E) staining 
 
Sample sections were cut and dewaxed as described above (section 2.6), they 
were stained in haematoxylin solution Gill III (Merck) for 3 minutes. Slides were then 
placed under running tap water for 2 min before briefly dipping acid alcohol solution 
(0.1 M HCl in 70 % ethanol). After the acid differentiation step the sections were placed 
in running tap water for 2 min and stained with eosin for 30 sec. Sections were washed 
again in running tap water for 2 min, dehydrated through 95 % ethanol (5min), 2 
changes of 100% ethanol (5 min each) and cleared in 2 changes of xylene (5 min each), 
and mounted in DEPEX. 
2.8 Gene expression analysis 	  
2.8.1 RNA extractions 	  
RNA was extracted from REKs was obtained using a standard 
Trizol:Chloroform extraction method followed by using RNeasy Plus mini Kit 
(Qiagen). Briefly, Cells were homogenized in chilled Trizol. Chloroform was added to 
separate the mixture into a phenol-chloroform phase, an interphase and an aqueous 
phase which contained the RNA. RNA was precipitated from the aqueous layer using 
isopropanol, pelleted and washed in 70 % ethanol, centrifuged at 7,500 x g for 4 min at 
4°C, and the pellet redissolved in RNase free water and proceeded with RNeasy Plus 
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mini Kit as per manufacturers protocol. Briefly, homogenizing buffer RLT was added to 
the sample and the solution was transferred to a genomic DNA eliminator spin column 
placed in a collection tube and centrifuged for 30s at 8000x g. Spin column was 
discarded and ethanol was added to the flow through and transferred to an RNeasy spin 
column and centrifuged for 15 sec at 8000x g and the flow through was discarded. The 
spin column membrane was washed couple of times with buffer RPE by centrifuging 
for 15 sec at 8000x g to remove traces of ethanol. The RNA was finally eluted by 
adding RNase-free water directly to the spin column placed in a new collection tube and 
centrifuging at 8000x g for 1 min. The concentration of RNA was determined by a 
Nanodrop Spectrophotometer (Agilent).	  	  
2.8.2 cDNA synthesis and PCR  
 
First strand cDNA was synthesized from RNA using random hexamers with 400 
ng/µl random hexamers (Life Technologies) per 1 µg of RNA. Master mix (Qiagen) 
was made up according to Table 2.7 and these were added to each RNA:hexamer mix 
and placed in a covered heated block for 42° C for 60 min and 70° C for 10 min. Both 
normal PCR and Real Time PCR was performed on cDNA from RNA extracted from 
normal REKs, transfected and overexpressed cells using the master mix recipe in Table 
2.7 and program in Table 2.8. Gene expression was normalized using the housekeeping 
gene ACTB (β-Actin). Quantitect primers were purchased from Qiagen and are listed in 
Table 2.9. For Real Time PCR, fold differences were calculated using the ΔΔCt method 
(Bustin and Mueller, 2005). Briefly, the cycle threshold (CT) was recorded for the 
target genes of interest and the housekeeping gene ACTB (β-Actin). Mean values for 
triplicate wells for each gene was calculated and using the following equation: ΔΔ CT = 
ΔCT (gene of interest) - ΔCT (ACTB), where 2 (-­‐ΔΔ	  CT) calculated fold change in target 
gene normalized to the endogenous house keeping gene.  
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Table 2-7 Master mix solutions for cDNA synthesis and PCR 
 
 
Table 2-8 PCR programs 
 
  
 
 
Table 2-9 QuantiTect Primer Assays  
 
 	  	  
Product Company Catalogue number 
Rat Filaggrin Qiagen QT00425691 
Rat β-Actin Qiagen QT00193473 
Rat Serpinb9 Qiagen QT00413840 
Rat Serpin b3 Qiagen QT00457800 
Rat F2rl2 Qiagen QT00454818 
Rat Ctsh Qiagen QT00182105 
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2.9 Microarray analysis and IPA analysis 
 
 0.1 mg RNA was extracted from 2 control (scrambled) REK lines and 2 
biological replicates of each Akt1 shRNA knockdown cell line. After second strand 
synthesis using Superscript II kit (Invitrogen), biotinylated cRNA was made from this 
cDNA using BioArray HighYield RNA Transcript Labeling Kit (Enzo Diagnostics). 
cRNA was then purified, fragmented and hybridised to the exon array rat genome chip 
(Affymetrix, Santa Clara, California) according to manufacturers’ specifications. 
Scrambled controls were used to provide baseline values in all analysis. Genes that were 
tagged as present and differentially expressed with ≥ 1.5 fold with a p-value ≤ 0.05 by 
Mann-Whitney analysis and a p-value less than 0.05 after Benjamini-Hochberg False 
Discover Rate correction were considered for analysis. For background correction and 
normalisation data was imported to GeneSpring (Agilent) for correction using the RMA 
16 (Robust Multi-array Analysis) summarizing method (Institute of Child Health 
Microarray and High Throughput Sequencing Facility, UCL Genomics). Differentially 
regulated genes were further analysed using Ingenuity Pathway Analysis (IPA) 
Software. Data sets including the gene identifiers and expression differences were 
uploaded into the application; these genes were overlaid onto a global molecular 
network produced by information available in the Ingenuity Pathways Knowledge Base 
(www.ingenuity.com).  
 
2.10 Mass spectrometry 
 
Total protein lysate of scrambled controls and Akt1 kd cells were separated on 
an SDS-PAGE gel, stained with colloidal Coomassie Blue for 30 minutes on a shaker at 
room temperature. Differentially expressed bands were excised, and de-stained 
overnight in distilled water. The gel pieces were then dehydrated and proteolysis 
performed by adding Trypsin and incubated overnight in a water bath at 37°C. Peptides 
were analysed by Kevin Mills and Wendy Heywood of the UCL proteomic facility 
using a combination of Nanoflow HPLC unit with ElectroSpray Ionisation-Time-of-
Flight Mass Spectrometry (ESI-QTOF MS) allowing desalting and separation of 
peptides prior to analysis which increases sequence coverage and number of peptides 
sequenced. Identified proteins were given a UniProt accession number and those with a 
PLGS (ProteinLynx Global SERVER) score of greater than 46 where p < 0.05 were 
considered for analysis. The formula for calculating the PLGS score is -10*log (P), 
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where P is the probability that the observed match between experimental and database 
sequence is a random event.  
2.11 Statistics 
 
Data is expressed as means (±SEM), with differences between means analysed 
with GraphPad Prism™ Software. The following tests were applied: Fishers exact test, 
Analysis Of Variance (ANOVA) and non-parametric Mann-Whitney U test with two-
tailed test of significance. Differences at P <0.05 were considered to be statistically 
significant. 
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 : Akt1 controls key processes in epidermal terminal Chapter 3
differentiation and cornified envelope formation 
 
3.1 Introduction 
 
Skin is comprised of a stratified epidermis with histologically distinct four 
layers, basal, spinuous, granular and cornified layer, each layer characterised by specific 
cell morphology and unique stage of differentiation (Fuchs, 2007; Watt, 2002). The 
keratinocyte is the main cellular constituent found within the human stratified squamous 
epithelium, and by a tightly controlled process of growth arrest and differentiation, the 
highly cross-linked protein component is enveloped by covalently linked lipid 
molecules thus forming the cornified layer or stratum corneum (Fuchs & Raghavan 
2002; Hardman et al., 1999). During the early stages of keratinocyte differentiation the 
early differentiation markers K1 and K10 are expressed and as the cells move into the 
granular layer, they begin the expression of cornified envelope precursors, also known 
as late differentiation markers, such as involucrin, loricrin and profilaggrin (Coulombe 
and Wong, 2004; Segre, 2006; Presland, 1992). The keratinocyte terminal 
differentiation culminates in the formation of the cornified layer, which begins when 
filaggrin binds to the keratin filament network in the upper granular layer of the 
epidermis ending with the formation of compact dead squame that forms the stratum 
corneum (Watt and Green, 1981; Manabe et al., 1991). These differentiated cells are 
eventually shed from the stratum corneum and continuously replaced through 
proliferation of stem cells in the basal layer (Proksch et al, 2008). 
 
Filaggrin is an important component of the stratum corneum contributing largely 
to its physical integrity, hydration, antimicrobial activity and pH amongst other 
properties (Rawlings and Harding, 2004; Kezic et al., 2008). Additionally filaggrin is 
also suggested to play a role in nuclear degradation, hence the extensive proteolytic 
processing of its precursor profilaggrin is a highly controlled process both temporally 
and spatially, to ensure the mature filaggrin monomers are produced in a timely manner 
that does not compromise the integrity of the epidermal barrier (Presland et al, 1997). In 
fact aberrant filaggrin processing has been reported to lead to defects in stratum 
corneum formation (Hewett et al., 2005 & List et al., 2003), and mutations in filaggrin 
predispose individuals to skin disorders such as AD and ichthyosis vulgaris (Palmer et 
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al., 2006; Smith et al., 2006 ; Weidinger et al., 2007). Filaggrin mutant mice (flaky tail) 
have a defective skin barrier and increased allergic sensitization, both of which are 
common characteristics of AD skin (Fallon et al., 2009; Oyoshi et al., 2009). Taken 
together these reports highlight the necessity for proper filaggrin expression in skin 
barrier formation. However only about 25 % of AD patients have filaggrin mutations 
suggesting the importance of other mechanisms involved in the processing of this 
protein in stratum corneum formation (Brown et al., 2009; Smith et al., 2006; Enomoto 
et al., 2008). 
 
Multiple signalling pathways act both sequentially and in parallel to regulate 
keratinocyte differentiation (Dotto, 1999). Signalling cues from both Notch and Wnt 
gene families have been reported to regulate commitment to differentiation (Fuchs and 
Raghavan , 2002; Dotto, 1999). Specific protein kinase C family members have been 
shown to regulate expression of late differentiation markers required for cornified 
envelope formation (Dotto, 1999). The p63 pathway is reported to be important for key 
events in the development and differentiation of the epidermis, including barrier 
formation (Koster et al., 2002). However, the complex events leading to skin barrier 
competence are still poorly understood and with the increase in prevalence of skin 
disorders (Aberg et al., 1995; Simpson et al., 2009; Danielsen et al., 2013), a wider 
knowledge is required for better therapeutic options. Akt, or protein kinase B, a major 
downstream effector of insulin and growth factor signalling pathway, has been 
implicated in regulating differentiation of many tissues such as bone, muscle and skin 
(Peng et al., 2002). In fact, Akt1 activity has been found to be required for filaggrin 
processing and skin barrier competence (O’Shaughnessy et al., 2007; Thrash et al., 
2006), and previous findings have established that both phosphorylation of heat shock 
protein 27 (Hsp27), a known substrate of Akt, in the upper granular layer and its 
transient co localisation with filaggrin in the keratohyalin granules in the cytoplasm 
occurs in an Akt1 dependent manner (O’Shaughnessy et al., 2007; Jonak et al., 2007).  
 
In this study, we generated Akt1 knockdown rat epidermal keratinocyte (REK) 
cell lines to more fully understand the role of Akt signalling in the keratinocyte 
differentiation program, with a specific aim to evaluate further the role of Hsp27 in 
filaggrin processing. We hypothesised that in the absence of or in reduced Akt1 
phosphorylation, Hsp27 forms complexes or interacts with other molecules and 
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therefore is not accessible to form interactions with filaggrin, hence interfering with 
filaggrin processing. 
 
3.2 Results 
3.2.1  Post confluent REKs mimic terminally differentiating cells in granular and 
transitional layer 
 
 As stages of keratinocyte differentiation are defined by specific expression 
patterns of keratinocyte markers (Fuchs, 2007), REKs were grown to post confluence 
and expression of differentiation markers at both pre- and post-confluent cultures were 
determined. Compared to pre-confluent cultures, post-confluent cultures expressed 
higher levels of early keratinocyte marker K1 and increased expression of profilaggrin 
and the monomeric mature subunit filaggrin, suggesting these cells are more 
differentiated and are a good model for granular and transitional layer keratinocytes 
(Fig 3.1). pSer473Akt phosphorylation is detected only in post confluent cultures and 
increases as cells become more confluent at days 5 and 6 (Fig 3.1). Previous findings 
have reported that Akt phosphorylation peaks in the terminally differentiating granular 
layer during barrier acquision stage of mouse embryonic development (O’Shaughnessy 
et al., 2007), suggesting that REKs at day 5 and 6 are likely to be at this terminal 
differentiation stage.  
 
Heat shock protein 27 (HspB1), co-localises with filaggrin in keratohyalin 
granules and the phosphorylated form (pSerHspB1) is most prominent in the granular 
layer during the mouse embryonic barrier acquisition (O’Shaughnessy et al., 2007). 
This report also showed the trimeric (75 kDa) phosphorylated form was increased 
during barrier acquisition while total HspB1 remain unchanged (O’Shaughnessy et al., 
2007). Agreeing with this data, an increase in the pSerHspB1 75 kDa phosphorylated 
form was observed in post confluent cultures while no obvious change was observed in 
monomeric total HspB1 25 kDa form (Fig 3.1). Taken together these results indicated 
that as REKs are grown to post confluence they achieve a differentiated state mimicking 
the granular and transitional layer of the skin. Hence in all further experiments, we 
chose the optimum time-point where the cells are terminally differentiated; all 
subsequent analyses were performed on cells cultured to post-confluent day 5. 
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Figure 3.1 Post confluent REKs mimic terminally differentiating cells in stratum granulosum. 
Western blot of epidermal differentiation markers, Akt and Hsp27 in pre and post-confluent REKs. Pre 
confluent cell cultures at days 2 and 3 showed low levels of the early differentiation marker K1, late 
differentiation marker profilaggrin and its mature subunit filaggrin in comparison with post confluent 
cultures at days 4, 5 and 6. Monomeric total Hsp27 remained unchanged with increase in the trimeric 
forms in both total and phosphorylated forms of Hsp27 in post confluent cultures. pAkt was undetectable 
in pre confluent cultures with increasing levels in post confluent cultures. Total Akt remained unchanged 
while basal keratin 5 showed a decrease in protein levels in day 6. All westerns are representative images 
from n=2. Protein lysates were prepared using total lysis buffer. 
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3.2.2 Filaggrin processing is Akt dependent and the Akt1 shRNA REK organotypic 
model phenocopies AD skin 
 
 Akt phosphorylation was reduced in REKs using Akt1 shRNA-mediated 
knockdown of Akt1 expression and by using the pharmacological PI3 kinase inhibitor 
wortmannin, a drug that can inhibit all downstream signaling pathways of PI3 kinase 
including Akt (O’Shaughnessy et al., 2007a; Lam et al., 1994). Real time PCR analyses 
of Akt1 knock down REKs showed no significant change in mRNA levels of filaggrin 
(Fig 3.2). In both A1 and A3 Akt shRNA REKs there was a reduction in Akt 
phosphorylation of more than 60 % in post confluent cultures (Fig 3.3A & B). Overall 
filaggrin processing, and total filaggrin levels were reduced with a significant reduction 
in the mature monomeric filaggrin subunit in both shRNA Akt1 knockdown REKs and 
Wortmannin-treated cells (Fig 3.3A & B) suggesting that Akt activity is required for 
filaggrin processing. No appreciable change was observed in the early differentiation 
markers K1 and K10 (Fig 3.3A). The late differentiation marker loricrin was reduced in 
the wortmannin treated cells (Fig 3.3B), and also in the Akt1 shRNA expressing cells, 
with line A3 showing the largest reduction. Expression levels of total Akt and keratin 5 
remained unchanged. These results were confirmed in post confluent human 
keratinocytes where a reduction in pAkt and overall filaggrin levels processing was 
observed after wortmannin treatment (Fig 3.4). 
 
 
 
 
 
Figure 3.2. Real Time PCR results of filaggrin mRNA expression levels in scram and both Akt1 
shRNA expressing cell lines.   
Statistical analysis was performed using the non-parametric Mann-Whitney U-test. Significance was 
defined as p<0.05. NS = not significantly different 
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Figure 3.3. Reduced Akt phosphorylation is associated with decrease in filaggrin processing. 
(A) Immunoblot of anti Akt-1 showed a reduction of Akt1 protein levels by more than 60% in both Akt1 
shRNA expressing cells. Western analysis also showed a reduction in pAkt and a reduction in late 
differentiation marker loricrin, greatest in A3. Overall filaggrin processing and levels were significantly 
reduced (n=3) in both Akt-1 shRNA expressing cells. The basal keratin 5 remained unchanged and no 
appreciable difference was observed in the early differentiation markers K1 and K10 in the Akt1 siRNA 
expressing cells. (B) Western analysis also showed a reduction of pAkt by more than 60 % in wortmannin 
treated REKs. Immunoblots of anti-loricrin showed a reduction in loricrin while the basal keratin 5 
remain unchanged in Akt inhibited cells. Overall filaggrin processing and levels were decreased 
significantly (n=3) in wortmannin treated cells. ** p ≤ 0.01(Mann-Whitney U test). Filaggrin western 
images are representative images from n=3. All the other western images are representative images from 
n=2. Protein lysates were prepared using total lysis buffer. 
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Figure 3.4. Reduced Akt activity is associated with over all reduction in filaggrin processing in human 
keratinocytes.  
Western analysis showed a reduction in pAkt and overall filaggrin processing and levels in cells treated 
with the pharmacological PI3 Kinase inhibitor, wortmannin. All western images are representative 
images from n=2. Protein lysates were prepared using total lysis buffer. 
 
 
When Akt1 knockdown REKs were grown in organotypic culture on a de-
epidermalized dermal scaffold and examined, they displayed hyperkeratosis, a 
thickened cornified layer, and parakeratosis (nuclei retention in the stratum corneum) 
(Fig 3.5 H&E), two features which are characteristic of AD skin (Guttman-Yasskey et 
al., 2011; Nakamura et al., 2011).  The expression patterns of keratinocyte 
differentiation markers were observed by immunofluorescent analysis. Consistent with 
the western data, confirmation of Akt1 knock down was observed along with a 
reduction in filaggrin protein expression in the granular layer of Akt1 shRNA 
expressing cultures. Similar to the western analysis, no obvious change was observed in 
the K1 or K10, while a reduction in loricrin was observed in A3 (Fig 3.5).  
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Figure 3.5. Akt1 shRNA REK model phenocopies AD skin.  
H&E sections of Akt1 deficient organotypic cultures displayed thickening of the stratum corneum 
(hyperkeratosis) and retention of nuclei (inset; black arrow heads) in the stratum corneum 
(parakeratosis) in comparison with the scrambled. Double sided black arrows indicate the thickened 
cornified layer. Organotypic cultures of scrambled and 2 cell lines expressing shAkt1 (Akt1 shRNA) were 
immunostained for expression of Akt1, early keratinocyte differentiation markers Keratin 1,Keratin 10 
and late differentiation markers loricrin and filaggrin. A reduction in Akt1 was observed in both shAkt1 
expressing cells. While no change was observed in K1 and K10, a small reduction was observed in 
loricrin in A3. Filaggrin protein levels were decreased in both shAkt1 expressing cell cultures. The 
sections were counterstained using Dapi (blue). Scale bar 50 µM. All images are representative images 
from n=2. 
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3.2.3 Akt inhibition reduced filaggrin and pSerHspB1 co-localisation 
 
HspB1 phosphorylation in the epidermis is Akt-dependent (O’Shaughnessy et 
al, 2007). Consistent with this, western blot analysis showed a reduction in pSerHspB1 
of both the trimeric 75 kDa form and the monomeric 25 kDa form in both Akt1 knock 
down cell line (A3) and Akt inhibited cells while the total HspB1 levels remained 
unchanged (Fig 3.6A & B). It is possible reduction of pSerHspB1 is dependent on level 
of Akt1 knock down which may explain why no change in pSerHspB1 monomeric and 
trimeric forms was observed in Akt1 A1 shRNA. Unphosphorylated HspB1 exists as a 
monomeric form but can form large oligomers (minimum 22 mers and over), whereas 
phosphorylation of HspB1 breaks down these large oligomers and dramatically changes 
the dynamics towards formation of small oligomers such as the dimeric and trimeric 
forms (Hayes et al., 2009).  
 
HspB1 phosphorylation and its transient interaction with filaggrin in the 
keratohyalin granules in the granular layer is Akt1 dependent (O’Shaughnessy et al., 
2007). To determine whether this interaction is observed in Akt inhibited REKs, co-
immunofluorescence was performed on confluent cells treated with wortmannin. 
Results indicated co-localisation with pSerHspB1 in the DMSO (control) treated cells, 
which was greatly reduced in the Akt inhibited REKs, consistent with the published 
data (O’Shaughnessy et al., 2007). In addition, in the Akt inhibited cells, pSerHspB1 
expression was more prominent in the periphery of the cells (Fig 3.7A), reminiscent of 
the F-actin staining observed in keratinocytes (Fig 3.7B) prompting the question 
whether F-actin and pSerHspB1 might be interacting. 
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Figure 3.6. Reduced Akt activity reduced levels of pSerHspB1.  
(A) Western blot analysis of Akt1 shRNA expressing cells showed a reduced protein expression levels of 
both the monomeric and trimeric pSerHspB1. (B) Treatment with the PI3 kinase inhibitor, wortmannin 
also decreased both the monomeric and trimeric forms of pSerHspB1 while total HspB1 remained 
unchanged. All westerns are representative images from n=2. Protein lysates were prepared using total 
lysis buffer. 
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Figure 3.7. Akt inhibition reduced filaggrin and pSerHspB1 co localisation. 
 (A) Co immunofluorescent analysis of filaggrin (green) and pSerHspB1 (red) on post confluent REKs 
treated with PI3 kinase inhibitor wortmannin compared with the control (DMSO). (B) Phalloidin stained 
F-actin (red) at the cell periphery in post confluent REKs. DAPI (blue) was used as a counter stain. Scale 
bar 10 µM. (C) Densitometric quantification of co-localised signals between filaggrin and pSerHspB1 in 
DMSO and wortmannin. Images displayed in this figure are representatives from n=2.  
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3.2.4 Increased HspB1-Actin interaction in Akt1 shRNA cells 
 
 Phosphorylated HspB1 has been reported to have a regulatory role in actin 
filament dynamics. In fact a well characterised role of monomeric HspB1 is its ability to 
bind to actin microfilaments and inhibit F-actin polymerization by capping the ends or 
by binding to G-actin and sequestering them (Lavoie et al., 1993; Guay et al, 1997), 
whereas pSerHspB1 inhibits G-actin sequestering (Guay et al, 1997). To investigate the 
potential interaction between HspB1 and actin, co-immunoprecipitation (co-IP) with an 
agarose-conjugated anti-HspB1 antibody, was performed on both Akt inhibited 
(Wortmannin treated) and Akt1 shRNA expressing REKs.  
 
IP western blot analysis showed an increased interaction between HspB1 and 
actin in both Akt inhibited and Akt1 knock down cells in comparison with the controls 
where the interaction was reduced. IP western analysis showed reduced interaction 
between HspB1 and filaggrin in Akt inhibited cells consistent with the reduced co-
localization observed in the co immunofluorescence results in Fig 3.7A (Fig 3.8). A 
specific subset of filaggrin intermediates associated with HspB1 consistent with 
previous reported data (O’Shaughnessy et al., 2007). Interestingly immunostaining of 
F-actin in wortmannin treated REKs showed enhanced F-actin polymers at the cell 
periphery compared to the control (Fig 3.9).  
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Figure 3.8. Decreased HspB1-filaggrin and increased HspB1-Actin interaction in REKs with reduced 
Akt phosphorylation. 
 (A) Co-IP western blot analysis of interaction between filaggrin and HspB1 in wortmannin treated cells 
showed a decreased HspB1-filaggrin association in comparison with the control (DMSO). (B) Co-IP 
western analysis of interaction between actin and HspB1 in both Akt1 shRNA cells and wortmannin 
treated cells showed an increased HspB1-actin association in both treatments in comparison with control 
(DMSO). Westerns are representative images form n=2. Protein lysates were prepared using RIPA lysis 
buffer. 
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Figure 3.9. Enhanced F-actin staining at the cell periphery in cells with reduced Akt phosphorylation.  
Phalloidin stained F actin (red) at the cell periphery. Dapi (blue) was used as a counter stain. Scale bar 
10 µM. All images are representative images from n=2. 
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3.3 Discussion 
 
Although the filaggrin gene (FLG) and the association of FLG null mutations 
with AD has been well characterised, the exact mechanism of the processing of 
profilaggrin to filaggrin is still incompletely understood. The data described here 
support Akt1 as an important signalling molecule in keratinocyte differentiation and 
identifies Akt1 as a key component in filaggrin processing, and furthermore establishes 
the Akt1 shRNA organotypic and cell culture model as an appropriate model to 
investigate the role of Akt1 in late stage terminal differentiation. 
 
The reduction in phosphorylated HspB1 observed in Akt1 knockdown cells and 
wortmannin inhibited cells, is consistent with previous findings (O’Shaughnessy et al., 
2007), and the reduction in filaggrin processing in both treatments suggests that Akt1 
activation is required for both HspB1 phosphorylation and filaggrin processing. Since 
HspB1 shRNA knockdown organotypic models displayed hyperkertosis and reduced 
filaggrin expression (O’Shaughnessy et al, 2007), the role of HspB1 in filaggrin 
processing may be Akt1 mediated. The Akt1 shRNA expressing organotypics 
demonstrated both hyperkeratosis and parakeratosis, which are two characteristics of 
AD skin (Leung and Bieber, 2003) suggesting that the Akt1 shRNA model phenocopies 
AD.  
 
These data show an Akt1-dependent co-localization of filaggrin with 
pSerHspB1 consistent with previously reported data (O’Shaughnessy et al., 2007), 
where Akt1 activation was required for filaggrin-HspB1 co-localisation. Results also 
indicated that reduction in Akt activity caused a change in pSerHspB1 localisation, 
leading to more pronounced expression in the cell periphery similar to F-actin staining 
observed in keratinocytes. Immunoprecipitation data showed that reduction in Akt1 
activity resulted in an increased association between HspB1 and actin. These results 
would imply that switch from a HspB1-actin interaction to a HspB1-filaggrin 
interaction is Akt1 mediated. Actin dynamics have been reported to change dramatically 
during proliferation and differentiation of cells (Watt, 1986; Ben-Ze’ev, 1987). It has 
been reported that in more stratified keratinocyte cultures, actin staining at the cell 
periphery in cells in the suprabasal layer is less defined and more diffuse in comparison 
with basal cells (Kubler et al., 1991; Lewis et al., 1987). However in the differentiated 
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cell cultures with reduced Akt activity, actin staining was more defined and prominent 
at the cell periphery, where as in the control cultures the F-actin staining was less 
defined similar to published data (Kubler et al., 1991). In stratified keratinocyte 
cultures, the subrabasal cells have more diffuse and less defined F-actin staining at the 
cell periphery similar to what is observed in the DMSO treated cells in Fig 3.9 (Kubler 
et al., 1991; Lewis et al., 1987). Hsp27 binds F actin, an action favoured by monomeric 
unphosphorylated Hsp27 (Graceffa, 2011; During et al., 2007). Furthermore, 
unphosphorylated Hsp27 binding is concentrated at F-actin polymerizing sites, and once 
phosphorylated, Hsp27 does not localize to these regions (During et al., 2007). Taken 
together, this data suggests that the unphosphorylated monomeric Hsp27 binds to the 
actin stabilizing the actin cytoskeleton, which will explain the persistent actin staining 
in Akt1 shRNA knock down cells. Since the phosphorylated trimeric form does not bind 
to actin, it thus binds to filaggrin facilitating proper filaggrin processing. It is also 
interesting to note that phosphorylation of Hsp27 enhances its chaperone activities 
(Hayes et al., 2009). 
 
The data presented here demonstrates that pSerHspB1-filaggrin interaction and 
filaggrin processing are both Akt1 dependent, and we propose that the reduced filaggrin 
processing observed in Akt1 shRNA knock down cells is due to maintained HspB1-
actin interaction. 
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 : Cathepsin H, an Akt1 dependent epidermal protease Chapter 4
in profilaggrin processing, is reduced in eczema 	  
4.1 Introduction 	  
Abnormalities in the immune system have been strongly attributed to the 
development of AD (Von Bubnoff et al., 2001; Novak et al., 2003). However, current 
evidence suggests that primary cause for disease development in the majority of AD 
cases is a defective skin barrier, suggesting the observed inflammation is a secondary 
effect of this inherent barrier defect (Callard and Harper, 2007; Jakasa et al., 2006). 
Epidemiological research has revealed a strong genetic component to AD and to skin 
barrier function in the disease (Schultz-Larsen, 1993; Cork et al., 2006). One protein of 
particular interest is the epidermal structural protein filaggrin, where null mutations in 
the FLG gene are associated with an inherited eczematous disease, ichthyosis vulgaris, 
and have been established as being a major predisposing factor for AD (Presland and 
Dale,  2000; Palmer et al., 2006). However several studies have shown that only ¼ of 
AD patients have filaggrin mutations (Smith et al., 2006; Weidinger et al., 2007; Brown 
et al., 2009), and not all individuals with filaggrin mutations have AD (reviewed in 
O’Regan et al., 2008), suggesting that other mechanisms might give rise to the barrier 
defect observed in AD patients. The importance of filaggrin for proper barrier function 
has been demonstrated by numerous studies using filaggrin mutant mouse models 
where filaggrin deficient mice display barrier dysfunction and heightened percutaneous 
immune responses (Man et al., 2008; Fallon et al., 2009; Oyoshi et al., 2009). 
Profilaggrin to filaggrin processing is a complex process requiring dephosphorylation 
and numerous proteolytic events (Presland et al., 2004; Sandilands et al., 2007). Several 
distinct proteinases have been identified that cleave profilaggrin at specific sites 
releasing the filaggrin monomers and both the N and the C termini (reviewed in De 
Veer et al., 2014). Proteases such as Elastase 2 (Bonnart et al., 2010), SASPase (Matsui 
et al., 2011), and serine proteases Matriptase/MT-SP1 (List et al., 2003) are reported to 
be involved in profilaggrin to filaggrin processing.  
 
Microarray analysis was performed to profile differentially expressed genes in 
Akt1 kd keratnocytes to identify proteases downstream of the Akt signaling pathway 
and elucidate further their potential involvement in filaggrin processing and barrier 
function. Additionally, expression patterns of any identified protein of interest from the 
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array analysis were characterized in skin biopsies from non-affected skin of AD 
patients. 	  
4.2 Results 	  
4.2.1 Ctsh is down regulated in Akt1 knock down REKs (microarray data) 	  
Affymetrix DNA microarray analysis was performed on both shRNA Akt-1 
knock down REK cell lines, and analysis was limited to genes that demonstrated a fold 
change of ≥1.5 within the dataset. Scrambled shRNA was used as a control. A total of 
86 genes were differentially expressed with 34 genes up-regulated and 52 genes down 
regulated (Fig 4.1A). Of these 86 genes, 17 genes had differential expression ≥ 2 –fold, 
with the most differentially expressed gene, Cathepsin H (Ctsh), being down regulated 
over 4-fold.  Ctsh belongs to a group of lysosomal cysteine proteases that are part of the 
papain super family of cysteine proteases and unlike most of other members of cysteine 
proteases, Ctsh can function in the cytosol, nucleus and also outside the cell (Tedelind 
et al., 2010; Reiser et al., 2010). Few proteases were identified as being differentially 
regulated and out of these Ctsh, F2rl2, Serpinb9 and Serpinb3 were altered ≥ 2 –fold 
(Fig 4.1B). Real time PCR was performed on these 4 proteases to validate the array data 
and results indicated only Serpinb9 and Ctsh were significantly down regulated in both 
Akt1 shRNA expressing cell lines in comparison with the normal scrambled shRNA 
expressing control (Fig 4.1C).  
 
Using Ingenuity Pathways Analysis (http://www.ingenuity.com), relevant 
canonical pathways, gene regulation networks and biological functions significant to the 
data set were determined. To achieve this, data set containing gene identifiers of the 86 
genes and corresponding expression values were uploaded into the application. The 
canonical pathways with most significant changes were lipid metabolic pathways and 
LXR/RXR pathway (Fig 4.2). Retinoid X Receptors (RXR) are nuclear receptors that 
are involved in retinoic acid mediated gene activation (Chawla et al., 2001). RXR 
dimerizes with other type II nuclear receptors such as the Liver X Receptor (LXR), and 
the resulting heterodimer, RXR/LXR, is an important regulator of keratinocyte anti 
inflammatory responses and lipid synthesis in the skin (Chawla et al., 2001; Fowler et 
al., 2003). Furthermore RXR/LXR activation stimulates keratinocyte differentiation and 
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lipid synthesis leading to barrier formation (Fowler et al., 2003; Kömüves et al., 2002; 
Man et al., 2008).  
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Figure 4.1  Cathepsin H is downregulated by 4 fold in Akt-1 knock down REKS.  
(A) Heat map showing differently regulated genes with a fold change ≥ 1.5. Scrambled shRNA was used 
as a control. Yellow corresponds to high expression, blue corresponding to low expression and black 
corresponding to intermediate expression. (B) Heat map of differentially regulated proteases in Akt-1 
shRNA expressing cells. (C) Real Time PCR mRNA levels of F2rl2, Serpinb3 Serpinb9 and Ctsh. 
Statistical analysis was performed using GraphPad Prism by two-way analysis of variance (ANOVA). 
Significance was defined as p<0.05. ** p ≤ 0.01. 
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Figure 4.2 Canonical pathways and gene networks in Akt1 knock down cells.  
Ingenuity Pathway Analysis (www.ingenuity.com) was used to identify the most significant canonical 
pathways and relevant gene networks based on the data set. A. The Most significantly overrepresented 
pathways altered included lipid metabolic pathways and LXR/RXR pathway. Numbers above the bars 
indicate the number of genes in the canonical pathway identified from the IPA knowledge base. Y-axis 
represents the percentage of these genes present in the microarray data set. Fisher’s Exact Test was used 
to calculate p-value to assess significance of enrichment of the gene expression data.  	  
Almost half of the 86 genes studies clustered into two major networks; one 
associated with lipid metabolism and molecular transport where majority of the genes 
were down regulated (Fig 4.3A). Interestingly PCSK6 (also known as PACE4) which is 
a protein convertase involved in profilaggrin N-terminal processing (Presland et al., 
2009) was up regulated (Fig 4.3A). The other potential network is associated with cell 
morphology and cellular development (Fig 4.3B). This network was centered on Akt, 
which included Ctsh as one of the clustered genes. The protein metalloproteinases 
(MMPs), which are elevated in AD skin (Harper et al., 2010), and the transcription 
factor complex AP-1 whose activity is dysregulated in AD (Pastore et al., 2000) was 
also present in this network suggesting a potential association with Akt (Fig 4.3B). As 
the array analysis identified Ctsh as the most downregulated gene in the Akt1 knock 
down cells, this protease was further investigated to determine its role in keratinocyte 
differentiation. 
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Figure 4.3 Two major networks based on 86 genes differentially regulated in Akt1 knockdown cells. 
(A) & (B) Networks were generated using Ingenuity Pathways Analysis (IPA: www.ingenuity.com) in 
which, using information from IPA Knowledge Base, focus genes are clustered together as nodes in a 
network based on their interactions. Green represents down-regulated genes and red represents up-
regulated genes. Colour intensity is an indication of the degree of fold change. The network is completed 
by filling in genes from the Knowledge Base (nodes in white).  
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4.2.2 Cathepsin H, a novel epidermal protease that co localizes with filaggrin  
 
 Epidermal barrier acquision in the mammalian fetus occurs during late intra-
uterine development (Hardman et al., 1999). In mice the period of barrier acquisition 
takes place between embryonic days 16.5 (E16.5) and 18.5 (E18.5) with a competent 
barrier achieved by E18.5 (Hardman et al., 1998; O’Shaughnessy et al., 2009). 
Expression of granular pSer473Akt activity and Akt1 along with the cornified envelope 
protein filaggrin peaks in expression during this barrier acquisition stage 
(O’Shaughnessy et al., 2009). Consistent with this, Akt1 expression was at its highest at 
days E17.5 and 18.5 (Fig 4.4).  Similarly granular layer expression of Ctsh also 
increased at days E17.5 and 18.5 suggesting a possible involvement in the barrier 
acquisition process in mice. 
 
To evaluate whether Ctsh is involved in keratinocyte differentiation, western 
blot analysis was performed on both pre-confluent and post-confluent REK cultures. 
Ctsh protein levels were detected only in the more differentiated post confluent cultures 
mirroring the expression patterns of pSerAkt (Fig 4.5A and Fig 3.1) and keratin 1 (Fig 
3.1), whose expression levels increase during keratinocyte differentiation (Schweitzer 
and Winter, 1983; O’Shaughnessy et al., 2007), thus implying a possible role for Ctsh 
in keratinocyte differentiation (Fig 4.5A). The total Akt and pSer473Akt western blots 
in Fig 4.5A are also displayed in Fig 3.1. The doublet Ctsh bands observed in fig 4.5A 
are the mature 28 kDa form and the 22 kDa form. Ctsh often migrates as the single 
chain 28 kDa mature form and the processed 22 kDa heavy chain (Kiahimoto & Itoi, 
2013; Lu et al., 2007). It has been reported that the 22 kDa form can sometimes be lost 
in the process of sample preparation. This smaller species is suspected to be more 
susceptible to catalytic process involved in Ctsh turn over (Lu et al., 2007). The single 
Ctsh band detected in Fig 4.5B and C are therefore likely to be the 28 kDa form. 
Western blot analysis of post-confluent REKs showed a reduction in Ctsh protein levels 
in both Akt1 shRNA knock down REKs (Fig 4.5B) and in normal human epidermal 
keratinocytes (NHEKs) treated with the PI3 kinase pharmacological inhibitor 
wortmannin, suggesting a role for Akt1 in regulating Ctsh expression (Fig 4.5C). 
Judging from the size, it is likely the single Ctsh band detected here is the mature 28 
kDa form. 
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Figure 4.4 Granular Ctsh expression peaks during barrier acquision. 
Immunofluorescence of mouse embryonic sections from day 15.5 (E15.5) to day 18.5 (E18.5). Both Ctsh 
and Akt1 staining peaks in the granular layer at E17.5 and E18.5. These are representative images from 
n=2. 
	  
	  
Most cathepsins are constitutively expressed in several mammalian tissues 
(Brasch et al., 2002), while some cathepsins display cell specific expression such as 
cathepsin K which is expressed mainly in osteoclasts where they are involved in bone 
remodeling (Bromme et al., 1996) and cathepsin L is found to have an important role in 
hair follicle morphogenesis and epidermal homeostasis (Roth et al., 2000). Ctsh is 
found in high concentrations in specific tissues such as kidney, spleen, macrophages 
(reviewed in Guha & Padh, 2008) and in type II pneumocytes where it is critically 
involved in the N- terminal processing step of pro- surfactant protein C (Buhling et al., 
2011), however there is no data about its role and expression patterns in the epidermis. 
 
To determine Ctsh expression patterns in the skin, immunofluorescence staining 
for Ctsh on paraffin embedded Akt1 knock down organotypic REK sections were 
performed. Consistent with the western analysis, both Ctsh and filaggrin protein levels 
were reduced in Akt1 shRNA knock down organotypic culture models in comparison 
with the control (scram). Interestingly results indicated that filaggrin co-localized with 
Ctsh in the granular layer both in the Akt1 knockdown organotypic cultures and in 
normal human skin (Fig 4.6).      
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Figure 4.5 Ctsh protein is detected only in differentiated cells and is reduced in Akt-1 knockdown cells. 
A. Western blot analysis of anti-pSer473Akt, anti-total Akt, anti-Ctsh and anti-GAPDH in both pre and 
post confluent REKs. Note now Ctsh is detected only in post-confluent day 5 and 6 lysates. The Ctsh 
bands detected here are the 28 kDa mature form and 22 kDa heavy chain form.  B. Immunoblot showing 
anti-Ctsh in Akt1 shRNA expressing REKs. Only the mature 28 kDa mature Ctsh form is detected here. C. 
Immunoblot of anti-Ctsh and anti GAPDH in human keratinocytes (NHEKs) treated with inhibitor 
wortmannin at a concentration of 2µM for 24 hours. All westerns are representative images from n=2. 
Western blots for pSer473Akt and total Akt are also displayed in fig 3.1. Protein lysates were prepared 
using total lysis buffer. 
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Figure 4.6 Ctsh co-localizes with filaggrin in the granular layer. 
Normal human skin sections and rat epidermal keratinocyte organotypic culture expressing scrambled 
shRNA and 2 Akt1 shRNA expressing cell lines were co-immunostained with anti-Ctsh (red) and anti-
filaggrin (green). First three rows are from REK organotypic cultures, last row represent normal human 
skin sections. All sections were counterstained using Dapi (blue). Scale bar, 50 µM. All images are 
representative images from n-3. 	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To further evaluate the role of Ctsh in filaggrin processing, REKs were 
transfected with Ctsh shRNA. Knock down of Ctsh was confirmed by western blot 
analysis, which showed a reduction in Ctsh protein levels in both Ctsh shRNA cell lines 
(Fig 4.7A). Results also showed a reduction in monomeric filaggrin and overall 
filaggrin levels in day 5 post confluent cells hence suggesting the protease Ctsh has a 
role in filaggrin processing. Interestingly, at day 6, filaggrin levels decrease is greater in 
Ctsh shRNA expressing cells suggesting filaggrin is getting degraded. No change in 
filaggrin was observed at the transcriptional level suggesting Ctsh knockdown caused 
changes either in the overall profilaggrin protein levels, or in proteolytic processing of 
profilaggrin to filaggrin (Fig 4.7B). To determine whether filaggrin levels could be 
rescued by increasing Ctsh levels, post confluent Akt1 shRNA knock down cells were 
transfected with a Ctsh expressing plasmid. Western blot analysis confirmed elevated 
Ctsh expression levels and an increase in overall filaggrin levels in Ctsh over-
expressing cells in compared with the vector transfected cells (Fig 4.7C). 	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Figure 4.7  Ctsh over expression restores filaggrin protein levels in Akt-1 knock down REKs. 
A.Immunnoblot of anti-filaggrin, anti-Ctsh and anti GAPDH on scram and Ctsh shRNA expressing REKs 
collected on days 5 and 6.  B. Real Time PCR results of filaggrin mRNA expression levels in scram and 
both Ctsh shRNA expressing cell lines. Statistical analysis was performed using the non-parametric 
Mann-Whitney U-test. Significance was defined as p<0.05. NS = not significantly different. C. Western 
analysis of anti-filaggrin, anti-Ctsh and anti-GAPDH on scram and Akt1 shRNA expressing cells 
transfected with vector and Ctsh overexpressing plasmid. Note filaggrin increase of 65% and 30% in 
Ctsh overexpressed scram and Akt1 shRNA cells respectively in comparison with vector. Ctsh expression 
increase of 40% and 20% is also seen in scram and Akt1 shRNA expressing cells respectively in 
comparison with vector. All westerns are representative images from n=2. Protein lysates were prepared 
using total lysis buffer. 
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4.2.3 Aberrant profilaggrin processing and hyperkeratosis observed in both Ctsh 
+/−  and Ctsh − /−  mice. 
 
One of the most characterized roles of Ctsh is its involvement in the processing 
and secretion of lung surfactant protein B (Sp-B) (Ueno et al., 2004; Buhling et al., 
2011).  Reinheckel and colleagues demonstrated that Ctsh knockout mice have reduced 
secretion of Sp-B leading to an impaired surface tension in the lungs (Buhling et al., 
2011).  Although no gross phenotype was reported in the Ctsh null mice (Buhling et al., 
2011), closer inspection of the skin is necessary to discern whether barrier is 
compromised to a degree that could result in AD. Hence to understand role of Ctsh in 
barrier formation, isolated neonatal skin was analysed from 4 Ctsh homozygous mutant 
mice (−/−), 5 heterozygous mutant mice (+/−) and 2 control wild type mice (+/+). 
Sonication experiments on isolated cornified envelopes showed that both Ctsh+/- and 
Ctsh-/-  cornified envelope more labile to destruction by sonication compared with wild 
type (Fig 4.8).  
 
Histological analysis of paraffin embedded skin sections showed hyperkeratosis 
in both Ctsh+/- and Ctsh-/- in comparison with the wild type (Fig 4.9, top panels). 
Immunofluorescence staining with anti-Ctsh primary antibody confirmed reduction in 
Ctsh protein levels in the granular layer in Ctsh+/- and Ctsh-/- epidermis  (Fig 4.9). 
Filaggrin staining in the granular layer was also reduced in both Ctsh+/- and Ctsh-/- in 
comparison with the wild type (Fig 4.9).  Taken together these results indicated that 
Ctsh is important for key aspects of the physical skin barrier and that this may be 
mediated this by either direct or indirect involvement in filaggrin processing. 	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Figure 4.8  Increased cornified envelope fragility in Ctsh+/- mice.  
Intact cornifed cells were counted after a 5 second sonication on isolated cornified envelopes from 
samples Ctsh+/+ (n=2), Ctsh+/- (n=5) and Ctsh-/- (n=4). Data is expressed as mean ± SEM. Statistical 
analysis was performed using the non-parametric Mann-Whitney U-test. ** p ≤ 0.01.  	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Figure 4.9 Hyperkeratosis observed in both Ctsh+/- and Ctsh-/- skin.  
H&E staining (top row panels) and immunostaining of anti-Ctsh (red, 2nd row of panels), anti-filaggrin 
(red, 3rd row of panels) of Ctsh+/+, Ctsh+/- and Ctsh-/-. These are representative images of Ctsh+/+ (n=2), 
Ctsh+/- (n=3) and Ctsh-/- (n=3). DAPI (blue) was used as a counter stain. Scale bar 50 µM. 
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4.2.4 Granular layer Akt phosphorylation and Ctsh reduced in AD non-affected 
skin 
 
Genetic abnormalities leading to altered serine protease / serine protease inhibitor 
or filaggrin protein levels have led to the development of AD to be linked to a defective 
barrier (Walley et al., 2001; Smith et al., 2006; Fallon et al., 2009). One interesting 
example is where mutations in a serine protease inhibitor, SPINK 5 (SP inhibitor 
lymphoepithelial Kazal-type trypsin inhibitor), lead to Netherton syndrome (NS) where 
infants with NS develop severe AD (Walley et al., 2001; Hachem et al., 2006). Both in 
vitro and in vivo studies have identified other proteases such as Elastase 2, aspartic 
protease SASpase and Matriptase as being required for profilaggrin processing pathway, 
where a deficiency in any of these proteases lead to barrier anomalies (reviewed in De 
Veer et al., 2014). 
 
Results reported here have so far established Ctsh as a downstream target of the 
Akt signaling pathway and an important epidermal protease for barrier formation. Akt 
knockout mouse studies and in vitro studies presented both here and in the literature 
have demonstrated the requirement of Akt in keratinocyte differentiation and barrier 
acquisition (Thrash et al., 2006; O’Shaughnessy et al., 2007). Furthermore reduced Akt 
activity resulted in hyperkeratosis and parakeratosis, 2 features commonly observed in 
AD (section 3.2.2), however pSerAkt expression levels have not previously been 
characterized in non-affected skin of AD patients. Immunofluorescence staining of non-
affected skin sections (with entire skin intact) of 5 AD patients showed a reduction in 
granular pSerAkt activity in comparison with the normal skin (Fig 4.10A). Additionally 
granular layer filaggrin staining was reduced in all 5 AD patients (Fig 4.10A). 
Densitometric quantification showed both pSerAkt activity and filaggrin protein levels 
in AD non-affected skin sections were significantly reduced over all in comparison with 
normal skin (Fig 4.10B & C). Consistent with the Akt1 knockdown cells, granular layer 
CTSH expression was also decreased in all AD patients with a significant overall 
reduction in comparison with normal skin (Fig 4.11). 
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Figure 4.10 Significant reduction in both granular pSerAkt and filaggrin in AD non-affected skin. 
(A) Immunofluorescence staining for anti-filaggrin (green) and anti-pAktSer473 (red) in AD non-affected 
skin sections (n=5) and normal human skin (n=3). DAPI (blue) was used as a counter stain. White 
arrowheads denote positive granular pSerAkt staining in normal human skin. Dotted line indicates the 
boundary between granular layer and stratum corneum. (B & C) Densitometric quantification of 
immunofluorescence of pSerAkt expression and filaggrin in both normal and AD non-affected skin. 
Normal skin used in B are frozen sections. Normal skin used in C are paraffin embedded tissue sections. 
Densitometric quatification of immunofluorescence signals of both filaggrin and pAktSer473 were 
determined using ImageJ software. Data expressed as mean ± SEM. Statistical analysis was performed 
using the non-parametric Mann-Whitney U-test. Significance was defined as p<0.05.  * p ≤ 0.05, ** p ≤ 
0.01. au (arbitrary units). Scale bar 50 µM.  
	  	   112	  
	  	  	  
Figure 4.11 CTSH expression reduced in AD non-affected skin.  
Immunofluorescence staining for anti-CTSH (green) in uninvolved AD skin (n=5) and normal skin. DAPI 
(blue) was used as a counter stain. Densitometry quantification of CTSH immunofluorescence signals 
analysis in AD skin (n = 5) in comparison with normal skin (n = 3). Densitometric quantification of 
immunofluorescence signals were determined using ImageJ software. Data expressed as mean ± SEM. 
Statistical analysis was performed using the non-parametric Mann-Whitney U-test. Significance was 
defined as p<0.05. au (arbitrary units). Scale bar 50 µM. 	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4.2.5 Increased RAPTOR leads to decreased filaggrin expression 	  
The previous section showed that Akt activity is reduced in non-affected skin of a 
subset of AD patients. Research has shown that knock down of RAPTOR (regulatory 
associated protein of mTOR) increases Akt activity (Sarbassov et al., 2005). RAPTOR 
forms complexes with the regulatory kinase mTOR, which is one of the main effectors 
of Akt signalling (Wullschleger et al., 2006; O’Reilly et al., 2006). Sully et al. (2013) 
have demonstrated that treatment of keratinocytes with rapamycin, a drug that 
specifically inhibits the RAPTOR/mTORC1 complex, increases Akt activity by 
inhibiting the negative feedback loop that exists between mTORC1 and the receptor 
accessory protein insulin receptor substrate 1 (Sully et al., 2013).  
 
To investigate whether reduced granular pSerAkt expression observed in AD non-
affected skin could be the result of an increase in RAPTOR, RAPTOR was 
overexpressed in REKs using increasing doses of myc-tagged RAPTOR plasmid and 
the effect on Akt phosphorylation and filaggrin processing determined. Results 
indicated successful transfection showing increasing protein levels of both myc-tagged 
protein and RAPTOR. Western analysis also showed a dose dependent decrease in both 
Akt phosphorylation and filaggrin protein levels and potentially proteolytic processing 
in RAPTOR over-expressing cells (Fig 4.12). 	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Figure 4.12 Raptor increase causes dose dependent decrease in pSerAkt and filaggrin. 
Immunoblot of anti-myc, anti-RAPTOR, anti-RICTOR, anti-pSer473Akt, anti-total Akt, anti-filaggrin and 
anti-GAPDH on post confluent REKs transfected transiently with both vector and increasing doses of 
myc-tagged RAPTOR clone. All westerns are representative images from n=2. Protein lysates were 
prepared using total lysis buffer. 
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Figure 4.13 Rapamycin restores pSerAkt, Ctsh and filaggrin protein levels and processing in Raptor 
overexpressing cells.  
Western blot analysis of post-confluent REKs transiently transfected with RAPTOR clone after treatment 
with 10nM Rapamycin for 2 hours. DMSO was used as a control. (A) Western analysis of anti-filaggrin, 
anti-pSer473Akt, anti-total Akt and anti-GAPDH. (B) Immunoblot of anti-Ctsh and anti-GAPDH. Note: 
Numbers indicate fold change (as a percentage) of Ctsh levels in RAPTOR overexpressed cells in 
comparison with vector in each treatment group (DMSO and rapamycin). All westerns are representative 
images from n=2. Protein lysates were prepared using total lysis buffer. 
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Rapamycin treatment in RAPTOR over-expressing cells restored both pSerAkt 
levels and filaggrin processing (Fig 4.13A). Similarly, Ctsh protein levels that were 
reduced in RAPTOR over expressing cells, was also increased after rapamycin 
treatment (Fig 4.13B).  Taken together these results suggest that an increase in 
RAPTOR causes a decrease in Ctsh expression, filaggrin protein levels and processing. 
Immunofluorescence staining was performed on non-affected skin sections from AD 
patients and compared with normal skin sections to determine how RAPTOR 
expression varied with filaggrin expression. Results showed positive granular RAPTOR 
expression in majority of AD patients and in a subset of normal skin sections as shown 
in representative images in fig 4.14A, where RAPTOR positive expression is indicated 
by a clearly detectable signal in the suprabasal epidermis. Results also indicated that 
positive RAPTOR expression in AD was greater than that in normal skin. Consistent 
with the western analysis, positive granular RAPTOR expression was accompanied 
with reduced granular filaggrin expression in AD and significantly reduced in normal 
skin (Fig 4.14A & B). These results suggest that abnormal granular positive of 
RAPTOR leads to a decrease in filaggrin, and in AD RAPTOR expression is increased 
in comparison with normal sections.  	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Figure 4.14 Increase in granular RAPTOR expression correlates with decrease in filaggrin.  
(A) Representative images showing immunofluorescence staining of filaggrin and RAPTOR in both AD 
non-affected skin (n = 5) and normal skin (n = 13). Dotted line indicates the boundary between granular 
layer and stratum corneum. RAPTOR positive indicate a clearly detectable signal in the suprabasal 
epidermis (below the dotted white line). Note how positive RAPTOR expression in suprabasal layer in 
both AD and normal skin are accompanied with reduced filaggrin expression. (B) Densitometric analysis 
of the immunofluorescence staining shows RAPTOR increase is accompanied with a significant reduction 
filaggrin levels in normal skin. Densitometric quatification of immunofluorescence signals were 
determined using ImageJ software. Data expressed as mean ± SEM. Statistical analysis was performed 
using the non-parametric Mann-Whitney U-test. Significance was defined as p<0.05. ** p ≤ 0.01. au 
(arbitrary units). Scale bar 50 µM. The images of AD uninvolved skin sections with filaggrin staining are 
also displayed in Fig 4.10 
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The Retinoid signaling pathway, which is involved in skin homeostasis, is 
dysregulated in skin disorders including atopic dermatitis (Gericke et al., 2013; Mihaly 
et al., 2011). Retinoid based therapy has been beneficial in treating skin conditions 
(Orfanos and Zouboulis, 1998) and has shown successful results in chronic hand 
eczema patients (Bissonnette et al., 2010). To evaluate RAPTOR expression in response 
to retinoic acids, REKs were treated with the retinoic acid receptor (RAR) agonist all 
trans retinoic acid (ATRA) and RAR antagonist AGN193109. Western analysis showed 
RAPTOR expression decreases with ATRA treatment, while the antagonist, AGN, 
increased RAPTOR protein levels (Fig 4.15). Interestingly retinoic acids have been 
reported to increase Ctsh expression (Flentke et al., 2004). Based on these results and 
the reported improvement in barrier following retinoid treatment (Bissonnette et al., 
2010), it is possible the retinoids in skin are working via a mechanism where decrease 
in RAPTOR leads to an increase in Ctsh and filaggrin (Fig 4.16).  	  	  	  
	  	  
Figure 4.15 Retinoic acid treatment reduces RAPTOR expression in keratinocytes.  
Western blot analysis of anti-RAPTOR and anti-GAPDH on REKs treated with the retinoic acid receptor 
(RAR) agonist, all-trans retinoic acid (ATRA) and RAR antagonist AGN193109. Numbers indicate fold 
change (as a percentage) in RAPTOR expression in comparison with control (DMSO). 	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Figure 4.16 Model of a possible mechanism of how retinoic acid treatment can increase both Ctsh and 
filaggrin expression, and restore barrier defects. 	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4.3 Discussion 	  	  
One of the most compelling arguments in support of barrier defect being a 
prerequisite for AD, comes from research into the function of the cornified envelope 
protein profilaggrin and how mutations in this gene have a profound association with 
AD (Presland and Dale, 2000; Smith et al., 2006; Brown et al., 2009). Since about 25 % 
of AD patients have been found to not have filaggrin mutations (reviewed in O’Regan 
et al., 2008) it is possible the observed barrier defect in AD can rise from misprocessing 
of profilaggrin to its functional subunit filaggrin. Akt null mice models display 
hyperkeratosis, have reduced cornified envelope strength and reduced filaggrin 
expression (Thrash et al., 2006; O’Shaughnessy et al., 2007), and over-activation of Akt 
results in hyperkeratosis and altered filaggrin expression demonstrating loss of Akt1 
activity and hyperactive Akt1 both cause hyperkeratosis. The data presented here 
proposes Ctsh as a novel epidermal protease, which is required for filaggrin processing 
and epidermal barrier formation, and that in the skin, RAPTOR regulates Ctsh 
expression and filaggrin processing in an Akt1 mediated manner.   
 
 Microarray analysis of Akt1 knock down cells revealed Ctsh as the most 
differentially regulated gene with a down-regulation of over 4 fold. Cathepsin H 
belongs to the papain- like family of cysteine proteases consisting of 11 members in 
humans with orthologous counterparts present in mice (Puzer et al., 2004; Hagemann et 
al., 2004). Though Ctsh is expressed ubiquitously and involved in bulk protein 
degradation, it does display cell specific functions such as its role in the processing and 
secretions of pro surfactant protein C in type II pneumocytes (Brasch et al., 2002; 
Buhling et al., 2011). Ctsh deficient mice have reduced lung surfactant, which may 
interfere with breathing mechanisms causing respiratory complications (Buhling et al., 
2011), and furthermore reduced Ctsh mRNA is reduced in airway smooth muscle cells 
in asthmatic individuals (Faiz et al., 2013). In the data presented here, a reduction in 
Ctsh in both Akt1 knock down cells and in cells treated with the PI3 kinase 
pharmacological inhibitor wortmannin demonstrates that Ctsh expression in 
keratinocytes is regulated by Akt signaling.  
 
Immunofluorescence staining of the mouse embryo sections show Ctsh increase 
during the barrier acquisition stage at E17.5 and E18.5 suggesting Ctsh might be 
involved in late keratinocyte differentiation. Furthermore, Ctsh protein levels were only 
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detected in post-confluent differentiated cells and it co-localized with filaggrin in the 
upper granular layer.  The overall reduction in filaggrin processing in day 5 Ctsh 
shRNA expressing cells and increase in overall filaggrin products upon over-expression 
of Ctsh in Akt1 knockdown cells is strong evidence that Ctsh is required for filaggrin 
processing. Ctsh functions predominantly as an aminopeptidase but may have limited 
substrate specific endo peptidase activity (Dodt & Reichwein, 2003), hence it may be 
directly involved in filaggrin processing, or it may be degrading an inhibitor and 
allowing another protease to process filaggrin. Interestingly there was a greater 
reduction in filaggrin intermediate bands and monomeric bands at day 6 suggesting 
filaggrin is getting degraded or proteolytically processed more rapidly in Ctsh shRNA 
knock down cells than the control. During the processing of profilaggrin to filaggrin, 
the large profilaggrin protein (> 400 kDa) is cleaved by numerous proteases to first 
yield the N- terminus and poly-filaggrin sequence, the latter is further processed to give 
different sized filaggrin intermediates which are eventually cleaved to give the 
monomeric filaggrin subunit (Pearton et al., 2002). Filaggrin is then degraded, a process 
involving Caspase-14, to release free amino acids that partially contribute to the 
production of natural moisturizing factors in stratum corneum (Harding et al., 2002; 
Rawlings and Matts, 2005). The proteolytic cascade in epidermis is executed by a 
careful balance between proteases and their inhibitors and is emerging as an important 
regulator of the keratinocyte differentiation program (reviewed in De Veer et al., 2014). 
An imbalance in the proteolytic cascade can have detrimental consequences such as 
reduction in proteases Elastase 2 or Matriptase (reviewed in De Veer et al., 2014) 
leading to reduced filaggrin processing and barrier defects, or as in the case of 
Netherton Syndrome where a reduction in the protease inhibitor LEKTI (lympho-
epithelial Kazal type inhibitor) leads to excessive activity of serine protease causing 
increased degradation of epidermal constituents such as lipid processing enzymes and 
desmosomal proteins and increased filaggrin processing resulting in a thin and barrier-
compromised stratum corneum (Hachem et al., 2006). 
 
Ctsh deficient mice were hyperkeratotic and had reduced filaggrin expression. It 
was interesting that Ctsh heterozygous mice were more barrier compromised that the 
Ctsh knockout mice. It has been reported that frequency of Ctsh-/- mouse resulting from 
heterozygous mating is reduced resulting in dead newborns (Buhling et al., 2011). 
Although the cause was not determined, it is possible the Ctsh-/- skin phenotype is more 
severe hence prompting compensatory mechanisms resulting in the surviving mice to 
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have a milder phenotype than the heterozygous littermates. Reduction in Akt activity 
resulting in reduced filaggrin processing and barrier function has previously been 
demonstrated (Thrash et al., 2006; O’Shaughnessy et al., 2007). The data presented here 
shows for the first time that granular layer Akt phosphorylation is significantly reduced 
in AD uninvolved skin. Furthermore CTSH and filaggrin were also significantly 
reduced reinforcing the rationale that reduction in Akt phosphorylation reduces 
expression of its downstream target CTSH leading to a reduction in filaggrin levels and 
proteolytic processing.  
 
RAPTOR, a regulatory component of the mTORC1 complex, is reported to 
modulate Akt activity (Sarbassov et al., 2005; Sully et al., 2013). In fact, over 
expression of RAPTOR in REKs decreased Akt phosphorylation, Ctsh expression and 
filaggrin processing. Furthermore, rapamycin treatment in RAPTOR overexpressing 
REKs caused an increase in Akt phosphorylation, Ctsh expression and mature filaggrin 
levels almost to those of the control. Rapamycin is a widely used immune suppressant 
and a dosage of 10 nM is currently used to maintain organ transplantation in children 
(Schachter et al., 2006; Goyal et al., 2013). Data presented here thus indicates that, at 
the same low dosage of 10 nM, rapamycin treatment is sufficient to restore Akt 
phosphorylation, Ctsh expression and correct the filaggrin processing defect. Taken 
together, these data suggest that Akt activity in keratinocytes can be modulated by 
RAPTOR, therefore RAPTOR should be increased in AD patients. Interestingly data 
indicates that high levels of epidermal RAPTOR expression are more common in AD 
than in normal population (p ≤ 0.01, two-sided fisher exact test). Retinoids have been 
successfully used in treating skin conditions including Eczema. Results show that 
RAPTOR gene responds to retinoic acid treatment by decreasing its expression. It is 
possible that RAPTOR over-expression is caused by a SNP, potentially very weakly 
associated with AD, and barrier correction caused by retinoic acid treatment might be 
via a mechanism where retinoid-mediated decrease in RAPTOR is restoring both Ctsh 
expression and filaggrin processing.  
 
In conclusion, these findings identify CTSH as a novel epidermal protease, and 
demonstrate that in AD an abnormal increase in RAPTOR reduces filaggrin processing 
via CTSH in an Akt1-mediated manner. Most importantly these data suggest that in 
those subset of patients without a filaggrin mutation, rapamycin treatment may be able 
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to restore the barrier defect by rescuing filaggrin protein levels and normal filaggrin 
proteolytic processing.  	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 : Reduced Akt activity alters Lamin A/C degradation Chapter 5
resulting in skin barrier abnormalities 	  
5.1 Introduction 
 
The skin barrier functions as both a structurally and immunologically competent 
organ that is absolutely essential for an adult to survive the terrestrial environment 
(Proksch et al., 2008). Skin barrier competence is achieved by various intricate 
regulatory mechanisms involving multiple components; Notch and Wnt signaling 
pathway have been reported to regulate keratinocyte growth and commitment to 
differentiation (Fuchs & Raghavan, 2002), Protein kinase C and Rho/ROCK signaling 
pathway has been shown to regulate keratinocyte differentiation (Dotto, 1999; 
McMullan et al, 2003), and studies including the research conducted on p63-/- mice, 
where they are reported to have  single layer of surface epithelium, have shown that p63 
is required for keratinocyte stratification (Koster et al, 2002; Yang et al, 1999). 
Previous chapters have demonstrated the importance of the Akt signaling pathway in 
skin barrier formation. Apart from evidence of filaggrin misprocessing, the Akt1 
shRNA expressing organotypic culture model displayed hyperkeratosis and 
parakeratosis, which are characteristic features of AD skin (Leung, 1995; Leung & 
Bieber, 2003). Parakeratosis, defined by nuclear retention in cornified layer, is often 
observed in AD and other inflammatory disorders such as psoriasis (Guttman-Yassky et 
al, 2011; Sakurai et al, 2002).  
 
During stratum corneum formation, major changes of intracellular organization 
occur eventually resulting in the establishment of corneocyte that is reinforced by both 
lipid and protein components (Hohl et al, 1991; Rawlings & Harding, 2004; Steinert & 
Marekov, 1995). A key step of this cornification process is nuclear degradation 
although the processes governing denucleation still remain elusive (Presland et al., 
1992; Lippens et al., 2005).  Nuclear degradation during cornification is similar to 
apoptosis but is thought to involve different mechanisms (Takahashi et al., 2000). For 
example, p53 has important roles in inducing apoptosis, however p53-deficient mice do 
not display impaired epidermal formation (Li et al., 1998). Additionally UV induced 
cell death in keratinocytes is marked by DNA cleavage caused by an apoptotic DNase 
called Caspase-activated DNase (CAD), however CAD-deficient mice did not display 
nuclear degradation defects during keratinocyte differentiation (Kawane et al., 2003). In 
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the process of cornification nuclei are completely degraded with no nuclear fragments 
detected in corneocytes, where as in apoptosis DNA fragments are visible in apoptotic 
bodies (Lippens et al., 2000). Furthermore the pro-apoptotic caspases-1,6 and 7 remain 
unprocessed and are not activated during epidermal differentiation (Lippens et al., 
2000) hence suggesting the mechanisms of nuclear degradation in keratinocyte 
differentiation is indeed different from pathways executed in apoptosis. Desquamin, a 
lectin-like glycoprotein that possess both trypsin-like serine protease and ribonuclease 
activity expressed in the upper granular layer, has been proposed to be involved in 
desquamation although its precise role remains to be established (Chen et al., 2000). In 
vitro experiments on human keratinocytes showed that this protease is capable of 
degrading nuclear matrix components in isolated nuclei leaving the nuclear inclusions 
intact (Selvanayagam et al., 1998; Chen et al., 2000). A study by Fischer et al identified 
the epidermal specific endonuclease, DNase-1-Like-2 (DNaseIL2), as degrading DNA 
during cornification (Fischer et al., 2007; Jager et al., 2007; Fischer et al., 2011). 
 
In this chapter, we explored the hypothesis that a downstream effector of the 
Akt1 signaling pathway is involved in nuclear degradation during keratinocyte terminal 
differentiation, and reduction of Akt1 activity disrupts nuclear degradation, potentially 
disturbing barrier function. To elucidate potential downstream targets, we decided to 
profile differentially expressed proteins in the Akt1 shRNA expressing cells and carry 
out functional analysis on potential candidates to gain insight into the mechanisms 
involved in nuclear destruction during cornification. 
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5.2 Results 
 
5.2.1 Parakeratosis is observed in AD uninvolved skin and the Akt-1 shRNA 
organotypic culture model 	  
Parakeratosis has been previously reported in inflammatory skin disorders 
including atopic dermatitis (Sakurai et al, 2002). Consistent with these reports, DAPI 
staining of uninvolved AD patient skin sections indicated retained nuclei (white 
arrowheads) in the stratum corneum in comparison with the normal human skin (Fig 
5.1, upper panels). Immunofluoresence indicated that granular layer pSerAkt activity 
was reduced in the AD uninvolved skin sections in comparison with the normal skin 
(Fig 5.1, lower panels).  	  
 
Figure 5.1 AD uninvolved skin is parakeratotic and displays reduced granular layer Akt 
phosphorlyation.  
Upper panels: White arrows highlight the retained nuclei in the cornified layer of unaffected skin sections 
from three AD patients. The dotted line indicates the boundary between granular and cornified layer. 
Lower panels: granular Akt activity was reduced in the AD uninvolved skin sections in comparison with 
the normal skin. White arrows indicate the positive pAkt Ser473 staining detected in the suprabasal 
epidermis. Scale bar, 50 µM. The images of AD uninvolved skin sections with pSerAkt staining are also 
displayed in Fig 4.10 
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Similar to AD uninvolved skin, parakeratosis was also observed in the shRNA 
Akt1 knockdown cultures while the scrambled shRNA expressing controls appeared 
similar to normal skin (Fig 5.2 A). Previous studies have shown DNA degradation in 
the upper stratum granulosum to be mediated by DNase1L2 (Fischer et al., 2005; Jager 
et al., 2007; Fischer et al., 2011). Fischer and colleagues demonstrated by knockdown 
of DNase1L2 in a human skin equivalent in vitro model, that DNA degradation was 
reduced, leading to parakeratotic regions in the stratum corneum. However no change in 
protein expression levels of DNase 1L2 were observed in the both Akt1 shRNA 
expressing cell lines and in Akt-inhibited cells when compared to the controls (Fig 5.2 
B). This suggests that the parakeratosis observed in our in vitro AD model was not due 
to altered levels of DNase1L2. 
 
 
 
 
Figure 5.2 Parakeratosis in the Akt1 shRNA expressing culture model.  
(A) H & E of Akt1 shRNA expressing organotypic cultures. Parakeratosis was observed. (B) Western blot 
of keratinocyte lysates for DNase1L2. Expression levels remained unchanged in both the Akt1 knock 
down and Akt inhibited cells in comparison with the controls. DNase1L2 protein expression levels 
relative to GAPDH were determined by densitometry using ImageJ software. Scale bar, 50 µM. au 
(arbitrary units). Westerns are representative images from n=2. Protein lysates were prepared using total 
lysis buffer. 
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5.3.2 Increased Lamin A/C expression in Akt-1 siRNA expressing cells 
 
In order to gain insight into other potential mechanisms of nuclear degradation 
during cornified envelope formation, we set out to identify differentially expressed 
proteins as a means to determine possible downstream targets of the Akt1 signaling 
pathway that are potentially involved in nuclear degradation. To profile differentially 
expressed proteins in Akt1 shRNA expressing cells, equal amounts of total protein 
lysate of scrambled controls and Akt1 kd cells were separated on an SDS-PAGE gel, 
stained with colloidal coomassie blue which revealed a highly expressed 60 kDa band 
(Fig 5.3). This band was excised, de-stained overnight in distilled water and in-gel 
tryptic protein identification by mass spectrometry was performed (Biological Mass 
Spectrometry Centre, ICH, UCL).   
                                                                                         
Figure 5.3 Coomassie stained gel showing the differentially expressed proteins in the Akt1 shRNA 
expressing cells at 60 – 80 kDa range.  
Black arrow marks the differentially expressed band that was excised and sent for mass spectrometry 
analysis. 	  
 
Table 5-1 lists the proteins within the target molecular weight range identified 
by ESI QTOF MS. Some of the identified proteins represent good candidates for further 
study; for example it has been reported that inhibition of Hsp90 prevented expression of 
keratin-1 and keratin-10 at both transcription and protein level, while no effect was 
observed on filaggrin (Miyoshi et al., 2012). However, in view of the fact that retained 
nuclei was one of the AD phenotypic characteristic observed in our organotypic model, 
and since prelamin is a nuclear lamin protein (Dechat et al., 2010; Lehner et al., 1986), 
we decided to focus further investigations on this protein and determine its role in skin 
barrier formation. 
	  	   129	  
Table 5-1 Proteins identified by ESI QTOF MS/MS 
  
 
 
Table shows proteins identified by ESI QTOF MS/MS. Identified proteins are given a UniProt accession 
number. Coverage % indicates the percentage of peptides residues identified in each protein sequence. 
Reported PLGS score is -10*log (P), where P is the probability that the observed match between 
experimental and database sequence is a random event. Scores > 46 indicate protein identity at p < 0.05. 
 
 
5.3.3 Reduced Akt activity decreases Lamin A/C degradation and causes lamin 
A/C expression around retained nuclei in the cornified layer 	  
Lamin A/C are type A lamins coded by a single gene LMNA that yields prelamin 
A and lamin C through alternate splicing. Prelamin is both farnesylated and cleaved to 
yield the mature lamin A (Lehner et al., 1986).  These A type lamins once translated are 
immediately transported into the nucleus where they are incorporated into the inner 
nuclear membrane (Dechat et al., 2010; Lehner et al., 1986). During mitosis, the 
complex nuclear lamin protofilaments form a dynamic structure that disassembles and 
reassembles following posttranslational modification (Ito et al., 2007; Thompson et al., 
1997). During apoptosis however, the nuclear lamin is proteolytically degraded, which 
opens up the nucleus, subsequently leading to nuclear disintegration (Lazebnik et al., 
1995; Rao et al., 1996). It has also been reported that Akt mediated lamin 
phosphorylation is required prior to lamin degradation (Cenni et al., 2008).  
 
Since terminal differentiation of keratinocytes has apoptosis-like events including 
the destruction of the nucleus, lamin degradation during keratinocyte differentiation was 
investigated by immunoblot and immunofluorescence in rat epidermal keratinocytes.  In 
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the time course experiment of rat epidermal keratinocytes cultured over 6 days to post 
confluence, prelamin A (74 kDa), lamin A (72 kDa) and lamin C (70 kDa) protein 
expression was increased in cells in post confluent cultures coinciding with increase in 
pAkt activity and the differentiation marker keratin-1 (Fig 5.4 A). An increase in the 
lamin degradation products at 45 kDa and 28 kDa is also observed suggesting that lamin 
degradation may be associated with keratinocyte differentiation. Western analysis of 
post-confluent day 5 cells of Akt1 siRNA expressing cells and wortmannin treated 
pSerAkt reduced cells, revealed a reduction in the lamin degradation products (Fig 5.4 
B). These findings are consistent with reported results that Akt mediated 
phosphorylation is a prerequisite for lamin degradation to proceed (Cenni et al., 2008). 
To evaluate whether this reduced degradation results in altered lamin A/C expression 
patterns in the skin, immunofluorescence staining for lamin A/C on paraffin embedded 
Akt1 knock down organotypic culture sections were performed. On examination of the 
parakeratotic regions in the AD in vitro model, lamin A/C staining can be seen 
surrounding the retained nuclei, while the lamin A/C staining in scrambled was 
confined to the granular layer (Fig 5.4 C). Lamin A/C degradation was also reduced 
dose dependently in RAPTOR overexpressing REKs (Fig 5.4 D). 
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Figure 5.4 Lamin A/C expression is retained in the cornified layer and degradation was reduced when 
in Akt1 shRNA knockdown cultures  
(A) Immunoblot of anti Lamin A/C and anti-GAPDH in both pre and post confluent rat epidermal 
keratinocyte cultures. Note the increase in prelamin, lamin A/C and the degraded products in days 5 and 
6 post confluent cultures. (B) Immunoblot of prelamin and lamin A/C in both 2 µM wortmannin treated 
REKs and Akt1 shRNA expressing cells. Note the decrease in Lamin A/C degradation in Akt1 reduced 
samples in comparison with the controls.  (C) Positive lamin staining in the parakeratotic regions in the 
Akt1 shRNA expressing organotypic culture model. White arrows highlight the retained nuclei with 
peripheral lamin A/C staining in the cornified layer. (D) Lamin degradation reduced in a dose dependent 
manner in RAPTOR overexpressing REKs.  Dapi (blue) was used as a counter stain. The dotted line 
indicates the boundary between granular and cornified layer. Scale bar, 50 µM. All westerns and 
immunofluorescence images are representative images from n=2. Protein lysates were prepared using 
total lysis buffer. 
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To further examine the role of lamin A/C physiology in terminally 
differentiating cells, Akt1 shRNA expressing cells were grown to post confluence on 
coverslips, co-immunostained with the late keratinocyte differentiation markers Loricrin 
and lamin A/C, and analysed by confocal microscopy. Lamin A/C staining in the 
terminally differentiating cells, as indicated by positive loricrin staining, were 
significantly higher in the two biological replicates of Akt1 shRNA expressing cells 
when compared to the normal. Results also showed a significant reduction in loricrin 
protein levels in the Akt1 knock down cells in comparison with the normal (Fig 5.5A & 
B). This suggests in addition to the morphological changes and filaggrin misprocessing, 
reduced Akt activity may have an impact on other keratinocyte differentiation markers. 
Interestingly the nuclei volume in terminally differentiating cells was significantly 
smaller in both Akt1 shRNA expressing cell lines in comparison with the normal (Fig 
5.6). Although the mechanisms governing nuclear volume changes remain unclear there 
is strong correlation between nuclear volume and RNA transcription suggesting a 
reduction in transcriptional activities in Akt1 shRNA expressing cells (Schmidt & 
Schibler, 1995; reviewed in Webster et al., 2009) 
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Figure 5.5 Reduced Akt activity increases lamin A/C protein levels in loricrin positive keratinocytes. 
 (A) Immunolocalization studies of control and Akt1 shRNA expressing REKs using anti-loricrin and anti-
lamin A/C antibodies. Note the elevated lamin A/C staining (red) in loricrin positive cells (green) in both 
biological replicates of Akt1 shRNA expressing cells (A1 & A3) in comparison with the control (scram). 
Images were taken by confocal microscopy. Dapi (blue) was used as a counter stain. Scale bar, 10 µM. 
(B) Scattergrams showing densitometry of both lamin A/C and loricrin immunofluorescence. Lamin A/C 
staining in loricrin positive Akt1 shRNA expressing cells (n=11) were significantly higher (p = 0.002) in 
comparison with the control. Loricrin protein expression was significantly lower (p = 0.003) in Akt1 
shRNA expressing cells than the control (n=11). Densitometric quatification of immunofluorescence 
signals were determined using ImageJ software. Data expressed as mean ± SEM calculated from 11 
different fields of view. Statistical analysis was performed using the non-parametric Mann-Whitney U-
test. Significance was defined as p<0.05.  ** p ≤ 0.01. au (arbitrary units) 
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Figure 5.6 Granular nuclei volume significantly reduced in Akt1 shRNA expressing cells.  
Nuclei volume of loricrin positive cells was calculated using Volocity 3D Image Analysis Software. Data 
represents mean ± SEM calculated from 10 nuclei in every group. Statistical analysis was performed 
using the non-parametric Mann-Whitney U-test. Significance was defined as p<0.05. *** p ≤ 0.001  ** p 
≤ 0.01. au, arbitrary units. 
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5.3.4 Reduced Akt-1 mediated Lamin phosphorylation, leads to a reduction in 
keratinocyte terminal differentiation markers. 
 
Lamin A/C has previously been established as a nuclear substrate of Akt (Cenni et 
al., 2008). Marmiroli and colleagues have recently reported, using myoblasts of murine 
skeletal origin, that prelamin A degradation is triggered by Akt mediated 
phosphorylation at the sites serine 301 and serine 404 (Bertacchini et al., 2013; Cenni et 
al., 2008).  To further explore lamin A phosphorylation by Akt in keratinocytes, flag-
tagged wild type and mutant lamin A rat constructs where both serine residues were 
mutated to alanine, (gift, Professor Marmiroli, University of Bologna, Italy), were used 
to stably transfect REKs. Western analysis on post-confluent cultures revealed that 
S301A-mutated lamin A is degraded to the same extent as the wild type lamin A (Fig 
5.7). Whereas lamin A degradation in cells transfected with S404A-mutated lamin A 
and double mutant (S301A/S404A) was much greater. There was also a reduction in 
endogenous lamin A/C degradation in all the mutant transfected cell lines in comparison 
with the wild type. In addition to affecting lamin degradation, there was a decrease in 
overall filaggrin processing in the single mutant transfected cells. Furthermore, the early 
differentiation markers keratin-1, keratin-10 and late differentiation marker loricrin was 
reduced in all of the mutant transfected cells, with the reduction greater in S404A-
mutated lamin A expressing cells. The basal keratin-5 and pSer473Akt levels remained 
unchanged in all the mutant expressing cells in comparison with the wild type cells (Fig 
5.7).  
 
Immunohistochemistry was performed on wild type, single mutants and double 
mutant lamin A expressing cells grown on coverslips. Consistent with the western data, 
loricrin expression was reduced in all the mutant transfected cells (Fig 5.8A). Similarly, 
keratin-10 expression was also reduced in all mutant lamin A expressing cells, hence 
corroborating the western results (Fig 5.8 B). These results suggest that lack of lamin 
phosphorylation not only affects its degradation, but also consequently alters the 
program of keratinocyte terminal differentiation. 
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Figure 5.7 Reduced lamin A degradation associated with reduction in altered filaggrin processing and 
expression of other keratinocyte differentiation markers.  
REKs were transfected with flag-tagged wild type lamin A rat constructs, and single S301A-mutant lamin 
A and S404A-mutant lamin A; and double mutant construct (S301A / S404A). All constructs express 
prelamin A and lamin A only. Immunoblot show a reduction in lamin A degradation products in laminA 
A404S expressing cells and double mutant construct expressing cells. An overall reduction in endogenous 
lamin A/C degradation products were observed in all lamin mutant construct expressing cells. The 
differentiation markers keratin-1, keratin-10, loricrin were also reduced in all of the lamin A mutant 
construct expressing cells. Western blot analysis of profilaggrin processing showed overall reduction in 
filaggrin processing in S301A-mutant transfected cells. Altered pattern of filaggrin intermediate products 
was observed in both S301A mutant and S301A/S404A double mutant construct expressing cells. Basal 
keratin-5 and pAkt levels remained unchanged. Protein expression levels relative to GAPDH were 
determined by densitometry using ImageJ software.  
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Figure 5.8 Reduced lamin A/C phosphorylion decreases expression of keratinocyte differentiation 
markers.  
Co-immunolocalization studies of REKs transfected with flag tagged wild-type lamin A rat construct 
expressing prelamin A and lamin A, and single mutant constructs (S301A and S404A) and double mutant 
construct (S301A / S404A) using anti-loricrin, anti-flag and anti-keratin-10 antibodies. A. Loricrin 
protein levels were reduced in all the mutant construct expressing samples in comparison with the wild 
type expressing sample. B. Keratin-10 protein expression was also reduced in all mutant construct 
expressing samples with the reduction more obvious in the cells expressing lamin A S404A. Anti flag 
expression was increased in the mutant expressing terminally differentiated cells. Scale bar, 10 µM. 
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5.4 Discussion 	  
A competent skin barrier depends on proper execution of the keratinocyte 
terminal differentiation program resulting in an anucleate cornified layer (Proksch et al., 
2008). Cell death during terminal keratinocyte differentiation is a highly regulated 
specialized process with similarities to apoptosis where DNA is degraded and nucleus 
destroyed leading to a suicidal program that targets cells for elimination. Instead of 
being engulfed by macrophages as in the case of apoptosis, during cornification, these 
non-viable cells remain to serve a functional purpose by forming the skin barrier 
(reviewed in Lippens et al., 2005). Surprisingly little is understood about the 
mechanisms regulating terminal differentiation-associated epidermal cell death in the 
stratum epithelium. Failure of nuclear degradation results in parakeratosis which has 
been reported in inflammatory skin diseases such as AD and psoriasis. Consistent with 
this, we observed retained nuclei in the cornified layer in AD uninvolved skin sections 
and in the Akt1 shRNA expressing culture model. The data presented up to now 
establish the Akt1 shRNA expressing organotypic culture model as an attractive model 
of the parakeratotic aspects of AD and these data reveal lamin A/C as a downstream 
target of Akt1 signaling involved in nuclear degradation during cornification.  
 
Studies have shown that migration of keratinocytes from basal to granular layer 
is accompanied with a gradual reduction in nuclei volume ending with complete loss of 
whole nucleus in the stratum corneum (Karasek et al., 1972; Gdula et al., 2013). These 
studies have revealed there is a general reduction in transcriptional events in the upper 
granular layer with cessation of all RNA activity just prior to formation of cornified 
layer (Karasek et al., 1972; Gdula et al., 2013). A strong correlation between nuclei 
volume and transcriptional activity has also been reported (Schmidt & Schibler, 1995; 
Webster et al., 2000). The data presented here shows a significant reduction in granular 
layer nuclei volume in Akt1 shRNA expressing cells in comparison with normal cells 
suggesting reduced transcriptional activity in these cells. The array analysis of Akt1 kd 
cells in chapter 3 showed that more than 50 % of the differentially expressed genes were 
down regulated with majority of these genes involved in lipid biosynthesis.  
 
The keratinocyte specific endonuclease, DNase 1L2, has been reported to be 
essential for nucleus degradation during cornification, and knock down of DNase 1L2 
have been reported to cause parakeratosis (Fischer et al., 2007). However, our data 
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demonstrated that its expression remained unchanged in Akt1 knock down cells. Similar 
results were observed in Akt inhibited cells using the PI3 kinase pharmacological 
inhibitor, wortmannin. These results indicate that the lack of nuclear degradation 
observed in the in vitro AD model is most likely not due to DNase 1L2. Even though 
DNase 1L2 is reported to be an important mediator of nuclear degradation during 
cornification, it lacks a nuclear localization signal, hence can only gain access to DNA 
after break down of nuclear membrane, which in keratinocytes occurs during terminal 
differentiation in the transitional stage (Fischer et al., 2007; Presland et al., 1992; 
Shiokawa & Tanuma, 2001). 
 
We show in Akt1 shRNA expressing cells, prelamin A protein levels were 
elevated. Prelamin A and lamin C are both alternate spliced products of the gene 
LMNA, where prelamin A undergoes modifications to yield lamin A. Lamin A/C is a 
major component of the inner nuclear membrane providing scaffolding for the cell 
nucleus and anchoring chromatin to the nuclear lamina (Goldman et al., 2004; Lehner et 
al, 1986; Rao et al., 1996). Studies have shown that lamin A/C degradation leads to 
nuclear dysregulation and apoptosis (Lazebnik et al., 1995; Rao et al., 1996). 
Furthermore, functions of lamin A/C also include maintenance of cell shape and 
mechanical properties; in fact studies have shown that ectopic expression of lamin A 
results in stiffness of nuclei and increased mechanical strength, hence making them 
more resistant to disintegration (Goldman et al., 2008). Our data demonstrated lamin 
A/C degradation was reduced in both Akt1 shRNA expressing cells and Akt inhibited 
cells. Persistant lamin A/C staining was observed around retained nuclei in Akt1 
shRNA expressing cultures.  This is consistent with the immunofluorescence data which 
showed a significant increase in lamin A/C expression intensity in loricrin positive cells 
in comparison with the normal controls. These findings define a new role for Akt in 
lamin A/C degradation in keratinocytes, where lack of degradation leads to retention of 
lamin A/C positive nuclei in the cornified layer. In addition, these results can also 
explain why DNase 1L2 might not able to degrade the DNA, as persistent presence of 
lamin A/C protein in the nuclear lamina might delay nuclear envelope disintegration 
and hence will block DNase 1L2 from accessing the DNA. 
 
Previous reports have demonstrated lamin A/C as a target of Akt signaling 
pathway (Barati et al., 2006; Cenni et al., 2008). It was reported that Akt 
phosphorylates lamin A/C at the sites S301 and S404, which upon phosphorylation 
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triggers lamin A/C degradation coinciding with nuclear lamina break up (Bertacchini et 
al., 2013). Our data demonstrates that in cells transfected with the S404A-mutated 
lamin A and S301A/S404A double mutant lamin A, there was reduced lamin 
degradation. Degradation in cells transfected with S301A-mutated lamin A was 
comparable to wild-type expressing cells, similar to previous findings (Cenni et al., 
2008). Moreover, we observed a reduction in early and late keratinocyte differentiation 
markers with the effect more obvious in cells expressing S404A-mutated lamin A. 
These results were consistent with the immunoflourescence results where loricrin and 
keratin 10 levels were reduced in all of the cells expressing mutant lamin constructs. 
These results coupled with the observed overall reduction in filaggrin processing, 
suggested that phosphorylation at S404 is important for lamin degradation in 
keratinocytes, and also suggest a role for lamin A in regulating expression of important 
keratinocyte differentiation markers such as loricrin, keratin 10 and keratin 1. Lamin 
A/C expression is differentially regulated during development; in fact several studies 
have reported its involvement in cell differentiation (reviewed in Marmiroli et al., 
2009). Therefore it is possible that in keratinocytes, apart from being involved in 
nuclear disintegration, lamin A/C play additional roles in the terminal differentiation 
program. The unusual filaggrin intermediate bands in the S404A and S301/404A mutant 
lamin A expressing cells were interesting. Filaggrin has been shown to be associated 
with nuclear degradation and keratin intermediate filament (IF) aggregation (Dale et al., 
1997; Kuechle et al., 2000). Studies have reported that keratohyalin granules with 
profilaggrin aggregates localize to the perinuclear region sometimes forming deep 
invaginations at the areas of association (Dale et al., 1997; Kuechle et al., 2000). It is 
thought this may facilitate entry of cleaved N terminal domain of profilaggrin, into the 
nucleus where it has roles in nuclear degradation (Dale et al., 1997). It has also been 
reported that nucleus can engulf keratohyalin granules as N terminal-domain positive 
keratohyalin granules have been detected inside nucleus with intact nuclear envelope 
(Zhang et al., 2002). The data presented here shows an extra filaggrin intermediate band 
just above the 37 kDa monomeric band visible in both S404A and S301/404A mutant 
lamin A expressing cells. There was also accumulation of a band around 40 kDa in both 
mutant constructs expressing cells suggesting accumulation of intermediate forms. This 
suggests abnormalities in the end stage of filaggrin processing leading to accumulation 
of filaggrin intermediates. One possible explanation could be that since the nuclear 
lamina is linked to the actin cytoskeleton, a defective nuclear lamina can affect 
cytoskeletal dynamics (Lammerding et al., 2004) and interfere with the processing or 
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filaggrin. However Akt1 knock down cells had altered actin dynamics (discussed in 
chapter 3) and this particular filaggrin processing defect was not observed, it is 
therefore possible this may not be the reason. Another explanation is that since filaggrin 
has also shown to interact with nuclear lamins via the conserved helical rod domain, it 
is possible persistent presence of lamin A/C is increasing its association with filaggrin 
intermediates at the nuclear lamina preventing its processing. Alternatively, the 
increased association may allow it to be engulfed into the nucleus preventing access to 
cytoplasmic enzymes needed for end stage processing. It will be interesting to 
determine whether filaggrin or profilaggrin aggregates are detected either localizing 
with or inside the nuclei of S404 and S301/S404 lamin-A mutant construct expressing 
cells.  
 
The indispensable role of A-type lamins in numerous cellular processes, 
including cell division, DNA replication and gene transcription may be attributed to 
their association in an expanding number of human diseases (reviewed in Marmiroli et 
al., 2009, Ivorra et al., 2005). These diseases collectively known as laminopathies 
include muscular dystrophy, lipodystrophy and progeria syndromes. Hutchinson-
Gilford Progeria Syndrome (HGPS), a rare form of progeria is characterized by 
prelamin A accumulation (DeBusk, 1972). Symptoms of HGPS include accelerated 
ageing, alopecia and scleroderma (DeBusk, 1972; Merideth et al, 2008). Notably a link 
between increase of lamin A expression and parakeratosis has previously been reported 
in a transgenic mouse model replicating the skin phenotype of HGPS (Sagelius et al, 
2008). When Sagelius and colleagues generated transgenic mice with tetracycline-
inducible keratin-5 promoter to drive high levels of lamin A expression in epidermal 
keratinocytes, the observed skin abnormalities included hyperkeratosis and 
parakeratosis (Sagelius et al, 2008). Although no effective treatment currently exists for 
HGPS, Rapamycin treatment has been shown in vivo to decrease prelamin A levels, 
without altering lamin C, through a mechanism involving activation of mTOR 
dependent autophagic pathway (Cenni et al, 2011). Laminopathies have been associated 
with elevated mTORC1 signaling, ERK 1/2 signaling leading to reduced autophagy 
(Cenni et al, 2011; Choi & Worman, 2013; Ramos et al, 2013). Rapamycin, an 
mTORC1 specific inhibitor, have been reported to increase autophagy by reducing 
mTORC1 signaling and rescuing the disease phenotype (Cenni et al, 2011; Choi & 
Worman, 2013; Ramos et al, 2013). Data presented here showed a dose dependent 
increase in lamin A/C degradation in RAPTOR overexpressing cells. It is therefore 
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possible the rescue in disease phenotype by reduction of prelamin A levels with 
rapamycin treatment is mediated through Akt1. For future work, it will be noteworthy 
to determine whether rapamycin treatment reduces lamin A in our in vitro AD model 
and eliminates the parakeratotic phenotype.  
 
The obvious reduction in expression of important early and late keratinocyte 
differentiation markers in the S404A-mutated lamin A transfected cells suggest a 
possible transcriptional regulation role for lamin A during cornification process. The 
transcription factor activator protein 1 proteins (AP-1), composed of jun and fos 
proteins that form homodimers (jun/jun) and heterodimers (jun/fos) which bind to AP-1 
factor DNA binding sites have been implicated in keratinocyte proliferation and 
differentiation (Han et al, 2012; Mehic et al, 2005; O'Shaughnessy et al, 2009).  
Interestingly it has been reported that c-fos is sequestered in the nuclear envelope in a 
lamin A/C dependent manner, which effectively reduces AP-1 factor DNA binding 
activity (Ivorra et al, 2006). Since filaggrin, keratin 1, keratin 10 and loricrin have been 
reported to have AP-1 factor binding sites in their promoter regions this might suggest 
an explanation for the reduction in their protein expression levels (Rossi et al., 1998; 
Jang & Steinert, 2002). 
 
In this study we show Akt-mediated lamin A/C phosphorylation is essential for 
nuclear degradation and possible transcriptional regulation of key keratinocyte 
differentiated-associated target genes, hence clearly defining a role for Lamin A/C in 
skin barrier formation. 
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 : General discussion Chapter 6	  
AD is a common disorder with a prevalence that may have increased 
considerably over the last three decades (Bieber, 2010; Asher et al., 2006). It has been 
established that a skin barrier defect is a major cause of AD development, with FLG 
mutations being an important risk factor (Presland et al., 2000; Palmer et al., 2006). 
However the mechanisms involved in processing of profilaggrin to filaggrin still need to 
be fully understood (List et al., 2003). The Akt signaling pathway is important for 
barrier formation as reduced Akt activity leads to reduced filaggrin levels and 
hyperkeratosis (Thrash et al., 2006; O’Shaughnessy et al., 2007 and this work). It has 
been reported that treatment of keratinocytes with the drug rapamycin, which 
specifically inhibits RAPTOR-mTORC1, increases Akt activity via inhibition of a 
negative feedback loop. This thesis therefore explored the hypothesis that in AD, a 
potential upregulation of epidermal RAPTOR causes a reduction in granular Akt 
phosphorylation that leads to misprocessing of profilaggrin and barrier defects. To 
address this an Akt1 shRNA expressing REK organotypic culture model was 
established. This thesis has identified downstream effectors of Akt signaling involved in 
key processes for forming strong cornified envelopes.  The work presented here provide 
evidence that Akt1 controls filaggrin processing, via different mechanisms, mediated 
through HspB1 and cathepsin H, which is identified here as a novel epidermal protease. 
The study also shows Akt controls epidermal Lamin A/C degradation leading to nuclear 
degradation, an event crucial for barrier formation. The thesis reveals a novel 
mechanism where RAPTOR mediated down regulation of Akt activity can cause the 
barrier disruption observed in AD through misprocessing of filaggrin and disruptive 
nuclear degradation.  
 
6.1 Akt1 is activity required for filaggrin processing and the normal 
cornification process 
 
The skin of atopic dermatitis patients has features of both parakeratosis and 
hyperkeratosis. Histological examination of the Akt1 shRNA REK culture model 
revealed presence of both features along with reduced filaggrin expression hence 
establishing this as an appropriate AD in vitro model. Lack of Akt-dependent 
phosphorylation of HspB1 and shRNA knockdown of HspB1 in keratinocytes leads to 
hyperkeratosis and impaired filaggrin processing (O’Shaughnessy et al., 2007) therefore 
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suggesting a role for pSerHspB1 in profilaggrin processing and cornification that may 
be Akt-mediated via mechanisms that remain to be elucidated. Consistent with these 
findings, the data presented here suggests HspB1 phosphorylation and its association 
with filaggrin is Akt1 dependent. Furthermore inhibition of Akt1 activity using the PI3 
kinase inhibitor, Wortmannin, not only decreased the association between HspB1 and 
filaggrin association but also revealed a HspB1 staining pattern at the cell periphery 
similar to actin staining. HspB1 and actin interaction is well established (Lavoie et al., 
1993; Guay et al., 1997; Graceffa, 2011), an action that is favoured by monomeric non-
phosphorylated form and prevented by the dimeric and trimeric phosphorylated HspB1 
forms. To further explore the potential HspB1 and actin interaction, co-
immunoprecipation assays were performed, and results revealed an increased 
interaction of actin with HspB1 in both Akt1 knock down and Akt inhibited REKs, 
which was not observed in the control cells. Actin dynamics alter during cell 
differentiation and it has been reported that in stratified cultures actin staining at the cell 
periphery is more diffuse in comparison to basal cells (Kubler et al., 1991; Lewis et al., 
1987). It is therefore possible increased HspB1 binding to actin in Akt inhibited cells, 
stabilises the actin cytoskeleton leading to persistent actin staining around the cell 
periphery. The data presented here suggests, in the absence of Akt activity, non-
phosphorylated monomeric HspB1 interacts with actin instead of filaggrin, hence 
interfering with filaggrin processing. The exact role HspB1 plays in profilaggrin 
processing remains to be determined. Since HspB1 is a well described chaperone 
protein that interacts with many proteins, it is therefore reasonable to assume that 
HspB1 is acting in its chaperone capacity by binding to filaggrin and facilitating the 
proteolytic processing of filaggrin. It is also interesting that HspB1 interacted with 
specific filaggrin intermediates (Fig 3.7 A). Association of HspB1 with a subset of 
filaggrin intermediates has previously been observed in Akt induced tamoxifen treated 
REK culture model (O’Shaughnessy et al., 2007). HspB1 has also been reported 
interacting with filaggrin inside keratohyalin granules (Jonak et al., 2005; 
O’Shaughnessy et al., 2007). Given the role of filaggrin in aggregating keratin filaments 
and nuclear degradation (Presland et al., 1992; Pearton et al., 2002; Lonsdale-Eccles et 
al., 1982), it is important to ensure mature filaggrin is released at the correct point in 
terminal differentiation. Profilaggrin is found sequestered in keratohyalin granules of 
which it forms the main constituent, an action which is thought to prevent its premature 
access to other cellular contents (Presland et al., 1992).  Taken together this suggests 
HspB1 binding to filaggrin may assist in sequestering it inside the keratohyalin granules 
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or the binding may facilitate proteolytic events at a specific stage of filaggrin 
processing.  
 
6.2 Granular layer pSer473Akt and cathepsin H, an Akt1 dependent 
epidermal protease in profilaggrin processing, is reduced in eczema 
 
 To elucidate further downstream targets of Akt signaling that may be involved 
in skin barrier function, microarray analysis was performed on Akt1 knock down REKs 
and genes altered with a fold change of ≥ 1.5 were analysed.  The array analysis 
revealed that many genes involved in lipid synthesis and retinoic acid signaling 
pathways were differentially expressed. Lipids play important roles in maintenance of 
water and permeability barrier of the epidermis (Furuse et al., 2002), and retinoid 
pathways are important regulators of keratinocyte differentiation (Fowler et al., 2003; 
Shen et al., 2011). The most differentially regulated gene down-regulated more than 4-
fold was the lysosomal cysteine protease, cathepsin H (Ctsh). Reports have indicated 
Ctsh is found in high concentrations in specific tissues such as kidney, spleen and in 
type II pneumocytes, although Ctsh expression has previously not been characterized in 
the epidermis (Guha & Padh, 2008; Buhling et al., 2011). The data presented here 
showed an increase in Ctsh levels during mouse embryo barrier acquisition (Fig 4.4). In 
keratinocyte culture the Ctsh expression was detected only in post confluent 
differentiated keratinocytes coincident with upregulation of both pSer473Akt and the 
keratinocyte terminal differentiation marker keratin 1 (Fig 4.5A) therefore suggesting a 
terminal differentiation related role for Ctsh in the epidermis. Studies have indicated 
tissue specific functions for Ctsh (Lu et al., 2007; Guha & Padh, 2008; Buhling et al., 
2011). For example, the most well characterized role of Ctsh is its involvement in 
processing of lung surfactant B in type II pneumocytes (Buhling et al., 2011). 
Additionally Ctsh expression pattern in lung development is both temporally and 
spatially regulated with an important role in lung branching morphogenesis (Lu et al., 
2007). Data presented here also showed Ctsh co-localized with filaggrin in the granular 
layer both in REK organotypic cultures and normal human skin (Fig 4.6). The reduction 
in filaggrin products in Ctsh shRNA expressing cells in day 5 and increase in overall 
filaggrin processing in Akt1 kd REKs overexpressing Ctsh, strongly suggests that Ctsh 
is required for the normal processing of filaggrin. The increase in processing of 
filaggrin intermediate products in day 6 Ctsh shRNA expressing cells suggests an 
increase in proteolytic activity of another enzyme leading to increased clearing of 
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filaggrin products. This implies an over activation of another protease involved in 
profilaggrin-filaggrin processing pathway, whose proteolytic activity may otherwise be 
controlled either directly or indirectly by Ctsh. Previous studies have indicated 
inhibition of Ctsh activity during lung branching morphogenesis lead to increased levels 
of mature bone morphogenetic protein 4 (Bmp4) which prevents lateral lung branching 
(Lu et al., 2007; Kishimoto & Itoi, 2013). Tight regulation of Bmp4 is required for 
proper lung development, where different levels of Bmp4 are required at different 
stages and this is achieved via local induction of Ctsh which degrades Bmp4 hence 
regulating its availability (Lu et al., 2007). Tight regulation of protease activity during 
keratinocyte differentiation is also important as evidenced by pathological conditions 
caused by dysregulation of proteolytic activity (Hachem et al., 2006; De Veer et al., 
2014). It will be interesting to investigate whether Ctsh affects BMP signaling in the 
epidermis. The importance of BMP signaling in hair morphogenesis is extensively 
studied (Guha et al., 2004; Kan et al., 2011; Rishikaysh et al., 2014) but less is known 
about its role in epidermal differentiation (Guha et al., 2004; Kan et al., 2011; 
Rishikaysh et al., 2014). An in vivo 2010 study by Yu et al., however showed that over 
expression of BMP signaling pathway caused reduced filaggrin expression and 
hyperkeratinization leading to Ichthyosis Vulgaris (IV) like skin disease (Yu et al., 
2010). Although this study reported a transcriptional down regulation in filaggrin levels 
(Yu et al., 2010), which was not observed in the AD in vitro model, it is worth 
investigating whether BMP signaling has an effect on filaggrin processing as well. 
Interestingly BMP2 was upregulated and Inhibin, an antagonist of BMP signaling 
(Wiater & Vale, 2003) was downregulated in the AD in in vitro model. 
 
Although the Ctsh-deficient mouse was reported as being phenotypically normal 
in comparison with their wild type littermates (Buhling et al., 2011), histological 
examination of both homozygous (Ctsh-/-) and heterozygous (Ctsh+/-) neonatal mice skin 
showed reduced filaggrin expression and hyperkeratosis. Additionally isolated cornified 
envelopes from Ctsh deficient mice are significantly weaker in comparison with wild 
type. These results define an important role for Ctsh in skin barrier function. Previous 
reports have established the importance of Akt in skin barrier formation with Akt1 null 
mice displaying cornified envelope fragility, reduced filaggrin processing and 
hyperkeratosis (Thrash et al., 2006; O’Shaughnessy et al., 2007), however epidermal 
Akt activity in AD skin has not been previously described. Data presented here shows a 
significant reduction in granular pSer473Akt in non-affected AD skin. Additionally 
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both filaggrin and Ctsh expression in the granular layer was also reduced significantly 
in non-affected AD skin sections. These data thus identify Ctsh as a novel epidermal 
protease that is a downstream target of the Akt1 signaling pathway and is involved in 
filaggrin processing and skin barrier function. Results also indicate that reduced Akt1 
activity, resulting in reduced Ctsh expression, may contribute to pathology of AD via 
impaired processing of filaggrin and subsequent skin barrier dysfunction. 
 
6.3 Reduced Akt activity alters Lamin A/C degradation resulting in skin 
barrier abnormalities 
 
 As parakeratosis was another feature observed in our AD in vitro model and in 
AD skin (Sakurai et al., 2002), we wanted to examine whether Akt signaling is involved 
in the nuclear degradation process during cornification. Examination of keratinocyte 
specific nuclease, DNase 1L2, revealed no apparent change in protein levels suggesting 
retention of nuclei in the parakeratotic regions was not due to changes in DNase 1L2, 
which is the main nuclease identified in nuclear degradation during cornification 
(Fischer et al., 2005; Jager et al., 2007; Fischer et al., 2011).  To profile differentially 
expressed proteins with functions potentially involved in nuclear degradation, protein 
lysates were run on an SDS-PAGE gel and stained with colloidal coomassie blue. Mass 
spectrometric analysis of highly expressed 60 - 80 kDa protein band identified nuclear 
lamin protein, Prelamin. Lamin A/C are type A lamins coded by the LMNA gene that 
yelds prelamin A and lamin C through alternate splicing (Dechat et al., 2010). Prelamin 
A is further processed to produce the mature lamin A (Lehner et al., 1986). It has been 
reported that lamin A/C degradation, is required prior nuclear disintegration during 
apoptosis (Lazebnik et al., 1995). It has also been shown that Akt mediated lamin 
phosphorylation is needed before lamin A/C degradation can occur (Cenni et al., 2008). 
Data presented here shows persistence of lamin A/C staining around the retained nuclei 
in the parakeratotic regions and a reduction in lamin A/C degradation products in the 
AD in vitro model. Reduced degraded lamin A/C products were also observed in Akt 
inhibited REKs treated with the PI3 kinase inhibitor, wortmannin. Quantification of 
immunofluorescence signals indicated lamin A/C expression in loricrin positive cells is 
significantly higher in comparison with normal cells (Fig 5.5B). Since DNase 1L2 does 
not have a nuclear localization signal, indicating it can only get access to nucleus once 
nuclear envelope is disrupted, this suggests that persistent lamin A/C presence around 
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the nuclear would hinder the nuclear degradation process and therefore may result in 
parakeratotic regions as observed in the AD in vitro model.  
 
 Reports have identified serine 301 and serine 404 as specific Akt 
phosphorylation sites on lamin A which when phosphorylated triggers degradation of 
lamin A (Bertacchini et al., 2013; Cenni et al., 2008). Mutant lamin A constructs where 
the serine residue at these sites have been substituted for alanine were obtained 
(generous gift from Professor Marmiroli, University of Bologna, Italy) to further 
investigate effect of lamin A phosphorylation in keratinocyte differentiation process. 
Data showed a reduction in lamin A degradation in the REKs expressing S404A (single 
mutant) and S301A/S404 (double mutant) with greater reduction observed in S404A 
single mutant expressing cells. Interestingly an overall reduction in protein levels of 
both early and late differentiation markers was also observed in these same lamin A-
mutant construct expressing REKs again with a greater reduction observed in S404A 
mutant expressing cells. Aberrant filaggrin processing was observed in all lamin A-
mutant expressing lines. The unusual filaggrin intermediate banding pattern observed in 
both S404A and S301A/S404A lamin A mutant expressing cells is suggestive of 
abnormalities at the end stage of filaggrin processing in these cells. Since filaggrin 
associates with nuclear lamins via the conserved helical rod domain (Kuechle et al., 
2000), an increased association with lamin due to its persistant presence may interrupt 
with the proteolysis of filaggrin. Additionally, nucleus have been shown to engulf 
keratohyalin granules while keeping nuclear envelope intact, in which case, lack of 
nuclear envelope degradation would prevent filaggrin intermediate products from 
accessing cytosolic enzymes (Zhang et al., 2002).  
 
 The overall reduction in keratinocyte differentiation markers including filaggrin 
suggests a possible transcriptional regulation role for lamin A. Several transcriptional 
factors have been implicated as being important regulators at different stages of 
keratinocyte differentiation (Eckert et al., 1997; Eckert et al., 2013), out of these Ap-1 
which is important for keratinocyte proliferation and differentiation, is found in the 
promoter regions of filaggrin, K1, K10 and loricrin (Jang & Steinert, 2002; Han et al., 
2012; Mehic et al., 2005). It has been reported that lamin A/C dependent sequestering 
of c-fos at the nuclear envelope reduces Ap-1 factor DNA binding activity, which may 
explain the reductions in the protein levels of the keratinocyte markers (Ivorra et al., 
2006). The data presented here suggests Akt-mediated phosphorylation of lamin A, 
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particularly at the residue S404, is important for nuclear degradation. Data also suggests 
apart from abnormal nuclear disintegration, lack of lamin A degradation may also affect 
other aspects of keratinocyte differentiation by altering the expression and processing of 
key epidermal proteins. 
 
6.4 Increased RAPTOR leads to decreased filaggrin expression 
 
The results discussed so far have identified possible mechanisms where reduced 
epidermal Akt activity can give rise to an AD-like phenotype. Data also showed 
granular pSerAkt activity is reduced in a subset of AD patients. To address whether 
RAPTOR can modulate Akt activity and its downstream targets, REKs were transfected 
with myc-tagged RAPTOR overexpressing plasmid. Data showed that low pSer473Akt 
and low filaggrin expression correlated with high RAPTOR expression. Additionally a 
reduction in lamin A/C degradation was also observed in RAPTOR over-expressing 
cells. Rapamycin treatment of RAPTOR-over expressing cells not only restored 
pSer473Akt levels, but also rescued filaggrin and Ctsh expression to an extent. This 
strongly suggests that the decrease in Akt activity and its altered barrier function related 
downstream effects are mediated by an increase in RAPTOR. Examination of normal 
skin sections and non-affected AD skin indicated RAPTOR increase can occur in both 
populations although data suggests the increase in RAPTOR levels in AD skin is greater 
compared to normal skin. Interestingly, granular RAPTOR increase was associated with 
a decrease in filaggrin expression. Altered filaggrin processing in AD skin have been 
identified independent of filaggrin mutations in an African population suggesting 
possible mechanisms leading to misprocessing of profilaggrin (Thawer-Esmail et al., 
2014). Reports have identified SNPs in the RAPTOR gene under climate selection and 
interestingly increased RAPTOR expression levels have been reported in sub-saharan 
African areas (Sun et al., 2010). Although Thawer-Esmail et al. did not report a cause 
for reduced filaggrin products in the African AD population, it is possible filaggrin 
expression and processing is impaired due to an increase in RAPTOR.  
 
Treatment of human keratinocytes with retinoic acid agonist resulted in a 
decrease in RAPTOR levels where treatment with an antagonist increased RAPTOR 
expression. The retinoid signaling pathway is dysregulated in AD and retinoic acid 
based therapy has been successful in hand eczema patients (Gericke et al., 2013; 
Bissonnette et al., 2010). It is possible the improvement in skin barrier with retinoic 
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acid treatment in the hand eczema patients is due to a mechanism where decrease in 
RAPTOR leads to increase in Akt activity and restoration of barrier-related downstream 
effects (Fig 6.1) 
6.5 Final conclusions and future work 
 
Barrier dysfunction is reported as the major cause of AD pathogenicity. 
Understanding key mechanisms that lead to barrier disruption should lead to better 
therapeutic approaches. This thesis has identified key roles of Akt1 in regulating 
filaggrin processing and nuclear degradation, which are two vital events involved in the 
normal cornification process.  
 
! The presented data showed how reduced in vitro Akt activity decreased the 
HspB1-filaggrin interaction while increasing HspB1-actin interaction. The exact 
role of HspB1 in filaggrin processing is unclear, however data presented here 
and in literature suggests that the HspB1-filaggrin interaction is required for 
normal filaggrin processing. Since HspB1 is a chaperone protein which can bind 
to numerous proteins (O’Shaughnessy et al., 2007; Jonak et al., 2005; During et 
al., 2007; Ojha et al., 2011), it may be interesting to do a co-
immunoprecipitation assay followed by mass spectrometry to identify novel 
HspB1 binding partners that may be involved in filaggrin processing. HspB1 
was also reported to co localize with the keratin filaments during differentiation 
(O’Shaughnessy et al., 2007). Further investigations will be needed to clarify 
whether HspB1 may have a role in cytoskeletal break down during cornification 
process.  
 
! The data also showed that reduced Akt activity led to decreased lamin A/C 
degradation disrupting nuclear disintegration process giving rise to 
parakeratosis. It would be interesting to evaluate how decreased lamin 
degradation and the lack of nuclear degradation alters filaggrin processing. 
Investigating the fate of filaggrin products by immunofluorescence staining in 
these lamin mutant expressing cells may further our understanding of end stage 
filaggrin proteolysis process. It will also be worthwhile to determine whether 
rapamycin treatment can rescue parakeratotic phenotype in the AD in vitro 
model. Increased BMP signaling in the epidermis of transgenic mice causes 
decrease in filaggrin expression and IV-like symptoms (Yu et al., 2010); and 
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leads to psoriasis like symptoms with hyperkeratosis and parakeratosis (Blessing 
et al., 1996). Additionally overexpression of BMP signaling in murine epidermis 
leads to downregulation of AP-1 (jun/fos) transcription factors (Wach et al., 
2001), which are key regulators of keratinocyte differentiation (Eckert et al., 
2013). As BMP signaling was increased in the AD in vitro model, it is therefore 
possible the observed parateratosis and down regulation of keratinocyte 
differentiation markers may be influenced by altered BMP signaling pathway. 
Further studies are needed to determine the contribution of BMP signaling 
towards skin barrier formation. 
 
! This study also demonstrated for the first time that granular pSer473Akt is 
reduced in non-affected AD skin. In vivo and in vitro results presented in this 
thesis strongly lends support to the hypothesis that increase in RAPTOR can 
lead to a reduction in epidermal granular Akt1 phosphorylation leading to 
impaired filaggrin processing and barrier defects in AD. The data presented here 
suggests a possible therapeutic route where in the subset of patients with 
impaired filaggrin processing, drugs aimed at reducing epidermal RAPTOR 
expression may restore the barrier defects in AD. 
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Figure 6.1 Proposed mechanism of how retinoic acid treatment may lead to skin barrier restoration in 
AD 
In AD, RAPTOR increase is associated with reduced Akt phosphorylation which subsequently decreases 
HspB1 phosphorylation, Ctsh expression and lamin degradation. This leads to reduced filaggrin 
processing, parakeratosis and reduction of keratinocyte differentiation markers resulting in skin barrier 
defects. All trans retinoic acid (ATRA) treatment binds to retinoic acid receptor (RAR) which is in 
complex with retinoic x receptor (RXR), that binds to RAPTOR promoter region causing a reduction in 
RAPTOR expression. This leads to an increase in Akt activity and its downstream signaling pathways 
leading to restoration of skin barrier defects. 
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